|
Delaware
(State or other jurisdiction of incorporation or organization) |
| |
6770
(Primary Standard Industrial Classification Code Number) |
| |
84-4618156
(I.R.S. Employer Identification Number) |
|
|
Carl P. Marcellino, Esq.
Paul D. Tropp, Esq. Rachel D. Phillips, Esq. Ropes & Gray LLP 1211 Avenue of the Americas New York, New York 10036 Telephone: (212) 596-9000 |
| |
Michael L. Fantozzi, Esq.
John P. Condon, Esq. Mintz, Levin, Cohn, Ferris, Glovsky and Popeo, P.C. One Financial Center Boston, Massachusetts 02111 Telephone: (617) 542-6000 |
| |
Laurent Faracci
Chief Executive Officer Butterfly Network, Inc. 530 Old Whitfield Street Guilford, Connecticut 06437 Telephone: (203) 689-5650 |
|
| ☐ Large accelerated filer | | | ☐ Accelerated filer | |
| ☒ Non-accelerated filer | | | ☒ Smaller reporting company | |
| | | | ☒ Emerging growth company | |
|
☐ Exchange Act Rule 13e-4(i)
(Cross-Border Issuer Tender Offer) |
| |
☐ Exchange Act Rule 14d-1(d)
(Cross-Border Third-Party Tender Offer) |
|
| | ||||||||||||||||
Title of Each Class of Securities to be Registered
|
| | |
Amount to be
Registered |
| | |
Proposed
Maximum Offering Price Per Share |
| | |
Proposed
Maximum Aggregate Offering Price |
| | |
Amount of
Registration Fee |
|
Class A common stock, par value $0.0001 per share
|
| | |
92,015,168(1)
|
| | |
$9.83(2)
|
| | |
$904,509,102(2)
|
| | |
$98,682
|
|
Class B common stock, par value $0.0001 per share
|
| | |
26,426,937(3)
|
| | |
$9.83(4)
|
| | |
$259,776,791(4)
|
| | |
$28,342
|
|
Class A common stock, par value $0.0001 per share
|
| | |
26,426,937(5)
|
| | |
—
|
| | |
—
|
| | |
—(6)
|
|
Total
|
| | | | | | | | | | |
$1,164,285,893
|
| | |
$127,024
|
|
| | | | | ix | | | |
| | | | | 1 | | | |
| | | | | 6 | | | |
| | | | | 8 | | | |
| | | | | 23 | | | |
| | | | | 23 | | | |
| | | | | 23 | | | |
| | | | | 24 | | | |
| | | | | 25 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 26 | | | |
| | | | | 27 | | | |
| | | | | 28 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 29 | | | |
| | | | | 30 | | | |
| | | | | 31 | | | |
| | | | | 31 | | | |
| | | | | 31 | | | |
| | | | | 33 | | | |
| | | | | 34 | | | |
| | | | | 34 | | | |
| | | | | 34 | | | |
| | | | | 35 | | | |
| | | | | 36 | | | |
| | | | | 36 | | | |
| | | | | 38 | | | |
| | | | | 40 | | | |
| | | | | 41 | | | |
| | | | | 43 | | | |
| | | | | 45 | | | |
| | | | | 45 | | | |
| | | | | 45 | | | |
| | | | | 46 | | | |
| | | | | 46 | | | |
| | | | | 58 | | | |
| | | | | 60 | | | |
| | | | | 72 | | |
| | | | | 85 | | | |
| | | | | 94 | | | |
| | | | | 96 | | | |
| | | | | 96 | | | |
| | | | | 96 | | | |
| | | | | 96 | | | |
| | | | | 97 | | | |
| | | | | 97 | | | |
| | | | | 97 | | | |
| | | | | 97 | | | |
| | | | | 97 | | | |
| | | | | 97 | | | |
| | | | | 98 | | | |
| | | | | 99 | | | |
| | | | | 100 | | | |
| | | | | 100 | | | |
| | | | | 100 | | | |
| | | | | 101 | | | |
| | | | | 102 | | | |
| | | | | 102 | | | |
| | | | | 102 | | | |
| | | | | 103 | | | |
| | | | | 103 | | | |
| | | | | 103 | | | |
| | | | | 104 | | | |
| | | | | 104 | | | |
| | | | | 104 | | | |
| | | | | 104 | | | |
| | | | | 105 | | | |
| | | | | 105 | | | |
| | | | | 108 | | | |
| | | | | 113 | | | |
| | | | | 113 | | | |
| | | | | 113 | | | |
| | | | | 115 | | | |
| | | | | 115 | | | |
| | | | | 116 | | | |
| | | | | 116 | | | |
| | | | | 116 | | | |
| | | | | 117 | | | |
| | | | | 118 | | | |
| | | | | 118 | | | |
| | | | | 118 | | | |
| | | | | 119 | | |
| | | | | 120 | | | |
| | | | | 120 | | | |
| | | | | 120 | | | |
| | | | | 122 | | | |
| | | | | 123 | | | |
| | | | | 124 | | | |
| | | | | 128 | | | |
| | | | | 128 | | | |
| | | | | 129 | | | |
| | | | | 129 | | | |
| | | | | 129 | | | |
| | | | | 130 | | | |
| | | | | 131 | | | |
| | | | | 131 | | | |
| | | | | 131 | | | |
| | | | | 133 | | | |
| | | | | 133 | | | |
| | | | | 133 | | | |
| | | | | 134 | | | |
| | | | | 135 | | | |
| | | | | 135 | | | |
| | | | | 135 | | | |
| | | | | 135 | | | |
| | | | | 136 | | | |
| | | | | 136 | | | |
| | | | | 137 | | | |
| | | | | 137 | | | |
| | | | | 137 | | | |
| | | | | 140 | | | |
| | | | | 141 | | | |
| | | | | 141 | | | |
| | | | | 142 | | | |
| | | | | 142 | | | |
| | | | | 142 | | | |
| | | | | 142 | | | |
| | | | | 143 | | | |
| | | | | 143 | | | |
| | | | | 143 | | | |
| | | | | 143 | | | |
| | | | | 144 | | | |
| | | | | 144 | | | |
| | | | | 144 | | | |
| | | | | 147 | | | |
| | | | | 147 | | |
| | | | | 148 | | | |
| | | | | 148 | | | |
| | | | | 148 | | | |
| | | | | 148 | | | |
| | | | | 148 | | | |
| | | | | 149 | | | |
| | | | | 149 | | | |
| | | | | 149 | | | |
| | | | | 149 | | | |
| | | | | 149 | | | |
| | | | | 150 | | | |
| | | | | 152 | | | |
| | | | | 153 | | | |
| | | | | 154 | | | |
| | | | | 155 | | | |
| | | | | 160 | | | |
| | | | | 160 | | | |
| | | | | 160 | | | |
| | | | | 161 | | | |
| | | | | 161 | | | |
| | | | | 161 | | | |
| | | | | 162 | | | |
| | | | | 164 | | | |
| | | | | 164 | | | |
| | | | | 165 | | | |
| | | | | 166 | | | |
| | | | | 166 | | | |
| | | | | 167 | | | |
| | | | | 167 | | | |
| | | | | 167 | | | |
| | | | | 168 | | | |
| | | | | 170 | | | |
| | | | | 170 | | | |
| | | | | 170 | | | |
| | | | | 171 | | | |
| | | | | 172 | | | |
| | | | | 172 | | | |
| | | | | 172 | | | |
| | | | | 172 | | | |
| | | | | 173 | | |
| | | | | 174 | | | |
| | | | | 174 | | | |
| | | | | 175 | | | |
| | | | | 177 | | | |
| | | | | 181 | | | |
| | | | | 183 | | | |
| | | | | 188 | | | |
| | | | | 188 | | | |
| | | | | 188 | | | |
| | | | | 189 | | | |
| | | | | 190 | | | |
| | | | | 191 | | | |
| | | | | 192 | | | |
| | | | | 194 | | | |
| | | | | 204 | | | |
| | | | | 204 | | | |
| | | | | 204 | | | |
| | | | | 205 | | | |
| | | | | 206 | | | |
| | | | | 208 | | | |
| | | | | 210 | | | |
| | | | | 210 | | | |
| | | | | 210 | | | |
| | | | | 211 | | | |
| | | | | 211 | | | |
| | | | | 213 | | | |
| | | | | 214 | | | |
| | | | | 214 | | | |
| | | | | 216 | | | |
| | | | | 217 | | | |
| | | | | 219 | | | |
| | | | | 221 | | | |
| | | | | 221 | | | |
| | | | | 222 | | | |
| | | | | 224 | | | |
| | | | | 225 | | | |
| | | | | 225 | | | |
| | | | | 226 | | | |
| | | | | 226 | | | |
| | | | | 227 | | | |
| | | | | 227 | | |
| | | | | 227 | | | |
| | | | | 228 | | | |
| | | | | 228 | | | |
| | | | | 228 | | | |
| | | | | 230 | | | |
| | | | | 230 | | | |
| | | | | 231 | | | |
| | | | | 231 | | | |
| | | | | 237 | | | |
| | | | | 237 | | | |
| | | | | 240 | | | |
| | | | | 241 | | | |
| | | | | 241 | | | |
| | | | | 241 | | | |
| | | | | 241 | | | |
| | | | | 241 | | | |
| | | | | 242 | | | |
| | | | | 242 | | | |
| | | | | 243 | | | |
| | | | | 243 | | | |
| | | | | 243 | | | |
| | | | | 256 | | | |
| | | | | 260 | | | |
| | | | | 260 | | | |
| | | | | 262 | | | |
| | | | | 262 | | | |
| | | | | 263 | | | |
| | | | | 263 | | | |
| | | | | 263 | | | |
| | | | | 264 | | | |
| | | | | 264 | | | |
| | | | | 265 | | | |
| | | | | 265 | | | |
| | | | | 267 | | | |
| | | | | 267 | | | |
| | | | | 267 | | | |
| | | | | 268 | | | |
| | | | | 268 | | | |
| | | | | 270 | | | |
| | | | | 270 | | | |
| | | | | 270 | | | |
| | | | | 270 | | | |
| | | | | 271 | | |
| | | | | 272 | | | |
| | | | | 272 | | | |
| | | | | 273 | | | |
| | | | | 276 | | | |
| | | | | 276 | | | |
| | | | | 278 | | | |
| | | | | 278 | | | |
| | | | | 278 | | | |
| | | | | 279 | | | |
| | | | | 280 | | | |
| | | | | 281 | | | |
| | | | | 282 | | | |
| | | | | 283 | | | |
| | | | | 284 | | | |
| | | | | 285 | | | |
| | | | | 285 | | | |
| | | | | 287 | | | |
| | | | | 288 | | | |
| | | | | 289 | | | |
| | | | | F-1 | | | |
| | | | | F-3 | | | |
| | | | | F-4 | | | |
| | | | | F-5 | | | |
| | | | | F-6 | | | |
| | | | | F-18 | | | |
| | | | | F-19 | | | |
| | | | | F-20 | | | |
| | | | | F-21 | | | |
| | | | | F-36 | | | |
| | | | | F-37 | | | |
| | | | | F-38 | | | |
| | | | | F-39 | | | |
| | | | | F-62 | | | |
| | | | | F-63 | | | |
| | | | | F-64 | | | |
| | | | | F-65 | | |
| | |
Assuming
No Redemptions of Public Shares |
| |
Percentage
|
| |
Assuming
Maximum Redemptions of Public Shares |
| |
Percentage
|
| ||||||||||||
Butterfly stockholders
|
| | | | 118,401,695 | | | | | | 63% | | | | | | 118,401,695 | | | | | | 77% | | |
Public Stockholders
|
| | | | 41,400,000 | | | | | | 22% | | | | | | —(1) | | | | | | — | | |
PIPE Investors
|
| | | | 17,500,000 | | | | | | 9% | | | | | | 17,500,000 | | | | | | 11% | | |
Forward Purchasers
|
| | | | — | | | | | | — | | | | | | 7,500,000 | | | | | | 5% | | |
Initial Stockholders
|
| | | | 10,350,000 | | | | | | 6% | | | | | | 10,350,000 | | | | | | 7% | | |
| | | | | 187,651,695 | | | | | | 100% | | | | | | 153,751,695 | | | | | | 100% | | |
| | |
Assuming No
Redemptions of Public Shares |
| |
Assuming
Maximum Redemptions of Public Shares |
| ||||||
Entities controlled by Jonathan M. Rothberg, Ph.D.
|
| | | | 76.6% | | | | | | 80.6% | | |
Other Butterfly Stockholders
|
| | | | 13.3% | | | | | | 14.0% | | |
Public Stockholders
|
| | | | 6.0% | | | | | | — | | |
PIPE Investors
|
| | | | 2.5% | | | | | | 2.7% | | |
Forward Purchasers
|
| | | | — | | | | | | 1.1% | | |
Initial Stockholders
|
| | | | 1.5% | | | | | | 1.6% | | |
Total
|
| | | | 100% | | | | | | 100% | | |
(in millions)
|
| |
Assuming No
Redemptions of Public Shares |
| |
Assuming
Maximum Redemptions of Public Shares |
| ||||||
Sources | | | | | | | | | | | | | |
Butterfly Rollover Equity
|
| | | $ | 1,293.8(1) | | | | | $ | 1,293.8(1) | | |
Proceeds from Trust Account
|
| | | | 414.0 | | | | | | — | | |
Forward Purchase
|
| | | | — | | | | | | 75.0 | | |
PIPE Investors
|
| | | | 175.0 | | | | | | 175.0 | | |
Total Sources
|
| | | $ | 1,882.8 | | | | | $ | 1,543.8 | | |
Uses | | | | | | | | | | | | | |
Equity Consideration to Existing Investors
|
| | | $ | 1,293.8 | | | | | $ | 1,293.8 | | |
Cash to Balance Sheet
|
| | | | 549.0 | | | | | | 210.0 | | |
Estimated Transaction Costs
|
| | | | 40.0 | | | | | | 40.0 | | |
Total Uses
|
| | | $ | 1,882.8 | | | | | $ | 1,543.8 | | |
Statement of Operations Data:
|
| |
Three Months
Ended September 30, 2020 (unaudited) |
| |
Period from
February 4, 2020 (inception) to September 30, 2020 (unaudited) |
| |
Period from
February 4, 2020 (Inception) Through February 12, 2020 |
| |||||||||
Formation and operating costs
|
| | | $ | 462,905 | | | | | $ | 584,134 | | | | | $ | 1,000 | | |
Net loss
|
| | | $ | (327,036) | | | | | $ | (391,135) | | | | | $ | (1,000) | | |
Weighted average shares outstanding of Class A redeemable common stock
|
| | | | 41,400,000 | | | | | | 40,617,323 | | | | | | 0 | | |
Basic and diluted income per share, Class A
|
| | | $ | 0.00 | | | | | $ | 0.00 | | | | | $ | 0.00 | | |
Weighted average shares outstanding of Class B non-redeemable common stock(1)
|
| | | | 10,350,000 | | | | | | 10,350,000 | | | | | | 9,000,000 | | |
Basic and diluted net loss per share, Class B
|
| | | $ | (0.03) | | | | | $ | (0.04) | | | | | $ | (0.04) | | |
Condensed Balance Sheet Data (at period end)
|
| |
September 30, 2020
(unaudited) |
| |
February 12, 2020
|
| ||||||
Total Assets
|
| | | $ | 415,221,855 | | | | | $ | 95,303 | | |
Total Liabilities
|
| | | $ | 14,799,842 | | | | | $ | 71,303 | | |
Class A common stock, $0.0001 par value (excluding 39,542,201 shares subject to possible redemption at September 30, 2020)
|
| | | | 186 | | | | | | — | | |
Class A common stock, $0.0001 par value (including 39,542,201 shares subject to possible redemption at September 30, 2020)
|
| | | $ | 395,422,010 | | | | | $ | — | | |
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 10,350,000 shares issued and outstanding
|
| | | | 1,035 | | | | | | 1,035 | | |
Total Stockholders’ Equity
|
| | | $ | 5,000,003 | | | | | $ | 24,000 | | |
|
Cash Flow Data
|
| |
Period from
February 4, 2020 (inception) to September 30, 2020 (unaudited) |
| |
Period from
February 4, 2020 (Inception) Through February 12, 2020 |
| ||||||
Net cash used in operating activities
|
| | | $ | (544,046) | | | | | $ | — | | |
Net cash used in investing activities
|
| | | $ | (414,000,000) | | | | | $ | — | | |
Net cash provided by financing activities
|
| | | $ | 415,303,148 | | | | | $ | 20,000 | | |
| | |
Nine Months Ended September 30,
|
| |
Year Ended December 31,
|
| ||||||||||||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
Revenue | | | | $ | 30,597 | | | | | $ | 16,846 | | | | | $ | 27,583 | | | | | $ | 1,526 | | |
Cost of revenue
|
| | | | 100,519 | | | | | | 23,639 | | | | | | 48,478 | | | | | | 2,255 | | |
Total operating expenses
|
| | | | 69,486 | | | | | | 54,973 | | | | | | 81,401 | | | | | | 52,357 | | |
Loss from operations
|
| | | | (139,408) | | | | | | (61,766) | | | | | | (102,296) | | | | | | (53,086) | | |
Non-operating income (expense)
|
| | | | (363) | | | | | | 2,305 | | | | | | 2,599 | | | | | | 2,321 | | |
Loss before income taxes
|
| | | | (139,771) | | | | | | (59,461) | | | | | | (99,697) | | | | | | (50,765) | | |
Provision for income taxes
|
| | | | 32 | | | | | | — | | | | | | — | | | | | | — | | |
Net loss
|
| | | | (139,803) | | | | | | (59,461) | | | | | | (99,697) | | | | | | (50,765) | | |
| | |
As of September 30, 2020
|
| |
As of December 31,
|
| ||||||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| ||||||||||||
Cash and cash equivalents
|
| | | $ | 51,686 | | | | | $ | 90,002 | | | | | $ | 214,578 | | |
Total assets
|
| | | | 130,093 | | | | | | 165,137 | | | | | | 248,070 | | |
Total liabilities
|
| | | | 113,050 | | | | | | 16,478 | | | | | | 6,076 | | |
Convertible preferred stock
|
| | | | 360,937 | | | | | | 360,937 | | | | | | 360,937 | | |
Total stockholders' deficit
|
| | | | (343,894) | | | | | | (212,278) | | | | | | (118,943) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
(in thousands, except per share data)
|
| |
Longview
|
| |
Butterfly
|
| |
No redemption
scenario |
| |
Maximum redemption
scenario |
| ||||||||||||
Statement of Operations Data – For the Nine Months Ended September 30, 2020
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Revenue
|
| | | $ | — | | | | | $ | 30,597 | | | | | $ | 30,597 | | | | | $ | 30,597 | | |
Cost of revenue
|
| | | | — | | | | | | 100,519 | | | | | | 100,519 | | | | | | 100,519 | | |
Total operating expenses
|
| | | | 584 | | | | | | 69,486 | | | | | | 70,070 | | | | | | 70,070 | | |
Loss from operations
|
| | | | (584) | | | | | | (139,408) | | | | | | (139,992) | | | | | | (139,992) | | |
Net loss
|
| | | | (391) | | | | | | (139,803) | | | | | | (140,018) | | | | | | (140,018) | | |
Basic and diluted net loss per share
|
| | | | 0.00 | | | | | | (24.09) | | | | | | (0.75) | | | | | | (0.91) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
| | |
Longview
|
| |
Butterfly
|
| |
No redemption
scenario |
| |
Maximum redemption
scenario |
| ||||||||||||
Statement of Operations Data – For the Year Ended December 31, 2019
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Revenue
|
| | | $ | — | | | | | $ | 27,583 | | | | | $ | 27,583 | | | | | $ | 27,583 | | |
Cost of revenue
|
| | | | — | | | | | | 48,478 | | | | | | 48,478 | | | | | | 48,478 | | |
Total operating expenses
|
| | | | — | | | | | | 81,401 | | | | | | 81,401 | | | | | | 81,401 | | |
Loss from operations
|
| | | | — | | | | | | (102,296) | | | | | | (102,296) | | | | | | (102,296) | | |
Net loss
|
| | | | — | | | | | | (99,697) | | | | | | (99,697) | | | | | | (99,697) | | |
Basic and diluted net loss per share
|
| | | | n/a | | | | | | (17.73) | | | | | | (0.53) | | | | | | (0.65) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
(in thousands)
|
| |
Longview
|
| |
Butterfly
|
| |
No redemption
scenario |
| |
Maximum redemption
scenario |
| ||||||||||||
Balance Sheet Data – As of September 30, 2020 | | | | | | | | | | | | | | | | | | | | | | | | | |
Total current assets
|
| | | $ | 1,000 | | | | | $ | 72,794 | | | | | $ | 652,366 | | | | | $ | 313,144 | | |
Total assets
|
| | | | 415,222 | | | | | | 130,093 | | | | | | 709,665 | | | | | | 370,443 | | |
Total current liabilities
|
| | | | 310 | | | | | | 85,942 | | | | | | 86,252 | | | | | | 86,252 | | |
Total liabilities
|
| | | | 14,800 | | | | | | 113,050 | | | | | | 92,341 | | | | | | 92,341 | | |
Common stock, subject to possible redemption
|
| | | | 395,422 | | | | | | — | | | | | | — | | | | | | — | | |
Convertible preferred stock
|
| | | | — | | | | | | 360,937 | | | | | | — | | | | | | — | | |
Total stockholders’ equity (deficit)
|
| | | | 5,000 | | | | | | (343,894) | | | | | | 617,324 | | | | | | 278,102 | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
| | |
Longview
|
| |
Butterfly
|
| |
No redemption
scenario |
| |
Maximum redemption
scenario |
| ||||||||||||
For the Nine Months ended September 30, 2020 | | | | | | | | | | | | | | | | | | | | | | | | | |
Book value per share – basic and diluted(1)
|
| | | $ | 2.69 | | | | | $ | (58.63) | | | | | $ | 3.29 | | | | | $ | 1.81 | | |
Net loss per share – basic and diluted(2)
|
| | | $ | — | | | | | $ | (24.09) | | | | | $ | (0.75) | | | | | $ | (0.91) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
| | |
Longview
|
| |
Butterfly
|
| |
No redemption
scenario |
| |
Maximum redemption
scenario |
| ||||||||||||
For the Year Ended December 31, 2019 | | | | | | | | | | | | | | | | | | | | | | | | | |
Net loss per share – basic and diluted(2)
|
| | | | n/a | | | | | $ | (17.73) | | | | | $ | (0.53) | | | | | $ | (0.65) | | |
| | |
Butterfly
|
| |
High Growth
Med-Tech(1) |
| |
Software-as-a-
Service(2) |
| |
Disruptive
Technologies(3) |
| ||||||||||||
EV/2022E Revenue
|
| | | | 10.6x | | | | | | 15.1x | | | | | | 13.4x | | | | | | 21.4x | | |
Revenue CAGR 2020 – 2022E
|
| | | | 77% | | | | | | 34% | | | | | | 27% | | | | | | 46% | | |
| | |
2020
|
| |
2021
|
| |
2022
|
| |
2023
|
| |
2024
|
| |||||||||||||||
Revenue ($ in millions)
|
| | | $ | 44.0 | | | | | $ | 78.1 | | | | | $ | 137.9 | | | | | $ | 235.2 | | | | | $ | 334.0 | | |
% Year over year revenue growth
|
| | | | 60% | | | | | | 77% | | | | | | 77% | | | | | | 71% | | | | | | 42% | | |
% gross margin
|
| | | | NM | | | | | | 43% | | | | | | 51% | | | | | | 60% | | | | | | 68% | | |
Contribution from wearables
|
| | | | — | | | | | | — | | | | | | — | | | | | | 5% | | | | | | 10% | | |
(in millions)
|
| |
Assuming No
Redemptions of Public Shares |
| |
Assuming
Maximum Redemptions of Public Shares |
| ||||||
Sources | | | | | | | | | | | | | |
Butterfly Rollover Equity
|
| | | $ | 1,293.8(1) | | | | | $ | 1,293.8(1) | | |
Proceeds from Trust Account
|
| | | | 414.0 | | | | | | — | | |
Forward Purchase
|
| | | | — | | | | | | 75.0 | | |
PIPE Investors
|
| | | | 175.0 | | | | | | 175.0 | | |
Total Sources
|
| | | $ | 1,882.8 | | | | | $ | 1,543.8 | | |
Uses | | | | | | | | | | | | | |
Equity Consideration to Existing Investors
|
| | | $ | 1,293.8 | | | | | $ | 1,293.8 | | |
Cash to Balance Sheet
|
| | | | 549.0 | | | | | | 210.0 | | |
Estimated Transaction Costs
|
| | | | 40.0 | | | | | | 40.0 | | |
Total Uses
|
| | | $ | 1,882.8 | | | | | $ | 1,543.8 | | |
|
Advisory Charter Amendment Proposal
|
| |
Longview Current
Charter/Bylaws |
| |
Proposed Charter/Bylaws
|
|
|
Advisory Proposal A – Changes in Share Capital
|
| | Under the Current Charter, Longview is currently authorized to issue 221,000,000 shares of capital stock, consisting of (a) 220,000,000 shares of common stock, including 200,000,000 shares of Class A common stock, par value $0.0001 per share, and 20,000,000 shares of Class B common stock, par value $0.0001 per share, and (b) 1,000,000 shares of preferred stock, par value $0.0001 per share. | | | Under the Proposed Charter, New Butterfly will be authorized to issue 628,000,000 shares of capital stock, consisting of (i) 600,000,000 shares of New Butterfly Class A common stock, par value $0.0001 per share, (ii) 27,000,000 shares of New Butterfly Class B common stock, par value $0.0001 per share, and (iii) 1,000,000 shares of preferred stock, par value $0.0001 per share. | |
|
Advisory Proposal B – Voting Rights of Common Stock
|
| | Under the Current Charter, the holders of Class A and Class B common stock are entitled to one vote for each such share on each matter properly submitted to Longview’s stockholders entitled to vote. | | | Under the Proposed Charter, holders of New Butterfly Class A common stock will be entitled to cast one vote per share of New Butterfly Class A common stock, while holders of New Butterfly Class B common stock will be entitled to cast 20 votes per share of New Butterfly Class B common stock. | |
|
Advisory Proposal C – Limiting the Ability to Act by Written Consent
|
| | Under the Current Charter, there is no limitation on any action required or permitted to be taken by the stockholders of Longview being effected by written consent of the stockholders. Under the Longview Bylaws, any action required or permitted to be taken at any annual or special meeting of stockholders may be taken by written consent if such written | | | Under the Proposed Charter, any action required or permitted to be taken by the stockholders of New Butterfly must be effected at an annual or special meeting of the stockholders and may not be effected by written consent; provided, however, prior to the first date on which the issued and outstanding shares of New Butterfly Class B common stock | |
|
Advisory Charter Amendment Proposal
|
| |
Longview Current
Charter/Bylaws |
| |
Proposed Charter/Bylaws
|
|
| | | | consent is signed by the holders of outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. | | | represent less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors, any action required or permitted to be taken at any annual or special meeting of New Butterfly stockholders, may be taken by written consent if such written consent is signed by the holders of the outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such matter were present and voted. | |
|
Advisory Proposal D – Required Vote to Amend the Charter
|
| | The Current Charter provides that the Current Charter may be amended in accordance with Delaware law; provided that, prior to an initial business combination, any amendment to the Current Charter that would alter or change the provisions relating to an initial business combination requires the affirmative vote of the holders of at least 65% of all common stock then outstanding. | | | Under the Proposed Charter, in addition to any vote required by Delaware law, (i) so long as any shares of New Butterfly Class B common stock remain outstanding, the affirmative vote of the holders of two-thirds (2/3) of the outstanding shares of New Butterfly Class B common stock, voting as a separate class, is required to amend the Proposed Charter (1) in a manner that changes any of the voting, conversion, dividend or liquidation provisions of the shares of New Butterfly Class B common stock or other rights, powers, preferences or privileges of the shares of Class B common stock, (2) to provide for each share of New Butterfly Class A common stock or any Preferred Stock to have more than one (1) vote per share or any rights to a separate class vote of the holders of shares of New Butterfly Class A common stock other than as provided by the Proposed Charter or required by the DGCL, or (3) to otherwise adversely impact the rights, powers, preferences or privileges of the shares of New Butterfly | |
|
Advisory Charter Amendment Proposal
|
| |
Longview Current
Charter/Bylaws |
| |
Proposed Charter/Bylaws
|
|
| | | | | | | Class B common stock in a manner that is disparate from the manner in which it affects the rights, powers, preferences or privileges of the shares of New Butterfly Class A common stock; and (ii) so long as any shares of New Butterfly Class A common stock remain outstanding, the affirmative vote of the holders of a majority of the outstanding shares of New Butterfly Class A common stock, voting as a separate class, is required to amend the Proposed Charter (1) in a manner that alters or changes the powers, preferences, or special rights of the shares of New Butterfly Class A common stock so as to affect them adversely; or (2) to provide for each share of New Butterfly Class B common stock to have more than twenty (20) votes per share or any rights to a separate class vote of the holders of shares of New Butterfly Class B common stock other than as provided by the Proposed Charter or required by the DGCL. | |
|
Advisory Proposal E – Required Vote to Amend the Bylaws
|
| | Under the Current Charter, the Longview Board is expressly authorized to adopt, alter, amend or repeal the Bylaws by the affirmative vote of a majority of the directors. The Bylaws may also be adopted, amended, altered or repealed by the affirmative vote of at least a majority of the voting power of all of the then outstanding shares of capital stock of Longview entitled to vote generally in the election of directors, voting together as a single class. | | | Under the Proposed Charter, the New Butterfly Board is expressly authorized to adopt, alter, amend or repeal the Bylaws by the affirmative vote of a majority of the directors. The Bylaws may also be amended (i) when outstanding Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors, the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the capital stock of New Butterfly or, prior to such time (ii) the affirmative vote of the holders of a majority of the voting power of the outstanding capital stock of New Butterfly. | |
|
Advisory Charter Amendment Proposal
|
| |
Longview Current
Charter/Bylaws |
| |
Proposed Charter/Bylaws
|
|
|
Advisory Proposal F – Required Vote to Change Number of Directors
|
| | Under the Current Charter, the number of directors of Longview, other than those who may be elected by the holders of one or more series of the preferred stock voting separately by class or series, will be fixed from time to time exclusively by the Longview Board pursuant to a resolution adopted by a majority of the Longview Board. | | | Under the Proposed Charter, the number of directors will be fixed from time to time by the New Butterfly Board; provided that, unless approved (i) when outstanding Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors, by the affirmative vote of the holders of at least two-thirds (2/3) of the voting power of the capital stock of New Butterfly or, prior to such time (ii) by the affirmative vote of the holders of a majority of the voting power of the outstanding capital stock of New Butterfly, the number of directors shall not exceed seven (7). | |
| | |
Longview
(Historical) |
| |
Butterfly
(Historical) |
| |
Butterfly
Adjustments (Note 3) |
| |
Butterfly
(Adjusted) |
| |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||||||||||||||
|
Pro Forma
Adjustments |
| |
Note 4
|
| |
Pro Forma
|
| |
Pro Forma
Adjustments |
| |
Note 4
|
| |
Pro Forma
|
| ||||||||||||||||||||||||||||||||||||||
ASSETS | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 759 | | | | | $ | 51,686 | | | | | $ | 29,350 | | | | | $ | 81,036 | | | | | $ | 549,222 | | | |
(a),(b)
|
| | | $ | 631,017 | | | | | $ | 210,000 | | | |
(a),(b)
|
| | | $ | 291,795 | | |
Accounts receivable, net
|
| | | | — | | | | | | 2,828 | | | | | | — | | | | | | 2,828 | | | | | | — | | | | | | | | | 2,828 | | | | | | — | | | | | | | | | 2,828 | | |
Inventories
|
| | |
|
—
|
| | | | | 14,942 | | | | | | — | | | | | | 14,942 | | | | | | — | | | | | | | | | 14,942 | | | | | | — | | | | | | | | | 14,942 | | |
Current portion of vendor
advances |
| | | | — | | | | | | 236 | | | | | | — | | | | | | 236 | | | | | | — | | | | | | | | | 236 | | | | | | — | | | | | | | | | 236 | | |
Prepaid expenses and other current assets
|
| | | | 241 | | | | | | 2,656 | | | | | | — | | | | | | 2,656 | | | | | | — | | | | | | | | | 2,897 | | | | | | — | | | | | | | | | 2,897 | | |
Due from related parties
|
| | | | — | | | | | | 446 | | | | | | — | | | | | | 446 | | | | | | — | | | | | | | | | 446 | | | | | | — | | | | | | | | | 446 | | |
Total current assets
|
| | | | 1,000 | | | | | | 72,794 | | | | | | 29,350 | | | | | | 102,144 | | | | | | 549,222 | | | | | | | | | 652,366 | | | | | | 210,000 | | | | | | | | | 313,144 | | |
Property and equipment, net
|
| | | | — | | | | | | 6,881 | | | | | | — | | | | | | 6,881 | | | | | | — | | | | | | | | | 6,881 | | | | | | — | | | | | | | | | 6,881 | | |
Investments held in Trust
Account |
| | | | 414,222 | | | | | | — | | | | | | — | | | | | | — | | | | | | (414,222) | | | |
(c)
|
| | | | — | | | | | | (414,222) | | | |
(c)
|
| | | | — | | |
Security deposits and non-current portion of vendor advances
|
| | | | — | | | | | | 48,837 | | | | | | — | | | | | | 48,837 | | | | | | — | | | | | | | | | 48,837 | | | | | | — | | | | | | | | | 48,837 | | |
Other assets – related party
|
| | | | — | | | | | | 1,581 | | | | | | — | | | | | | 1,581 | | | | | | — | | | | | | | | | 1,581 | | | | | | — | | | | | | | | | 1,581 | | |
Total assets
|
| | | $ | 415,222 | | | | | $ | 130,093 | | | | | $ | 29,350 | | | | | $ | 159,443 | | | | | $ | 135,000 | | | | | | | | $ | 709,665 | | | | | $ | (204,222) | | | | | | | | $ | 370,443 | | |
Liabilities, commitments and
contingencies and stockholders’ equity (deficit) |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Accounts payable
|
| | | | — | | | | | | 8,330 | | | | | | — | | | | | | 8,330 | | | | | | — | | | | | | | | | 8,330 | | | | | | — | | | | | | | | | 8,330 | | |
Deferred revenue, current
|
| | | | — | | | | | | 5,350 | | | | | | — | | | | | | 5,350 | | | | | | — | | | | | | | | | 5,350 | | | | | | — | | | | | | | | | 5,350 | | |
Due to related parties
|
| | | | — | | | | | | 7 | | | | | | — | | | | | | 7 | | | | | | — | | | | | | | | | 7 | | | | | | — | | | | | | | | | 7 | | |
Accrued purchase commitments, current
|
| | | | — | | | | | | 63,376 | | | | | | — | | | | | | 63,376 | | | | | | — | | | | | | | | | 63,376 | | | | | | — | | | | | | | | | 63,376 | | |
Accrued expenses and other current liabilities
|
| | | | 310 | | | | | | 8,879 | | | | | | — | | | | | | 8,879 | | | | | | — | | | | | | | | | 9,189 | | | | | | — | | | | | | | | | 9,189 | | |
Total current liabilities
|
| | | | 310 | | | | | | 85,942 | | | | | | — | | | | | | 85,942 | | | | | | — | | | | | | | | | 86,252 | | | | | | — | | | | | | | | | 86,252 | | |
Deferred revenue, non-current
|
| | | | — | | | | | | 1,099 | | | | | | — | | | | | | 1,099 | | | | | | — | | | | | | | | | 1,099 | | | | | | — | | | | | | | | | 1,099 | | |
Convertible debt
|
| | | | — | | | | | | 21,019 | | | | | | 30,070 | | | | | | 51,089 | | | | | | (51,089) | | | |
(d)
|
| | | | — | | | | | | (51,089) | | | |
(d)
|
| | | | — | | |
Loan payable
|
| | | | — | | | | | | 4,366 | | | | | | — | | | | | | 4,366 | | | | | | — | | | | | | | | | 4,366 | | | | | | — | | | | | | | | | 4,366 | | |
Other non-current liabilities
|
| | | | — | | | | | | 624 | | | | | | — | | | | | | 624 | | | | | | — | | | | | | | | | 624 | | | | | | — | | | | | | | | | 624 | | |
Deferred underwriting fee payable
|
| | | | 14,490 | | | | | | — | | | | | | — | | | | | | — | | | | | | (14,490) | | | |
(b)
|
| | | | — | | | | | | (14,490) | | | |
(b)
|
| | | | — | | |
Total liabilities
|
| | | | 14,800 | | | | | | 113,050 | | | | | | 30,070 | | | | | | 143,120 | | | | | | (65,579) | | | | | | | | | 92,341 | | | | | | (65,579) | | | | | | | | | 92,341 | | |
Commitments and contingencies | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Class A common stock, subject to possible redemption
|
| | | | 395,422 | | | | | | — | | | | | | — | | | | | | — | | | | | | (395,422) | | | |
(e)
|
| | | | — | | | | | | (395,422) | | | |
(e)
|
| | | | — | | |
Convertible preferred stock
|
| | | | — | | | | | | 360,937 | | | | | | — | | | | | | 360,937 | | | | | | (360,937) | | | |
(e)
|
| | | | — | | | | | | (360,937) | | | |
(e)
|
| | | | — | | |
Stockholders’ equity | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Common stock
|
| | | | — | | | | | | 1 | | | | | | — | | | | | | 1 | | | | | | (1) | | | |
(e)
|
| | | | — | | | | | | (1) | | | |
(e)
|
| | | | — | | |
Class A common stock
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 16 | | | |
(e)
|
| | | | 16 | | | | | | 12 | | | |
(e)
|
| | | | 12 | | |
Class B common stock
|
| | | | 1 | | | | | | — | | | | | | — | | | | | | — | | | | | | 2 | | | |
(e)
|
| | | | 3 | | | | | | 2 | | | |
(e)
|
| | | | 3 | | |
Additional paid-in capital
|
| | | | 5,390 | | | | | | 27,969 | | | | | | — | | | | | | 27,969 | | | | | | 956,530 | | | |
(e)
|
| | | | 989,889 | | | | | | 617,312 | | | |
(e)
|
| | | | 650,671 | | |
Accumulated deficit
|
| | | | (391) | | | | | | (371,864) | | | | | | (720) | | | | | | (372,584) | | | | | | 391 | | | |
(e)
|
| | | | (372,584) | | | | | | 391 | | | |
(e)
|
| | | | (372,584) | | |
Total stockholder’s equity
(deficit) |
| | | | 5,000 | | | | | | (343,894) | | | | | | (720) | | | | | | (344,614) | | | | | | 956,938 | | | | | | | | | 617,324 | | | | | | 617,716 | | | | | | | | | 278,102 | | |
Total liabilities, commitments and contingencies and stockholders’ equity (deficit)
|
| | | $ | 415,222 | | | | | $ | 130,093 | | | | | $ | 29,350 | | | | | $ | 159,443 | | | | | $ | 135,000 | | | | | | | | $ | 709,665 | | | | | $ | (204,222) | | | | | | | | $ | 370,443 | | |
|
| | | | | | | | | | | | | | |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||
| | |
Longview
(Historical) |
| |
Butterfly
(Historical) |
| |
Pro Forma
Adjustments |
| |
Note 4
|
| |
Pro Forma
|
| |
Pro Forma
Adjustments |
| |
Note 4
|
| |
Pro Forma
|
| ||||||||||||||||||
Revenue: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | $ | — | | | | | $ | 25,820 | | | | | $ | — | | | | | | | | $ | 25,820 | | | | | $ | — | | | | | | | | $ | 25,820 | | |
Subscription
|
| | | | — | | | | | | 4,777 | | | | | | — | | | | | | | | | 4,777 | | | | | | — | | | | | | | | | 4,777 | | |
Total revenue
|
| | | | — | | | | | | 30,597 | | | | | | — | | | | | | | | | 30,597 | | | | | | — | | | | | | | | | 30,597 | | |
Cost of revenue: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | | — | | | | | | 99,259 | | | | | | — | | | | | | | | | 99,259 | | | | | | — | | | | | | | | | 99,259 | | |
Subscription
|
| | | | — | | | | | | 1,260 | | | | | | — | | | | | | | | | 1,260 | | | | | | — | | | | | | | | | 1,260 | | |
Total cost of revenue
|
| | | | — | | | | | | 100,519 | | | | | | — | | | | | | | | | 100,519 | | | | | | — | | | | | | | | | 100,519 | | |
Gross margin
|
| | | | — | | | | | | (69,922) | | | | | | — | | | | | | | | | (69,922) | | | | | | — | | | | | | | | | (69,922) | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and
development |
| | | | — | | | | | | 36,427 | | | | | | — | | | | | | | | | 36,427 | | | | | | — | | | | | | | | | 36,427 | | |
Sales and marketing
|
| | | | — | | | | | | 17,408 | | | | | | — | | | | | | | | | 17,408 | | | | | | — | | | | | | | | | 17,408 | | |
General and administrative
|
| | | | — | | | | | | 15,651 | | | | | | — | | | | | | | | | 15,651 | | | | | | — | | | | | | | | | 15,651 | | |
Formation and operational costs
|
| | | | 584 | | | | | | — | | | | | | — | | | | | | | | | 584 | | | | | | — | | | | | | | | | 584 | | |
Total operating expenses
|
| | | | 584 | | | | | | 69,486 | | | | | | — | | | | | | | | | 70,070 | | | | | | — | | | | | | | | | 70,070 | | |
Loss from operations
|
| | | | (584) | | | | | | (139,408) | | | | | | — | | | | | | | | | (139,992) | | | | | | — | | | | | | | | | (139,992) | | |
Interest income
|
| | | | — | | | | | | 238 | | | | | | | | | | | | | | | 238 | | | | | | — | | | | | | | | | 238 | | |
Interest expense
|
| | |
|
—
|
| | | | | (418) | | | | | | 369 | | | |
(f)
|
| | | | (49) | | | | | | 369 | | | |
(f)
|
| | | | (49) | | |
Interest earned on marketable securities
held in Trust Account |
| | | | 222 | | | | | | — | | | | | | (222) | | | |
(g)
|
| | | | — | | | | | | (222) | | | |
(g)
|
| | | | — | | |
Other income (expense), net
|
| | | | — | | | | | | (183) | | | | | | — | | | | | | | | | (183) | | | | | | — | | | | | | | | | (183) | | |
Loss before provision for income
taxes |
| | | | (362) | | | | | | (139,771) | | | | | | 147 | | | | | | | | | (139,986) | | | | | | 147 | | | | | | | | | (139,986) | | |
Provision for income taxes
|
| | | | 29 | | | | | | 32 | | | | | | (29) | | | |
(g)
|
| | | | 32 | | | | | | (29) | | | |
(g)
|
| | | | 32 | | |
Net loss
|
| | | $ | (391) | | | | | $ | (139,803) | | | | | $ | 176 | | | | | | | | $ | (140,018) | | | | | $ | 176 | | | | | | | | $ | (140,018) | | |
Net loss per share | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Weighted average shares outstanding, basic and diluted
|
| | | | 40,617,323 | | | | | | 5,804,354 | | | | | | | | | |
(h)
|
| | | | 187,651,695 | | | | | | | | | |
(h)
|
| | | | 153,751,695 | | |
Basic and diluted net loss per
share |
| | | | 0.00 | | | | | | (24.09) | | | | | | | | | |
(h)
|
| | | | (0.75) | | | | | | | | | |
(h)
|
| | | | (0.91) | | |
| | | | | | | | | | | | | | |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||
| | |
Longview
(Historical) |
| |
Butterfly
(Historical) |
| |
Pro Forma
Adjustments |
| |
Note 4
|
| |
Pro Forma
|
| |
Pro Forma
Adjustments |
| |
Note 4
|
| |
Pro Forma
|
| ||||||||||||||||||
Revenue: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | $ | — | | | | | $ | 25,081 | | | | | $ | — | | | | | | | | $ | 25,081 | | | | | $ | — | | | | | | | | $ | 25,081 | | |
Subscription
|
| | | | — | | | | | | 2,502 | | | | | | — | | | | | | | | | 2,502 | | | | | | — | | | | | | | | | 2,502 | | |
Total revenue
|
| | | | — | | | | | | 27,583 | | | | | | — | | | | | | | | | 27,583 | | | | | | — | | | | | | | | | 27,583 | | |
Cost of revenue: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | | — | | | | | | 47,857 | | | | | | — | | | | | | | | | 47,857 | | | | | | — | | | | | | | | | 47,857 | | |
Subscription
|
| | | | — | | | | | | 621 | | | | | | — | | | | | | | | | 621 | | | | | | — | | | | | | | | | 621 | | |
Total cost of revenue
|
| | | | — | | | | | | 48,478 | | | | | | — | | | | | | | | | 48,478 | | | | | | — | | | | | | | | | 48,478 | | |
Gross margin
|
| | | | — | | | | | | (20,895) | | | | | | — | | | | | | | | | (20,895) | | | | | | — | | | | | | | | | (20,895) | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | | — | | | | | | 48,934 | | | | | | — | | | | | | | | | 48,934 | | | | | | — | | | | | | | | | 48,934 | | |
Sales and marketing
|
| | | | — | | | | | | 14,282 | | | | | | — | | | | | | | | | 14,282 | | | | | | — | | | | | | | | | 14,282 | | |
General and administrative
|
| | | | — | | | | | | 18,185 | | | | | | — | | | | | | | | | 18,185 | | | | | | — | | | | | | | | | 18,185 | | |
Total operating expenses
|
| | | | — | | | | | | 81,401 | | | | | | — | | | | | | | | | 81,401 | | | | | | — | | | | | | | | | 81,401 | | |
Loss from operations
|
| | | | — | | | | | | (102,296) | | | | | | — | | | | | | | | | (102,296) | | | | | | — | | | | | | | | | (102,296) | | |
Interest income
|
| | | | — | | | | | | 2,695 | | | | | | — | | | | | | | | | 2,695 | | | | | | — | | | | | | | | | 2,695 | | |
Other income (expense), net
|
| | | | — | | | | | | (96) | | | | | | — | | | | | | | | | (96) | | | | | | — | | | | | | | | | (96) | | |
Loss before provision for income
taxes |
| | | | — | | | | | | (99,697) | | | | | | — | | | | | | | | | (99,697) | | | | | | — | | | | | | | | | (99,697) | | |
Provision for income taxes
|
| | | | — | | | | | | — | | | | | | — | | | | | | | | | — | | | | | | — | | | | | | | | | — | | |
Net loss
|
| | | $ | — | | | | | $ | (99,697) | | | | | $ | — | | | | | | | | $ | (99,697) | | | | | $ | — | | | | | | | | $ | (99,697) | | |
Net loss per share | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Weighted average shares outstanding, basic and diluted
|
| | | | n/a | | | | | | 5,622,752 | | | | | | | | | |
(h)
|
| | | | 187,651,695 | | | | | | | | | |
(h)
|
| | | | 153,751,695 | | |
Basic and diluted net loss per share
|
| | | | n/a | | | | | | (17.73) | | | | | | | | | |
(h)
|
| | | | (0.53) | | | | | | | | | |
(h)
|
| | | | (0.65) | | |
| | |
No redemption scenario
|
| |
Maximum redemption scenario
|
| ||||||||||||||||||||||||||||||
| | |
Shares
|
| |
Ownership,
% |
| |
Voting rights,
% |
| |
Shares
|
| |
Ownership,
% |
| |
Voting rights,
% |
| ||||||||||||||||||
Butterfly stockholders
|
| | | | 118,401,695 | | | | | | 63.10% | | | | | | 89.96% | | | | | | 118,401,695 | | | | | | 77.01% | | | | | | 94.61% | | |
Public Stockholders
|
| | | | 41,400,000 | | | | | | 22.06% | | | | | | 6.00% | | | | | | — | | | | | | 0.00% | | | | | | 0.00% | | |
Initial Stockholders
|
| | | | 10,350,000 | | | | | | 5.52% | | | | | | 1.50% | | | | | | 10,350,000 | | | | | | 6.73% | | | | | | 1.58% | | |
PIPE Investors
|
| | | | 17,500,000 | | | | | | 9.32% | | | | | | 2.54% | | | | | | 17,500,000 | | | | | | 11.38% | | | | | | 2.67% | | |
Forward Purchasers
|
| | | | — | | | | | | 0.00% | | | | | | 0.00% | | | | | | 7,500,000 | | | | | | 4.88% | | | | | | 1.14% | | |
Total
|
| | |
|
187,651,695
|
| | | |
|
100%
|
| | | |
|
100%
|
| | | |
|
153,751,695
|
| | | |
|
100%
|
| | | |
|
100%
|
| |
(in thousands)
|
| |
Note
|
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||
Longview cash held in Trust Account
|
| |
(1)
|
| | | | 414,222 | | | | | | 414,222 | | |
PIPE Financing
|
| |
(2)
|
| | | | 175,000 | | | | | | 175,000 | | |
Proceeds from Forward Purchase Agreement
|
| |
(3)
|
| | | | — | | | | | | 75,000 | | |
Payment to redeeming Public Stockholders
|
| |
(4)
|
| | | | — | | | | | | (414,222) | | |
Payment of deferred underwriting fees
|
| |
(5)
|
| | | | (14,490) | | | | | | (14,490) | | |
Payment of other transaction costs
|
| |
(6)
|
| | | | (25,510) | | | | | | (25,510) | | |
Excess cash to balance sheet from Business Combination
|
| | | | | | $ | 549,222 | | | | | $ | 210,000 | | |
| | |
Number of Shares
|
| |
Par Value
|
| | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||
(in thousands, except share amounts)
|
| |
Class A
common stock |
| |
Class B
common stock |
| |
Class A
common stock, subject to possible redemption |
| |
Class A
common stock |
| |
Class B
common stock |
| |
Class A
common stock, subject to possible redemption |
| |
Butterfly’s
convertible preferred stock and common stock |
| |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |||||||||||||||||||||||||||
Longview common stock as of September 30,2020 – pre Business Combination
|
| | | | 1,857,799 | | | | | | 10,350,000 | | | | | | 39,542,201 | | | | | $ | — | | | | | $ | 1 | | | | | $ | 395,422 | | | | | $ | — | | | | | $ | 5,390 | | | | | $ | (391) | | |
Butterfly equity as of September 30,2020 – pre Business Combination, as adjusted
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 360,938 | | | | | | 27,969 | | | | | | (372,584) | | |
Pro forma adjustments: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Reclassification of Longview’s redeemable shares to Class A common stock
|
| | | | 39,542,201 | | | | | | — | | | | | | (39,542,201) | | | | | | 4 | | | | | | — | | | | | | (395,422) | | | | | | — | | | | | | 395,418 | | | | | | — | | |
Initial Stockholders
|
| | | | 10,350,000 | | | | | | (10,350,000) | | | | | | — | | | | | | 1 | | | | | | (1) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
PIPE Investors
|
| | | | 17,500,000 | | | | | | — | | | | | | — | | | | | | 2 | | | | | | — | | | | | | — | | | | | | — | | | | | | 174,998 | | | | | | — | | |
Butterfly stockholders
|
| | | | 91,974,758 | | | | | | 26,426,937 | | | | | | — | | | | | | 9 | | | | | | 3 | | | | | | — | | | | | | — | | | | | | 51,077 | | | | | | — | | |
Estimated transaction costs
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (25,510) | | | | | | — | | |
Elimination of historical accumulated
deficit of Longview |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (391) | | | | | | 391 | | |
Elimination of historical Butterfly convertible preferred stock and common stock
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (360,938) | | | | | | 360,938 | | | | | | — | | |
Total pro forma adjustments
|
| | | | 159,366,959 | | | | | | 16,076,937 | | | | | | (39,542,201) | | | | | | 16 | | | | | | 2 | | | | | | (395,422) | | | | | | (360,938) | | | | | | 956,530 | | | | | | 391 | | |
Post-Business Combination
|
| | | | 161,224,758 | | | | | | 26,426,937 | | | | | $ | — | | | | | $ | 16 | | | | | $ | 3 | | | | | $ | — | | | | | $ | — | | | | | $ | 989,889 | | | | | $ | (372,584) | | |
|
| | |
Number of Shares
|
| |
Par Value
|
| | | | | | | | | | | | | | | | | | | | | | | | | ||||||||||||||||||||||||
(in thousands, except share amounts)
|
| |
Class A
common stock |
| |
Class B
common stock |
| |
Class A
common stock, subject to possible redemption |
| |
Class A
common stock |
| |
Class B
common stock |
| |
Class A
common stock, subject to possible redemption |
| |
Butterfly’s
convertible preferred stock and common stock |
| |
Additional
paid-in capital |
| |
Accumulated
deficit |
| |||||||||||||||||||||||||||
Longview equity as of September 30,2020 – pre Business Combination
|
| | | | 1,857,799 | | | | | | 10,350,000 | | | | | | 39,542,201 | | | | | $ | — | | | | | $ | 1 | | | | | $ | 395,422 | | | | | $ | — | | | | | | 5,390 | | | | | $ | (391) | | |
Butterfly equity as of September 30,2020 – pre Business Combination, as adjusted
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 360,938 | | | | | | 27,969 | | | | | | (372,584) | | |
Pro forma adjustments: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Reclassification of Longview’s redeemable
shares to Class A common stock |
| | | | 39,542,201 | | | | | | — | | | | | | (39,542,201) | | | | | | 4 | | | | | | — | | | | | | (395,422) | | | | | | — | | | | | | 395,418 | | | | | | — | | |
Less: Redemption of redeemable stock
|
| | | | (41,400,000) | | | | | | — | | | | | | — | | | | | | (4) | | | | | | — | | | | | | — | | | | | | — | | | | | | (414,218) | | | | | | — | | |
Initial Stockholders
|
| | | | 10,350,000 | | | | | | (10,350,000) | | | | | | — | | | | | | 1 | | | | | | (1) | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
PIPE Investors
|
| | | | 17,500,000 | | | | | | — | | | | | | — | | | | | | 2 | | | | | | — | | | | | | — | | | | | | — | | | | | | 174,998 | | | | | | — | | |
Forward Purchasers
|
| | | | 7,500,000 | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 75,000 | | | | | | — | | |
Butterfly stockholders
|
| | | | 91,974,758 | | | | | | 26,426,937 | | | | | | — | | | | | | 9 | | | | | | 3 | | | | | | — | | | | | | — | | | | | | 51,077 | | | | | | — | | |
Estimated transaction costs
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (25,510) | | | | | | — | | |
Elimination of historical accumulated deficit of Longview
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (391) | | | | | | 391 | | |
Elimination of historical Butterfly
convertible preferred stock and common stock |
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (360,938) | | | | | | 360,938 | | | | | | — | | |
Total pro forma adjustments
|
| | | | 125,466,959 | | | | | | 16,076,937 | | | | | | (39,542,201) | | | | | | 12 | | | | | | 2 | | | | | | (395,422) | | | | | | (360,938) | | | | | | 617,312 | | | | | | 391 | | |
Post-Business Combination
|
| | | | 127,324,758 | | | | | | 26,426,937 | | | | | | — | | | | | $ | 12 | | | | | $ | 3 | | | | | | — | | | | | $ | — | | | | | $ | 650,671 | | | | | | (372,584) | | |
|
Name
|
| |
Age
|
| |
Position
|
|
Larry Robbins | | |
51
|
| | Chairman | |
John Rodin | | |
45
|
| | Chief Executive Officer and Director | |
Mark Horowitz | | |
49
|
| | Chief Financial Officer | |
Westley Moore | | |
42
|
| | Director | |
Derek Cribbs | | |
49
|
| | Director | |
Randy Simpson | | |
51
|
| | Director | |
Statement of Operations Data:
|
| |
Three Months
Ended September 30, 2020 (unaudited) |
| |
Period from
February 4, 2020 (inception) to September 30, 2020 (unaudited) |
| |
Period from
February 4, 2020 (Inception) Through February 12, 2020 |
| |||||||||
Formation and operating costs
|
| | | $ | 462,905 | | | | | $ | 584,134 | | | | | $ | 1,000 | | |
Net loss
|
| | | $ | (327,036) | | | | | $ | (391,135) | | | | | $ | (1,000) | | |
Weighted average shares outstanding of Class A redeemable common stock
|
| | | | 41,400,000 | | | | | | 40,617,323 | | | | | | 0 | | |
Basic and diluted income per share, Class A
|
| | | $ | 0.00 | | | | | $ | 0.00 | | | | | $ | 0.00 | | |
Weighted average shares outstanding of Class B non-redeemable common stock(1)
|
| | | | 10,350,000 | | | | | | 10,350,000 | | | | | | 9,000,000 | | |
Basic and diluted net loss per share, Class B
|
| | | $ | (0.03) | | | | | $ | (0.04) | | | | | $ | (0.04) | | |
Condensed Balance Sheet Data (at period end)
|
| |
September 30, 2020
(unaudited) |
| |
February 12, 2020
|
| ||||||
Total Assets
|
| | | $ | 415,221,855 | | | | | $ | 95,303 | | |
Total Liabilities
|
| | | $ | 14,799,842 | | | | | $ | 71,303 | | |
Class A common stock, $0.0001 par value (excluding 39,542,201 shares subject to possible redemption at September 30, 2020)
|
| | | | 186 | | | | | | — | | |
Class A common stock, $0.0001 par value (including 39,542,201 shares subject to possible redemption at September 30, 2020)
|
| | | $ | 395,422,010 | | | | | $ | — | | |
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 10,350,000 shares issued and outstanding
|
| | | | 1,035 | | | | | | 1,035 | | |
Total Stockholders’ Equity
|
| | | $ | 5,000,003 | | | | | $ | 24,000 | | |
|
Cash Flow Data
|
| |
Period from
February 4, 2020 (inception) to September 30, 2020 (unaudited) |
| |
Period from
February 4, 2020 (Inception) Through February 12, 2020 |
| ||||||
Net cash used in operating activities
|
| | | $ | (544,046) | | | | | $ | — | | |
Net cash used in investing activities
|
| | | $ | (414,000,000) | | | | | $ | — | | |
Net cash provided by financing activities
|
| | | $ | 415,303,148 | | | | | $ | 20,000 | | |
| | |
Nine Months Ended
September 30, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
Revenue | | | | $ | 30,597 | | | | | $ | 16,846 | | | | | $ | 27,583 | | | | | $ | 1,526 | | |
Cost of revenue
|
| | | | 100,519 | | | | | | 23,639 | | | | | | 48,478 | | | | | | 2,255 | | |
Total operating expenses
|
| | | | 69,486 | | | | | | 54,973 | | | | | | 81,401 | | | | | | 52,357 | | |
Loss from operations
|
| | | | (139,408) | | | | | | (61,766) | | | | | | (102,296) | | | | | | (53,086) | | |
Non-operating income (expense)
|
| | | | (363) | | | | | | 2,305 | | | | | | 2,599 | | | | | | 2,321 | | |
Loss before income taxes
|
| | | | (139,771) | | | | | | (59,461) | | | | | | (99,697) | | | | | | (50,765) | | |
Provision for income taxes
|
| | | | 32 | | | | | | — | | | | | | — | | | | | | — | | |
Net loss
|
| | | | (139,803) | | | | | | (59,461) | | | | | | (99,697) | | | | | | (50,765) | | |
(in thousands)
|
| |
As of
September 30, 2020 |
| |
As of December 31,
|
| ||||||||||||
|
2019
|
| |
2018
|
| ||||||||||||||
Cash and cash equivalents
|
| | | $ | 51,686 | | | | | $ | 90,002 | | | | | $ | 214,578 | | |
Total assets
|
| | | | 130,093 | | | | | | 165,137 | | | | | | 248,070 | | |
Total liabilities
|
| | | | 113,050 | | | | | | 16,478 | | | | | | 6,076 | | |
Convertible preferred stock
|
| | | | 360,937 | | | | | | 360,937 | | | | | | 360,937 | | |
Total stockholders' deficit
|
| | | | (343,894) | | | | | | (212,278) | | | | | | (118,943) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
(in thousands, except per share data)
|
| |
Longview
|
| |
Butterfly
|
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||
Statement of Operations Data – For the Nine Months Ended
September 30, 2020 |
| | | | | | | | | | | | | | | | | | | | | | | | |
Revenue
|
| | | $ | — | | | | | $ | 30,597 | | | | | $ | 30,597 | | | | | $ | 30,597 | | |
Cost of revenue
|
| | | | — | | | | | | 100,519 | | | | | | 100,519 | | | | | | 100,519 | | |
Total operating expenses
|
| | | | 584 | | | | | | 69,486 | | | | | | 70,070 | | | | | | 70,070 | | |
Loss from operations
|
| | | | (584) | | | | | | (139,408) | | | | | | (139,992) | | | | | | (139,992) | | |
Net loss
|
| | | | (391) | | | | | | (139,803) | | | | | | (140,018) | | | | | | (140,018) | | |
Basic and diluted net loss per share
|
| | | | 0.00 | | | | | | (24.09) | | | | | | (0.75) | | | | | | (0.91) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
| | |
Longview
|
| |
Butterfly
|
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||
Statement of Operations Data – For the Year Ended December 31, 2019
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Revenue
|
| | | $ | — | | | | | $ | 27,583 | | | | | $ | 27,583 | | | | | $ | 27,583 | | |
Cost of revenue
|
| | | | — | | | | | | 48,478 | | | | | | 48,478 | | | | | | 48,478 | | |
Total operating expenses
|
| | | | — | | | | | | 81,401 | | | | | | 81,401 | | | | | | 81,401 | | |
Loss from operations
|
| | | | — | | | | | | (102,296) | | | | | | (102,296) | | | | | | (102,296) | | |
Net loss
|
| | | | — | | | | | | (99,697) | | | | | | (99,697) | | | | | | (99,697) | | |
Basic and diluted net loss per share
|
| | | | n/a | | | | | | (17.73) | | | | | | (0.53) | | | | | | (0.65) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
(in thousands)
|
| |
Longview
|
| |
Butterfly
|
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||
Balance Sheet Data – As of September 30, 2020 | | | | | | | | | | | | | | | | | | | | | | | | | |
Total current assets
|
| | | $ | 1,000 | | | | | $ | 72,794 | | | | | $ | 652,366 | | | | | $ | 313,144 | | |
Total assets
|
| | | | 415,222 | | | | | | 130,093 | | | | | | 709,665 | | | | | | 370,443 | | |
Total current liabilities
|
| | | | 310 | | | | | | 85,942 | | | | | | 86,252 | | | | | | 86,252 | | |
Total liabilities
|
| | | | 14,800 | | | | | | 113,050 | | | | | | 92,341 | | | | | | 92,341 | | |
Common stock, subject to possible redemption
|
| | | | 395,422 | | | | | | — | | | | | | — | | | | | | — | | |
Convertible preferred stock
|
| | | | — | | | | | | 360,937 | | | | | | — | | | | | | — | | |
Total stockholders’ equity (deficit)
|
| | | | 5,000 | | | | | | (343,894) | | | | | | 617,324 | | | | | | 278,102 | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
| | |
Longview
|
| |
Butterfly
|
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||
For the Nine Months ended September 30, 2020 | | | | | | | | | | | | | | | | | | | | | | | | | |
Book value per share – basic and diluted(1)
|
| | | $ | 2.69 | | | | | $ | (58.63) | | | | | $ | (3.29) | | | | | $ | 1.81 | | |
Net loss per share – basic and diluted(2)
|
| | | $ | — | | | | | $ | (24.09) | | | | | $ | (0.75) | | | | | $ | (0.91) | | |
| | |
Historical
|
| |
Pro forma
|
| ||||||||||||||||||
| | |
Longview
|
| |
Butterfly
|
| |
No
redemption scenario |
| |
Maximum
redemption scenario |
| ||||||||||||
For the Year Ended December 31, 2019
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Net loss per share – basic and diluted(2)
|
| | | | n/a | | | | | $ | (17.73) | | | | | $ | (0.53) | | | | | $ | (0.65) | | |
| | |
Nine Months Ended
September 30, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
| | |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
Units fulfilled
|
| | | | 12,564 | | | | | | 7,928 | | | | | | 12,941 | | | | | | 782 | | |
| | |
Nine Months Ended
September 30, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
| | |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
Subscription Mix
|
| | | | 15.6% | | | | | | 8.6% | | | | | | 9.1% | | | | | | 0.7% | | |
| | |
Nine Months Ended
September 30, |
| |
Year Ended
December 31, |
| ||||||||||||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
2019
|
| |
2018
|
| ||||||||||||
Net loss
|
| | | | (139,803) | | | | | | (59,461) | | | | | | (99,697) | | | | | | (50,765) | | |
Interest income
|
| | | | (238) | | | | | | (2,332) | | | | | | (2,695) | | | | | | (2,321) | | |
Interest expense
|
| | | | 418 | | | | | | — | | | | | | — | | | | | | — | | |
Other expense, net
|
| | | | 183 | | | | | | 27 | | | | | | 96 | | | | | | — | | |
Provision for income taxes
|
| | | | 32 | | | | | | — | | | | | | — | | | | | | — | | |
Depreciation and amortization
|
| | | | 904 | | | | | | 497 | | | | | | 758 | | | | | | 391 | | |
Stock based compensation
|
| | | | 7,727 | | | | | | 4,112 | | | | | | 6,038 | | | | | | 5,589 | | |
Losses on purchase commitments
|
| | | | 63,993 | | | | | | — | | | | | | 9,500 | | | | | | — | | |
Inventory write-down
|
| | | | 2,570 | | | | | | — | | | | | | — | | | | | | — | | |
Adjusted EBITDA
|
| | | | (64,214) | | | | | | (57,157) | | | | | | (86,000) | | | | | | (47,106) | | |
| | |
Nine Months Ended September 30,
|
| |
Year Ended December 31,
|
| ||||||||||||||||||||||||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
%
|
| |
2019
|
| |
2018
|
| |
%
|
| ||||||||||||||||||
Revenue: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | | 25,820 | | | | | | 15,405 | | | | | | 67.6% | | | | | | 25,081 | | | | | | 1,516 | | | | | | 1544.4% | | |
Subscription
|
| | | | 4,777 | | | | | | 1,441 | | | | | | 231.5% | | | | | | 2,502 | | | | | | 10 | | | | | | 24920.0% | | |
Total revenue:
|
| | | | 30,597 | | | | | | 16,846 | | | | | | 81.6% | | | | | | 27,583 | | | | | | 1,526 | | | | | | 1707.5% | | |
Cost of revenue: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Product (including losses on purchase commitments of $64.0 million for nine months ended September 30, 2020 and $9.5 million for the year ended December 31, 2019)
|
| | | | 99,259 | | | | | | 23,212 | | | | | | 327.6% | | | | | | 47,857 | | | | | | 2,079 | | | | | | 2201.9% | | |
Subscription
|
| | | | 1,260 | | | | | | 427 | | | | | | 195.1% | | | | | | 621 | | | | | | 176 | | | | | | 252.8% | | |
Total cost of revenue:
|
| | | | 100,519 | | | | | | 23,639 | | | | | | 325.2% | | | | | | 48,478 | | | | | | 2,255 | | | | | | 2049.8% | | |
Gross margin
|
| | | | (69,922) | | | | | | (6,793) | | | | | | 929.3% | | | | | | (20,895) | | | | | | (729) | | | | | | 2766.3% | | |
Operating expenses: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Research and development
|
| | | | 36,427 | | | | | | 34,593 | | | | | | 5.3% | | | | | | 48,934 | | | | | | 34,954 | | | | | | 40.0% | | |
Sales and marketing
|
| | | | 17,408 | | | | | | 8,216 | | | | | | 111.9% | | | | | | 14,282 | | | | | | 6,075 | | | | | | 135.1% | | |
General and administrative
|
| | | | 15,651 | | | | | | 12,164 | | | | | | 28.7% | | | | | | 18,185 | | | | | | 11,328 | | | | | | 60.5% | | |
Total operating expenses
|
| | | | 69,486 | | | | | | 54,973 | | | | | | 26.4% | | | | | | 81,401 | | | | | | 52,357 | | | | | | 55.5% | | |
Loss from operations
|
| | | | (139,408) | | | | | | (61,766) | | | | | | 125.7% | | | | | | (102,296) | | | | | | (53,086) | | | | | | 92.7% | | |
Interest income
|
| | | | 238 | | | | | | 2,332 | | | | | | (89.8)% | | | | | | 2,695 | | | | | | 2,321 | | | | | | 16.1% | | |
Interest expense
|
| | | | (418) | | | | | | — | | | | | | 100.0% | | | | | | — | | | | | | — | | | | | | — | | |
Other income (expense), net
|
| | | | (183) | | | | | | (27) | | | | | | 577.8% | | | | | | (96) | | | | | | — | | | | | | 100.0% | | |
Loss before provision for income taxes
|
| | | | (139,771) | | | | | | (59,461) | | | | | | 135.1% | | | | | | (99,697) | | | | | | (50,765) | | | | | | 96.4% | | |
Provision for income taxes
|
| | | | 32 | | | | | | — | | | | | | 100% | | | | | | — | | | | | | — | | | | | | 0% | | |
Net loss
|
| | | | (139,803) | | | | | | (59,461) | | | | | | 135.1% | | | | | | (99,697) | | | | | | (50,765) | | | | | | 96.4% | | |
|
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Revenue: | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | | 25,820 | | | | | | 15,405 | | | | | | 10,415 | | | | | | 67.6% | | |
Subscription
|
| | | | 4,777 | | | | | | 1,441 | | | | | | 3,336 | | | | | | 231.5% | | |
Total revenue:
|
| | | $ | 30,597 | | | | | $ | 16,846 | | | | | $ | 13,751 | | | | | | 81.6% | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Cost of revenue: | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | | 99,259 | | | | | | 23,212 | | | | | | 76,047 | | | | | | 327.6% | | |
Subscription
|
| | | | 1,260 | | | | | | 427 | | | | | | 833 | | | | | | 195.1% | | |
Total cost of revenue
|
| | | $ | 100,519 | | | | | $ | 23,639 | | | | | $ | 76,880 | | | | | | 325.2% | | |
Percentage of Revenue
|
| | | | 328.5% | | | | | | 140.3% | | | | | | | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Research and development
|
| | | $ | 36,427 | | | | | $ | 34,593 | | | | | $ | 1,834 | | | | | | 5.3% | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||
Percentage of Revenue
|
| | | | 119.1% | | | | | | 205.3% | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Sales and marketing
|
| | | $ | 17,408 | | | | | $ | 8,216 | | | | | $ | 9,192 | | | | | | 111.9% | | |
Percentage of Revenue
|
| | | | 56.9% | | | | | | 48.8% | | | | | | | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
General and administrative
|
| | | $ | 15,651 | | | | | $ | 12,164 | | | | | $ | 3,487 | | | | | | 28.7% | | |
Percentage of Revenue
|
| | | | 51.2% | | | | | | 72.2% | | | | | | | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Interest income
|
| | | $ | 238 | | | | | $ | 2,332 | | | | | $ | (2,094) | | | | | | (89.8)% | | |
Percentage of Revenue
|
| | | | 0.8% | | | | | | 13.8% | | | | | | | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Interest expense
|
| | | $ | (418) | | | | | $ | — | | | | | $ | 418 | | | | | | 100.0% | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||
Percentage of Revenue
|
| | | | (1.4)% | | | | | | — | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Other income (expense), net
|
| | | $ | (183) | | | | | $ | (27) | | | | | $ | 156 | | | | | | 577.8% | | |
Percentage of Revenue
|
| | | | (0.6)% | | | | | | (0.2)% | | | | | | | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2020
|
| |
2019
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Provision for income taxes
|
| | | $ | 32 | | | | | $ | — | | | | | $ | 32 | | | | | | 100.0% | | |
| | |
Year Ended December 31,
|
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Cost of revenue | | | | | | | | | | | | | | | | | | | | | | | | | |
Product
|
| | | $ | 47,857 | | | | | $ | 2,079 | | | | | $ | 45,778 | | | | | | 2201.9% | | |
Subscription
|
| | | $ | 621 | | | | | $ | 176 | | | | | $ | 445 | | | | | | 252.8% | | |
Total cost of revenue
|
| | | $ | 48,478 | | | | | $ | 2,255 | | | | | $ | 46,223 | | | | | | 2049.8% | | |
Percentage of Revenue
|
| | | | 175.8% | | | | | | 147.8% | | | | | | | | | | | | | | |
| | |
Year Ended December 31,
|
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Research and development
|
| | | $ | 48,934 | | | | | $ | 34,954 | | | | | $ | 13,980 | | | | | | 40.0% | | |
Percentage of Revenue
|
| | | | 177.4% | | | | | | 2290.6% | | | | | | | | | | | | | | |
| | |
Year Ended December 31,
|
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Sales and marketing
|
| | | $ | 14,282 | | | | | $ | 6,075 | | | | | $ | 8,207 | | | | | | 135.1% | | |
Percentage of Revenue
|
| | | | 51.8% | | | | | | 398.1% | | | | | | | | | | | | | | |
| | |
Year Ended December 31,
|
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| |
Change
|
| |
% Change
|
| ||||||||||||
General and administrative
|
| | | $ | 18,185 | | | | | $ | 11,328 | | | | | $ | 6,857 | | | | | | 60.5% | | |
Percentage of Revenue
|
| | | | 65.9% | | | | | | 742.3% | | | | | | | | | | | | | | |
| | |
Year Ended December 31,
|
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Interest income
|
| | | $ | 2,695 | | | | | $ | 2,321 | | | | | $ | 374 | | | | | | 16.1% | | |
Percentage of Revenue
|
| | | | 9.8% | | | | | | 152.1% | | | | | | | | | | | | | | |
| | |
Year Ended December 31,
|
| | | | | | | | | | | | | |||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| |
Change
|
| |
% Change
|
| ||||||||||||
Other income (expense), net
|
| | | $ | (96) | | | | | $ | — | | | | | $ | 96 | | | | | | 100.0% | | |
Percentage of Revenue
|
| | | | (0.3)% | | | | | | — | | | | | | | | | | | | | | |
| | |
Nine Months Ended
September 30, |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Net cash used in operating activities
|
| | | | (61,077) | | | | | | (98,008) | | |
Net cash used in investing activities
|
| | | | (2,597) | | | | | | (2,477) | | |
Net cash provided by financing activities
|
| | | | 25,358 | | | | | | 201 | | |
Net decrease in cash and cash equivalents
|
| | | | (38,316) | | | | | | (100,284) | | |
| | |
Year Ended December 31,
|
| |||||||||
(in thousands)
|
| |
2019
|
| |
2018
|
| ||||||
Net cash used in operating activities
|
| | | | (120,432) | | | | | | (69,581) | | |
Net cash used in investing activities
|
| | | | (4,468) | | | | | | (1,098) | | |
Net cash provided by financing activities
|
| | | | 324 | | | | | | 247,843 | | |
Net (decrease) increase in cash and cash equivalents
|
| | | | (124,576) | | | | | | 177,164 | | |
(in thousands)
|
| |
Total
|
| |
< 1 Year
|
| |
1-3 Years
|
| |
3-5 Years
|
| |
> 5 Years
|
| |||||||||||||||
Operating leases(1)
|
| | | | 16,908 | | | | | | 1,634 | | | | | | 3,392 | | | | | | 3,609 | | | | | | 8,273 | | |
Purchase obligations(2)(3)
|
| | | | 35,320 | | | | | | 21,410 | | | | | | 13,910 | | | | | | | | | | | | | | |
Total contractual obligations
|
| | | | 52,228 | | | | | | 23,044 | | | | | | 17,302 | | | | | | 3,609 | | | | | | 8,273 | | |
Redemption Date
(period to expiration of warrants) |
| |
≤ 10.00
|
| |
11.00
|
| |
12.00
|
| |
13.00
|
| |
14.00
|
| |
15.00
|
| |
16.00
|
| |
17.00
|
| |
≥ 18.00
|
| |||||||||||||||||||||||||||
57 months
|
| | | | 0.257 | | | | | | 0.277 | | | | | | 0.294 | | | | | | 0.310 | | | | | | 0.324 | | | | | | 0.337 | | | | | | 0.348 | | | | | | 0.358 | | | | | | 0.365 | | |
54 months
|
| | | | 0.252 | | | | | | 0.272 | | | | | | 0.291 | | | | | | 0.307 | | | | | | 0.322 | | | | | | 0.335 | | | | | | 0.347 | | | | | | 0.357 | | | | | | 0.365 | | |
51 months
|
| | | | 0.246 | | | | | | 0.268 | | | | | | 0.287 | | | | | | 0.304 | | | | | | 0.320 | | | | | | 0.333 | | | | | | 0.346 | | | | | | 0.357 | | | | | | 0.365 | | |
48 months
|
| | | | 0.241 | | | | | | 0.263 | | | | | | 0.283 | | | | | | 0.301 | | | | | | 0.317 | | | | | | 0.332 | | | | | | 0.344 | | | | | | 0.356 | | | | | | 0.365 | | |
45 months
|
| | | | 0.235 | | | | | | 0.258 | | | | | | 0.279 | | | | | | 0.298 | | | | | | 0.315 | | | | | | 0.330 | | | | | | 0.343 | | | | | | 0.356 | | | | | | 0.365 | | |
42 months
|
| | | | 0.228 | | | | | | 0.252 | | | | | | 0.274 | | | | | | 0.294 | | | | | | 0.312 | | | | | | 0.328 | | | | | | 0.342 | | | | | | 0.355 | | | | | | 0.364 | | |
39 months
|
| | | | 0.221 | | | | | | 0.246 | | | | | | 0.269 | | | | | | 0.290 | | | | | | 0.309 | | | | | | 0.325 | | | | | | 0.340 | | | | | | 0.354 | | | | | | 0.364 | | |
36 months
|
| | | | 0.213 | | | | | | 0.239 | | | | | | 0.263 | | | | | | 0.285 | | | | | | 0.305 | | | | | | 0.323 | | | | | | 0.339 | | | | | | 0.353 | | | | | | 0.364 | | |
33 months
|
| | | | 0.205 | | | | | | 0.232 | | | | | | 0.257 | | | | | | 0.280 | | | | | | 0.301 | | | | | | 0.320 | | | | | | 0.337 | | | | | | 0.352 | | | | | | 0.364 | | |
30 months
|
| | | | 0.196 | | | | | | 0.224 | | | | | | 0.250 | | | | | | 0.274 | | | | | | 0.297 | | | | | | 0.316 | | | | | | 0.335 | | | | | | 0.351 | | | | | | 0.364 | | |
27 months
|
| | | | 0.185 | | | | | | 0.214 | | | | | | 0.242 | | | | | | 0.268 | | | | | | 0.291 | | | | | | 0.313 | | | | | | 0.332 | | | | | | 0.350 | | | | | | 0.364 | | |
24 months
|
| | | | 0.173 | | | | | | 0.204 | | | | | | 0.233 | | | | | | 0.260 | | | | | | 0.285 | | | | | | 0.308 | | | | | | 0.329 | | | | | | 0.348 | | | | | | 0.364 | | |
21 months
|
| | | | 0.161 | | | | | | 0.193 | | | | | | 0.223 | | | | | | 0.252 | | | | | | 0.279 | | | | | | 0.304 | | | | | | 0.326 | | | | | | 0.347 | | | | | | 0.364 | | |
18 months
|
| | | | 0.146 | | | | | | 0.179 | | | | | | 0.211 | | | | | | 0.242 | | | | | | 0.271 | | | | | | 0.298 | | | | | | 0.322 | | | | | | 0.345 | | | | | | 0.363 | | |
15 months
|
| | | | 0.130 | | | | | | 0.164 | | | | | | 0.197 | | | | | | 0.230 | | | | | | 0.262 | | | | | | 0.291 | | | | | | 0.317 | | | | | | 0.342 | | | | | | 0.363 | | |
12 months
|
| | | | 0.111 | | | | | | 0.146 | | | | | | 0.181 | | | | | | 0.216 | | | | | | 0.250 | | | | | | 0.282 | | | | | | 0.312 | | | | | | 0.339 | | | | | | 0.363 | | |
9 months
|
| | | | 0.090 | | | | | | 0.125 | | | | | | 0.162 | | | | | | 0.199 | | | | | | 0.237 | | | | | | 0.272 | | | | | | 0.305 | | | | | | 0.336 | | | | | | 0.362 | | |
6 months
|
| | | | 0.065 | | | | | | 0.099 | | | | | | 0.137 | | | | | | 0.178 | | | | | | 0.219 | | | | | | 0.259 | | | | | | 0.296 | | | | | | 0.331 | | | | | | 0.362 | | |
3 months
|
| | | | 0.034 | | | | | | 0.065 | | | | | | 0.104 | | | | | | 0.150 | | | | | | 0.197 | | | | | | 0.243 | | | | | | 0.286 | | | | | | 0.326 | | | | | | 0.361 | | |
0 months
|
| | | | — | | | | | | — | | | | | | 0.042 | | | | | | 0.115 | | | | | | 0.179 | | | | | | 0.233 | | | | | | 0.281 | | | | | | 0.323 | | | | | | 0.361 | | |
|
Longview
|
| |
New Butterfly
|
|
|
Authorized Capital Stock
|
| |||
| Longview is currently authorized to issue 221,000,000 shares of capital stock, consisting of (a) 220,000,000 shares of common stock, including 200,000,000 shares of Class A common stock and 20,000,000 shares of Class B common stock, and (b) 1,000,000 shares of preferred stock. | | |
New Butterfly will be authorized to issue 628,000,000 shares of capital stock, consisting of (i) 600,000,000 shares of New Butterfly Class A common stock, par value $0.0001 per share, (ii) 27,000,000 shares of New Butterfly Class B common stock, par value $0.0001 per share, and (iii) 1,000,000 shares of preferred stock, par value $0.0001 per share.
Upon consummation of the Business Combination, based on an assumed Closing Date of January 31, 2021, we expect there will be 161,224,758 shares of New Butterfly Class A common stock and 26,426,937 shares of New Butterfly Class B common stock (in each case, assuming no redemptions) outstanding. Following consummation of the Business Combination, New Butterfly is not expected to have any preferred stock outstanding.
|
|
|
Rights of Preferred Stock
|
| |||
| The Longview Board may fix for any series of preferred stock such voting powers, full or limited, or no voting powers, and such preferences, designations, powers and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as may be stated in the resolutions of the Longview Board providing for the issuance of such series. | | | The New Butterfly Board may fix for any class or series of preferred stock such voting powers, full or limited, or no voting powers, and such designations, preferences and relative, participating, optional or other special rights and such qualifications, limitations or restrictions thereof, as may be stated in the resolutions of the New Butterfly Board providing for the issuance of such class or series. | |
|
Longview
|
| |
New Butterfly
|
|
|
Number and Qualification of Directors
|
| |||
| The number of directors of Longview, other than those who may be elected by the holders of one or more series of preferred stock voting separately by class or series, will be fixed from time to time exclusively by the Longview Board pursuant to a resolution adopted by a majority of the Longview Board. | | |
Subject to any rights of holders of preferred stock to elect directors under specified circumstances, the number of directors will be fixed from time to time pursuant to a resolution adopted by the New Butterfly Board, provided further, that unless approved by the holders of a majority in voting power of the shares of capital stock (prior to the Voting Threshold Date, as defined below) or the holders of two-thirds (2/3) of the voting power of the shares of capital stock (after the Voting Threshold Date), the number of directors shall not exceed seven (7).
The Voting Threshold Date is the first date on which the issued and outstanding shares of New Butterfly Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would then be entitled to vote for the election of directors.
|
|
|
Classification of the Board of Directors
|
| |||
| The Current Charter provides that directors are elected annually for a term of one year. | | | Delaware law permits a corporation to classify its board of directors into as many as three classes with staggered terms of office. However, the Proposed Charter does not provide for a classified board of directors, and thus all directors will be elected each year for one-year terms. | |
|
Election of Directors
|
| |||
|
At Longview’s annual meeting, stockholders elect directors to hold office until the next annual meeting, or until his or her successor is duly elected and qualified, subject to such director’s earlier death, resignation or removal.
The election of directors shall be determined by a plurality of the votes cast at an annual meeting of stockholders by holders of Longview’s common stock.
|
| |
The stockholders shall elect directors each of whom shall hold office for a term of one year until the next annual meeting of stockholders or until his or her successor is duly elected and qualified, subject to such director’s earlier death, resignation, disqualification or removal.
At stockholder meetings for the election of directors, the vote required for election of a director shall, except in a contested election, be the affirmative vote of a majority of the votes cast in favor or against the election of a nominee.
In a contested election, the directors shall be elected by a plurality of the votes cast at a meeting of stockholders by the holders of stock entitled to vote in such election, and stockholders will not be permitted to vote against a nominee. An election is considered contested if, as of the tenth (10th) day preceding the date that New Butterfly first mails its notice of meeting for such meeting to the stockholders of New Butterfly, there are more nominees for election than directorships to be filled by election at the meeting.
|
|
|
Longview
|
| |
New Butterfly
|
|
| | | | New Butterfly will not be permitted to authorize or issue any shares of any class or series of capital stock entitling the holder thereof to more than one (1) vote for each share or entitling any class or series of securities to designate or elect directors as a class or series separate from the New Butterfly Class A common stock and the New Butterfly Class B common stock. | |
|
Removal of Directors
|
| |||
| Subject to the rights of the holders of any series of preferred stock, any or all of the directors may be removed from office at any time, with or without cause, by the affirmative vote of holders of a majority of the voting power of all then outstanding shares of capital stock entitled to vote generally in the election of directors, voting together as a single class. | | |
Subject to the rights of the holders of any series of preferred stock (as set forth in a New Butterfly Preferred Stock Designation and adopted in compliance with the Proposed Charter), any director or the entire New Butterfly Board may be removed from office at any time with or without cause and for any or no reason and immediately upon the approval of the holders of a majority in voting power of the shares of capital stock (prior to the Voting Threshold Date) or the holders of two-thirds (2/3) of the voting power of the shares of capital stock (after the Voting Threshold Date).
The Voting Threshold Date is the first date on which the issued and outstanding shares of New Butterfly Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would then be entitled to vote for the election of directors.
|
|
|
Voting
|
| |||
|
Except as otherwise required by law or the Current Charter, holders of the Longview Class A common stock and the Longview Class B common stock possess all voting power with respect to Longview. The holders of shares of Longview common stock shall be entitled to one vote for each such share on each matter properly submitted to Longview’s stockholders on which the holders of shares of Longview common stock are entitled to vote.
Except as otherwise required by applicable law, holders of Longview Class A common stock and Longview Class B common stock are not entitled to vote on any amendment to the Current Charter that relates solely to the terms of one or more outstanding series of Longview preferred stock if the holders of such affected series of Longview preferred stock are entitled, either separately or together with the holders of one or more other such series, to vote thereon pursuant to the Current Charter or applicable law.
|
| |
Holders of New Butterfly Class A common stock will be entitled to cast one (1) vote per Class A share, while holders of New Butterfly Class B common stock will be entitled to cast twenty (20) votes per share of New Butterfly Class B common stock. Except as otherwise required by law or the Proposed Charter, holders of all classes of New Butterfly common stock vote together as a single class, while directors are elected by a plurality of the votes cast in contested elections.
Except as otherwise required by applicable law, holders of New Butterfly Class A common stock and New Butterfly Class B common stock will not be entitled to vote on any amendment to the Proposed Charter that relates solely to the terms of one or more outstanding series of New Butterfly preferred stock if the holders of such affected series of New Butterfly preferred stock are exclusively entitled to vote thereon pursuant to the Proposed Charter or applicable law.
|
|
|
Longview
|
| |
New Butterfly
|
|
|
Cumulative Voting
|
| |||
| Delaware law allows for cumulative voting only if provided for in the Current Charter; however, the Current Charter does not authorize cumulative voting. | | | Delaware law allows for cumulative voting only if provided for in the Proposed Charter; however, the Proposed Charter does not authorize cumulative voting. | |
|
Vacancies on the Board of Directors
|
| |||
|
Subject to the rights of the holders of any series of preferred stock, newly created directorships resulting from an increase in the number of directors and any vacancies on the board resulting from death, resignation, retirement, disqualification, removal or other cause are filled by a majority vote of the remaining directors then in office, even if less than a quorum or by a sole remaining director.
Any director so chosen will hold office for the remainder of the one-year term and until his or her successor has been elected and qualified, subject, however, to such director’s earlier death, resignation, retirement, disqualification or removal.
|
| | Any newly created directorship on the New Butterfly Board that results from an increase in the number of directors and any vacancy occurring in the New Butterfly Board may be filled by (i) prior to the first date on which the issued and outstanding shares of New Butterfly Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors at an annual meeting of stockholders, solely by the stockholders of New Butterfly with the majority in voting power of the shares of capital stock of New Butterfly that would be entitled to vote in the election of directors at an annual meeting of stockholders; or (ii) on or after the first date on which the issued and outstanding shares of New Butterfly Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors at an annual meeting of stockholders, solely by the affirmative vote of a majority of the directors then in office, even if less than a quorum or by a sole remaining director, provided, however, prior to the Voting Threshold Date, any vacancy may be filled by the holders of a majority in voting power of the shares of capital stock of New Butterfly that would be then entitled to vote in the election of directors at an annual meeting of stockholders. | |
|
Special Meeting of the Board of Directors
|
| |||
| Special meetings of the Longview Board may be called by the Chairman of the Board, President or Secretary on the written request of at least a majority of directors then in office, or the sole director, as the case may be. | | | Special meetings of the New Butterfly Board may be called by the Chairperson of the Board, the Chief Executive Officer, the affirmative vote of a majority of the directors then in office, or by one director in the event there is only a single director in office. | |
|
Stockholder Action by Written Consent
|
| |||
| Under the Current Charter, there is no limitation on any action required or permitted to be taken by the stockholders of Longview being effected by written consent of the stockholders. Under Longview’s Bylaws, any action required to be taken at any annual or special meeting of stockholders, or any action which may be taken at any annual or special meeting of such stockholders, may be taken without | | | Subject to the terms of any series of preferred stock, any action required or permitted to be taken by the stockholders of New Butterfly must be effected at an annual or special meeting of the stockholders and may not be effected by written consent; provided however, prior to the Voting Threshold Date, any action required or permitted to be taken at any annual or special meeting of New Butterfly | |
|
Longview
|
| |
New Butterfly
|
|
| a meeting, without prior notice and without a vote, if a consent in writing, setting forth the action so taken, shall be signed by the holders of outstanding stock entitled to vote on such matters having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote thereon were present and voted. | | |
stockholders, may be taken by written consent if such written consent is signed by the holders of the outstanding stock having not less than the minimum number of votes that would be necessary to authorize or take such action at a meeting at which all shares entitled to vote on such matter were present and voted.
The Voting Threshold Date is the first date on which the issued and outstanding shares of New Butterfly Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors at an annual meeting of stockholders.
|
|
|
Amendment to Certificate of Incorporation
|
| |||
|
Pursuant to Delaware law, an amendment to a charter generally requires the approval of the Longview Board and a majority of the combined voting power of the then-outstanding shares of voting stock, voting together as a single class.
Article IX of the Current Charter relating to business combination requirements may not be amended prior to the consummation of the initial business combination unless approved by the affirmative vote of the holders of at least 65% of all then outstanding shares of Longview common stock.
|
| |
Under the Proposed Charter, so long as any shares of New Butterfly Class B common stock remain outstanding, the New Butterfly shall not, without the prior affirmative vote of the holders of two-thirds (2/3) of the outstanding shares of New Butterfly Class B common stock, voting as a separate class, in addition to any other vote required by applicable law or the Proposed Charter, amend the Proposed Charter (1) in a manner that changes any of the voting, conversion, dividend or liquidation provisions of the shares of New Butterfly Class B common stock or other rights, powers, preferences or privileges of the shares of Class B common stock, (2) to provide for each share of New Butterfly Class A common stock or preferred stock to have more than one (1) vote per share or any rights to a separate class vote of the holders of shares of New Butterfly Class A common stock other than as provided by the Proposed Charter or required by the DGCL or (3) otherwise adversely impact the rights, powers, preferences or privileges of the shares of New Butterfly Class B common stock in a manner that is disparate from the manner in which it affects the rights, powers, preferences or privileges of the shares of New Butterfly Class A common stock.
Under the Proposed Charter so long as any shares of New Butterfly Class A common stock remain outstanding, the prior affirmative vote of the holders of a majority of the outstanding shares of New Butterfly Class A common stock, voting as a separate class, in addition to any other vote required by applicable law or the Proposed Charter, is required to amend the Proposed Charter (1) in a manner that alters or changes the powers, preferences, or special rights of the shares of New Butterfly Class A common stock so as to affect
|
|
|
Longview
|
| |
New Butterfly
|
|
| | | |
them adversely; or (2) to provide for each share of New Butterfly Class B common stock to have more than twenty (20) votes per share or any rights to a separate class vote of the holders of shares of New Butterfly Class B common stock other than as provided by the Proposed Charter or required by the DGCL.
Amending the Proposed Charter to modify a provision providing for specific approval requirements by the New Butterfly stockholders (or any class of capital stock of the New Butterfly) must be approved by the greater of (i) the specific approval requirement contemplated in such provision or (ii) the approval requirements generally required to amend the Proposed Charter.
|
|
|
Amendment of the Bylaws
|
| |||
| The Longview Board is expressly authorized to make, alter, amend or repeal the amended and restated Bylaws by the affirmative vote of a majority of the Longview Board. The Bylaws may also be adopted, amended, altered or repealed by the Longview stockholders representing a majority of the voting power of all of the then-outstanding shares of capital stock of Longview entitled to vote generally in the election of directors. | | |
The New Butterfly Board is expressly authorized to make, alter, amend or repeal the Bylaws by the affirmative vote of a majority of the directors, provided that the changes are not in any manner inconsistent with the laws of the State of Delaware or the Proposed Charter.
New Butterfly stockholders may not adopt, amend, alter or repeal any provision of the Bylaws unless such action is approved by the holders of a majority in voting power of the shares of capital stock of New Butterfly that would then be entitled to vote in the election of directors at an annual meeting or if after the Voting Threshold Date, by the holders of two-thirds (2/3) of the voting power of the shares of capital stock of New Butterfly.
The Voting Threshold Date is the first date on which the issued and outstanding shares of New Butterfly Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors.
|
|
|
Quorum
|
| |||
|
Board of Directors. A majority of the Longview Board constitutes a quorum at any meeting of the Longview Board.
Stockholders. The presence, in person or by proxy, at a stockholders meeting of the holders of shares of outstanding capital stock representing a majority of the voting power of all outstanding shares of capital stock entitled to vote at such meeting constitutes a quorum; expect that when specified business is to be voted on by a class or series of stock voting as a class, the holders of shares representing a majority of the voting power of the
|
| |
Board of Directors. The greater of (i) a majority of directors at any time in office and (ii) one-third (1/3) of the number of directors established by the New Butterfly Board in Section 2.2 of the New Butterfly Bylaws pertaining to the number of directors constituting the New Butterfly Board, shall constitute a quorum of the New Butterfly Board.
Stockholders. The presence, in person or by proxy, at a stockholders meeting of the holders of shares of issued and outstanding capital stock of New Butterfly representing a majority of the voting power of all issued and outstanding shares of
|
|
|
Longview
|
| |
New Butterfly
|
|
| outstanding shares of such class or series will constitute a quorum. | | | capital stock of New Butterfly entitled to vote at such meeting constitutes a quorum; provided, however, that where a separate vote by a class or classes of capital stock is required, the holders of a majority in voting power of the shares of such class and entitled to vote on such matter, present in person or represented by proxy, shall constitute a quorum. | |
|
Interested Directors
|
| |||
| Longview renounces any expectancy that any of the Longview directors or officers will offer any corporate opportunity in which he or she may become aware to Longview, except with respect to any of the directors or officers of Longview with respect to a corporate opportunity that was offered to such person solely in his or her capacity as a director or officer of Longview and (i) such opportunity is one that Longview is legally and contractually permitted to undertake and would otherwise be reasonable for Longview to pursue and (ii) to the extent the director or officer is permitted to refer that opportunity to Longview without violating another legal obligation. | | | New Butterfly renounces any interest or expectancy of New Butterfly in, or in being offered an opportunity to participate in, any matter, transaction or interest that is presented to, or acquired, created or developed by, or which otherwise comes into the possession of, any director of New Butterfly who is not an employee of New Butterfly or any of its subsidiaries, unless such matter, transaction or interest is presented to, or acquired, created or developed by, or otherwise comes into the possession of, such person expressly and solely in such person’s capacity as a director of New Butterfly. | |
|
Special Stockholder Meeting
|
| |||
| The Longview Bylaws provide that a special meeting of stockholders may be called by the Chairman of the Board, Chief Executive Officer of Longview, or the Longview Board pursuant to a resolution adopted by a majority of the members of the Longview board then in office. | | |
Special meetings of the New Butterfly stockholders may be called at any time by the New Butterfly Board, the Chairperson of the New Butterfly Board or the Chief Executive Officer of New Butterfly; provided that until such time as no New Butterfly Class B common stock is outstanding, special meetings of stockholder may be called for any purpose or purposes by, if prior to the Voting Threshold Date, the holders of a majority in voting power of the shares of capital stock of New Butterfly that would then be entitled to vote in the election of directors at an annual meeting or if after the Voting Threshold Date, by the holders of two-thirds (2/3) of the voting power of the shares of capital stock of New Butterfly.
The Voting Threshold Date is the first date on which the issued and outstanding shares of New Butterfly Class B common stock represents less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would be entitled to vote for the election of directors.
|
|
|
Notice of Stockholder Meeting
|
| |||
| Written notice stating the place, if any, date and time of each meeting of Longview’s stockholders, the means of remote communication, if any, by which stockholders and proxy holders may be deemed to be present in person and vote at such | | | Except as otherwise provided by law or the Proposed Charter or New Butterfly Bylaws, notice of each meeting of the New Butterfly stockholders, whether annual or special, shall be given not less than ten (10) nor more than sixty (60) days before | |
|
Longview
|
| |
New Butterfly
|
|
|
meeting and the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting) must be delivered not less than ten (10) nor more than sixty (60) days before the date of the meeting, unless otherwise required by Delaware law.
Whenever notice is required to be given to any Longview stockholder, such notice may be given (i) in writing and sent either by hand delivery, through the United States mail, or by a nationally recognized overnight delivery service for next day delivery, or (ii) by means of a form of electronic transmission consented to by the stockholder, to the extent permitted by, and subject to the conditions set forth in Section 232 of the DGCL.
|
| |
the date of the meeting to each stockholder entitled to vote at such meeting as of the record date for determining the New Butterfly stockholders entitled to notice of the meeting.
Without limiting the manner by which notice otherwise may be given to New Butterfly stockholders, any notice to New Butterfly stockholders given by New Butterfly shall be effective if given by electronic transmission in accordance with the DGCL. The notices of all meetings shall state the place, if any, date and time of the meeting, the means of remote communications, if any, by which stockholders and proxyholders may be deemed to be present in person and vote at such meeting, and the record date for determining the stockholders entitled to vote at the meeting (if such date is different from the record date for stockholders entitled to notice of the meeting). The notice of a special meeting shall state, in addition, the purpose or purposes for which the meeting is called.
|
|
|
Stockholder Proposals (Other than Nomination of Persons for Election as Directors)
|
| |||
|
No business may be transacted at an annual meeting of Longview stockholders, other than business that is either (i) specified in Longview’s notice of meeting (or any supplement thereto) delivered pursuant to the Bylaws, (ii) otherwise properly brought before the annual meeting by or at the direction of the Longview Board or (iii) otherwise properly brought before the annual meeting by any Longview stockholder who is entitled to vote at the meeting, who complies with the notice procedures set forth in the Longview Bylaws.
The Longview stockholder must (i) give timely notice thereof in proper written form to the Secretary of Longview, and (ii) the business must be a proper matter for stockholder action. To be timely, a Longview stockholder’s notice must be received by the Secretary at the principal executive offices of Longview not later than the close of business on the ninetieth (90th) day nor earlier than the opening of business on the one-hundred twentieth (120th) day before the anniversary date of the immediately preceding annual meeting; provided, however, that in the event that the annual meeting is more than 30 days before or more than 70 days after such anniversary date, notice must be delivered not earlier than the close of business on the 120th day before the meeting and not later than the later of (x) the close of business on the 90th day before the meeting or (y) the close of business on the 10th day following the day on which public announcement of
|
| |
No business may be conducted at an annual meeting of New Butterfly stockholders, other than business that is either (i) specified in New Butterfly notice of meeting delivered pursuant to the Bylaws, (ii) otherwise properly brought before the annual meeting by or at the direction of the board (or a committee thereof) or (iii) otherwise properly brought before the annual meeting by any stockholder of New Butterfly who was a stockholder of record of the New Butterfly both at the time of giving the notice provided for in the Current Charter and at the time of the meeting and is entitled to vote at the meeting, who complies with the notice procedures set forth in the Bylaws and who is a stockholder of record at the time such notice is delivered to the Secretary of New Butterfly.
The New Butterfly stockholder must (i) give timely notice thereof in proper written form to the Secretary of New Butterfly and (ii) provide any updates or supplements to such notice at the times and in the forms required by the Current Charter. To be timely, a stockholder’s notice must be received at the principal executive offices of New Butterfly not less than ninety (90) or more than one-hundred twenty (120) days prior to the one-year anniversary of the preceding year’s annual meeting; provided however if the date of the annual meeting is more than thirty (30) days before or more than seventy (70) days after such anniversary date, the notice must be delivered not later than the ninetieth (90th)
|
|
|
Longview
|
| |
New Butterfly
|
|
| the date of the annual meeting, is first made by Longview. The public announcement of an adjournment of an annual meeting shall not commence a new time period for the giving of a stockholder’s notice. | | | day prior to such annual meeting or, if later, the tenth (10th) day following the day on which public disclosure of such meeting was first made. The public announcement of an adjournment or postponement of an annual meeting will not commence a new time period (or extend any time period) for the giving of a stockholder’s notice. Additionally, the stockholder must provide information pursuant to the advance notice provisions in the New Butterfly Bylaws. | |
|
Stockholder Nominations of Persons for Election as Directors
|
| |||
|
Nominations of persons for election to the Longview Board may be made by any stockholder of Longview who is a stockholder of record entitled to vote in the election of directors on the date of the giving of the notice required (as described below) and on the record date for the determination of stockholders entitled to vote at such meeting and who gives proper notice.
To give timely notice, a stockholder’s notice must be given to the Secretary of Longview at the principal executive offices of Longview either (i) in the case of an annual meeting, not later than the close of business on the ninetieth (90th) day nor earlier than the opening of business on the one hundred twentieth (120th) day before the anniversary date of the immediately preceding annual meeting of stockholders (in most cases) and (ii) in the case of a special meeting of stockholders called for the purpose of electing directors, not later than the close of business on the tenth (10th) day following the day on which public announcement of the date of the special meeting is first made.
|
| | Nominations of persons for election to the New Butterfly’s Board may be made by any stockholder of New Butterfly who provides a timely notice (i.e. provides notice which must be received in writing by the secretary of New Butterfly at New Butterfly’s principal executive officers either (i) in the case of an election of directors at an annual meeting, not less than ninety (90) days nor more than one hundred twenty (120) days prior to the first anniversary of the preceding year’s annual meeting (in most cases) or (ii) in the case of an election of directors at a special meeting, not earlier than one hundred twentieth (120th) day prior to such special meeting and not later than the close of business on the later of (a) the ninetieth (90th) day prior to such special meeting and (b) the tenth (10th) day following the day on which public disclosure of the date of such special meeting for the election of directors is first made), is a stockholder of record on the date of giving such notices and on the record date for the determination of stockholders entitled to vote at such a meeting, and is entitled to vote at such meeting and on such election. | |
|
Limitation of Liability of Directors and Officers
|
| |||
|
The DGCL permits limiting or eliminating the monetary liability of a director to a corporation or its stockholders, except with regard to breaches of the duty of loyalty, intentional misconduct, unlawful repurchases or dividends, or improper personal benefit.
The Current Charter provides that no director will be personally liable to Longview or its stockholders for monetary damages for breach of fiduciary duty as a director, except to the extent an exemption from liability or limitation is not permitted under the DGCL.
|
| |
The DGCL permits limiting or eliminating the monetary liability of a director to a corporation or its stockholders, except with regard to breaches of the duty of loyalty, intentional misconduct, unlawful repurchases or dividends, or improper personal benefit.
The Proposed Charter provides that no director will be personally liable, except to the extent an exemption from liability or limitation is not permitted under the DGCL, unless a director breached his or her duty of loyalty to New Butterfly or its stockholders, performed acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, pursuant to Section 174 of the DGCL, or for any transaction from which the director derived an improper personal benefit.
|
|
|
Longview
|
| |
New Butterfly
|
|
|
Indemnification of Directors, Officers, Employees and Agents
|
| |||
|
The DGCL generally permits a corporation to indemnify its directors and officers acting in good faith. Under the DGCL, the corporation through its stockholders, directors or independent legal counsel, will determine that the conduct of the person seeking indemnity conformed with the statutory provisions governing indemnity.
The Current Charter provides that Longview will indemnify each director, officer, employee and agent to the fullest extent permitted by Delaware law.
|
| |
The DGCL generally permits a corporation to indemnify its directors and officers acting in good faith. Under the DGCL, the corporation through its stockholders, directors or independent legal counsel, will determine that the conduct of the person seeking indemnity conformed with the statutory provisions governing indemnity.
The Proposed Charter provides that New Butterfly may indemnify each director, officer, employee and agent to the fullest extent permitted by applicable law.
|
|
|
Dividends
|
| |||
|
Unless further restricted in the certificate of incorporation, the DGCL permits a corporation to declare and pay dividends out of either (i) surplus, or (ii) if no surplus exists, out of net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). The DGCL defines surplus as the excess, at any time, of the net assets of a corporation over its stated capital. In addition, the DGCL provides that a corporation may redeem or repurchase its shares only when the capital of the corporation is not impaired and only if such redemption or repurchase would not cause any impairment of the capital of a corporation.
The Current Charter provides that, subject to applicable law and the rights, if any, of outstanding shares of preferred stock, the holders of shares of Longview common stock will be entitled to receive dividends (payable in cash, property, or capital stock of Longview) when, as, and if declared by the board of directors from time to time out of any assets or funds of Longview legally available thereof, and shall share equally on a per share basis in such dividends and distributions.
|
| |
Unless further restricted in the certificate of incorporation, the DGCL permits a corporation to declare and pay dividends out of either (i) surplus, or (ii) if no surplus exists, out of net profits for the fiscal year in which the dividend is declared and/or the preceding fiscal year (provided that the amount of capital of the corporation is not less than the aggregate amount of the capital represented by the issued and outstanding stock of all classes having a preference upon the distribution of assets). The DGCL defines surplus as the excess, at any time, of the net assets of a corporation over its stated capital. In addition, the DGCL provides that a corporation may redeem or repurchase its shares only when the capital of the corporation is not impaired and only if such redemption or repurchase would not cause any impairment of the capital of a corporation.
With limited exceptions in the case of certain stock dividends or disparate dividends approved by the affirmative vote of the holders of a majority of the New Butterfly Class A common stock and New Butterfly Class B common stock, each voting separately as a class, the Proposed Charter provides that New Butterfly common stock shall be treated equally, identically, and ratably, on a per share basis, with respect to any dividends or distributions that may be declared and paid from time to time by the New Butterfly Board out of any assets of New Butterfly legally available for dividends or distributions.
|
|
|
Liquidation
|
| |||
| Subject to applicable law and the rights, if any, of the holders of any outstanding shares of preferred stock, the Current Charter provides that following the payment or provision for payment of the debts and other liabilities of Longview in the event of an voluntary or involuntary liquidation, dissolution, or | | | Subject to applicable law and the preferential or other rights of any holders of preferred stock then outstanding, the Proposed Charter provides that in the event of the liquidation or winding up of New Butterfly, whether voluntary or involuntary, holders of New Butterfly common stock will be entitled to | |
|
Longview
|
| |
New Butterfly
|
|
| winding up of Longview, the holders of shares of Longview common stock shall be entitled to receive all the remaining assets of Longview available for distribution to its stockholders, ratably in proportion to the number of shares of Longview common stock held by them. | | | receive ratably all assets of New Butterfly available for distribution to its stockholders unless disparate or different treatment of the shares of each such class with respect to distributions upon any liquidation, dissolution, distribution of assets, or winding up is approved by the affirmative vote of the holders of a majority of the outstanding shares of New Butterfly common stock, each voting separately as a class. | |
|
Supermajority Voting Provisions
|
| |||
| Article IX of the Current Charter relating to business combination requirements may not be amended prior to the consummation of the initial business combination unless approved by the affirmative vote of the holders of at least 65% of all then outstanding shares of Longview common stock. | | | Following the first date on which the issued and outstanding shares of New Butterfly Class B common stock represent less than 50% of the voting power of the then outstanding shares of capital stock of New Butterfly that would then be entitled to vote for the election of directors at an annual meeting of stockholders, the affirmative vote of two-thirds (2/3) of the voting power of the shares of capital stock of New Butterfly that would then be entitled to vote in the election of directors at an annual meeting of stockholders will be required in order for the stockholders of New Butterfly to amend New Butterfly’s Charter in certain circumstances, amend New Butterfly’s Bylaws, increase or decrease the number of directors, fill vacancies on the board of directors, remove a director from office, or call a special meeting of stockholders. | |
|
Anti-Takeover Provisions and Other Stockholder Protections
|
| |||
| The anti-takeover provisions and other stockholder protections in the Current Charter include the ability of the board of directors to designate the terms of and issue new series of preferred shares. Section 203 of the DGCL prohibit a Delaware corporation from engaging in a “business combination” with an “interested stockholder” (i.e. a stockholder owning 15% or more of Longview voting stock) for three years following the time that the “interested stockholder” becomes such, subject to certain exceptions. | | | The anti-takeover provisions and other stockholder protections included in the Proposed Charter include a prohibition on stockholder action by written consent and blank check preferred stock. Section 203 of the DGCL prohibit a Delaware corporation from engaging in a “business combination” with an “interested stockholder” (i.e. a stockholder owning 15% or more of Longview voting stock) for three years following the time that the “interested stockholder” becomes such, subject to certain exceptions. | |
|
Preemptive Rights
|
| |||
| There are no preemptive rights relating to the Longview common stock. | | | There are no preemptive rights relating to the shares of New Butterfly common stock. | |
|
Fiduciary Duties of Directors
|
| |||
| Under Delaware law, the standards of conduct for directors have developed through Delaware court case law. Generally, directors must exercise a duty of care and duty of loyalty and good faith to the company and its stockholders. Members of the board of directors or any committee designated by the board of directors are similarly entitled to rely | | | Under Delaware law, the standards of conduct for directors have developed through Delaware court case law. Generally, directors must exercise a duty of care and duty of loyalty and good faith to the company and its stockholders. Members of the board of directors or any committee designated by the board of directors are similarly entitled to rely | |
|
Longview
|
| |
New Butterfly
|
|
|
in good faith upon the records of the corporation and upon such information, opinions, reports and statements presented to the corporation by corporate officers, employees, committees of the board of directors or other persons as to matters such member reasonably believes are within such other person’s professional or expert competence, provided that such other person has been selected with reasonable care by or on behalf of the corporation. Such appropriate reliance on records and other information protects directors from liability related to decisions made based on such records and other information.
The Longview Board may exercise all such powers of Longview and do all such lawful acts and things as are not by statute or Longview’s Charter or Longview’s Bylaws directed or required to be exercised or done solely by stockholders.
|
| |
in good faith upon the records of the corporation and upon such information, opinions, reports and statements presented to the corporation by corporate officers, employees, committees of the board of directors or other persons as to matters such member reasonably believes are within such other person’s professional or expert competence, provided that such other person has been selected with reasonable care by or on behalf of the corporation. Such appropriate reliance on records and other information protects directors from liability related to decisions made based on such records and other information.
The New Butterfly Board may exercise all such authority and powers of New Butterfly and do all such lawful acts and things as are not by statute or the New Butterfly’s Charter or New Butterfly’s Bylaws directed or required to be exercised or done solely by the stockholders.
|
|
|
Inspection of Books and Records
|
| |||
| Under the DGCL, any stockholder or beneficial owner has the right, upon written demand under oath stating the proper purpose thereof, either in person or by attorney or other agent, to inspect and make copies and extracts from the corporation’s stock ledger, list of stockholders and its other books and records for a proper purpose during the usual hours for business. Longview’s Bylaws permit Longview’s books and records to be kept within or outside Delaware. | | | Under the DGCL, any stockholder or beneficial owner has the right, upon written demand under oath stating the proper purpose thereof, either in person or by attorney or other agent, to inspect and make copies and extracts from the corporation’s stock ledger, list of stockholders and its other books and records for a proper purpose during the usual hours for business. | |
|
Choice of Forum
|
| |||
| The Current Charter generally designates the Court of Chancery of the State of Delaware as the sole and exclusive forum for any stockholder (including a beneficial owner) to: (i) any derivative action or proceeding brought on behalf of Longview, (ii) any action asserting a claim of breach of a fiduciary duty owed by any director, officer, employee or agent of Longview to Longview or Longview’s stockholders, or any claim for aiding and abetting such alleged breach (iii) any action asserting a claim against Longview, its directors, officers or employees arising pursuant to any provision of the DGCL or the Current Charter or Longview’s Bylaws, or (iv) any action asserting a claim against Longview, its directors, officers, or employees governed by the internal affairs doctrine. | | | The Proposed Charter generally designates Court of Chancery of the State of Delaware as the sole and exclusive forum for: (i) any derivative action or proceeding brought on behalf of New Butterfly, (ii) any action asserting a claim of breach of a fiduciary duty owed by, or any other wrongdoing by, any current or former director, officer, other employee, or stockholder of New Butterfly, (iii) any action asserting a claim against New Butterfly arising pursuant to any provision of the DGCL, the Proposed Charter, or New Butterfly’s Bylaws, (iv) any action to interpret, apply, enforce, or determine the validity of any provisions in the Proposed Charter or New Butterfly’s Bylaws, or (v) any action asserting a claim governed by the internal affairs doctrine and if brought outside of Delaware in the name of any stockholder, the stockholder bringing the suit will be deemed to have consented to (a) the personal jurisdiction of the state and federal courts within Delaware and (b) service of process on such stockholder’s counsel, | |
|
Longview
|
| |
New Butterfly
|
|
| | | | subject to certain exceptions. In addition, notwithstanding anything to the contrary in the foregoing, the federal district courts of the United States are the exclusive forum for the resolution of any action, suit or proceeding asserting a cause of action under the Securities Act. The exclusive forum provision does not apply to suits brought to enforce any liability or duty created by the Exchange Act. | |
| | |
Before the Business Combination
|
| |
After the Business Combination
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| | | | | | | | | | | | | | | | | | | | |
Assuming No Redemption
|
| |
Assuming Maximum Redemption
|
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||
Name and Address of
Beneficial Owner |
| |
Number of
shares of Longview common stock |
| |
%**
|
| |
% of
Total Voting Power** |
| |
Number of
shares of New Butterfly Class A Common Stock |
| |
%**
|
| |
Number of
shares of New Butterfly Class B Common Stock |
| |
%**
|
| |
% of
Total Voting Power** |
| |
Number of
shares of New Butterfly Class A Common Stock |
| |
%**
|
| |
Number of
shares of New Butterfly Class B Common Stock |
| |
%**
|
| |
% of
Total Voting Power** |
| |||||||||||||||||||||||||||||||||||||||
Directors and Executive
Officers of Longview Before the Business Combination |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Larry Robbins(1)(2)
|
| | | | 10,275,000 | | | | | | 19.8% | | | | | | 19.8% | | | | | | 15,290,499 | | | | | | 9.5% | | | | | | — | | | | | | — | | | | | | 2.2% | | | | | | 22,790,499 | | | | | | 17.9% | | | | | | — | | | | | | — | | | | | | 3.5% | | |
John Rodin
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Mark Horowitz
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Westley Moore(1)
|
| | | | 25,000 | | | | | | * | | | | | | * | | | | | | 25,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 25,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Derek Cribbs(1)
|
| | | | 25,000 | | | | | | * | | | | | | * | | | | | | 25,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 25,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
Randy Simpson(1)
|
| | | | 25,000 | | | | | | * | | | | | | * | | | | | | 25,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 25,000 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
All Directors and Executive Officers of Longview as a Group (6 Individuals)
|
| | | | 10,350,000 | | | | | | 20% | | | | | | 20% | | | | | | 15,365,499 | | | | | | 9.5% | | | | | | — | | | | | | — | | | | | | 2.2% | | | | | | 22,865,499 | | | | | | 18.0% | | | | | | — | | | | | | — | | | | | | 3.5% | | |
Directors and Executive
Officers of New Butterfly After Consummation of the Business Combination |
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Jonathan M. Rothberg, Ph.D.(3)(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 26,426,937 | | | | | | 100.0% | | | | | | 76.6% | | | | | | — | | | | | | — | | | | | | 26,426,937 | | | | | | 100.0% | | | | | | 80.6% | | |
Larry Robbins(1)(2)
|
| | | | 10,275,000 | | | | | | 19.8% | | | | | | 19.8% | | | | | | 15,290,499 | | | | | | 9.5% | | | | | | — | | | | | | — | | | | | | 2.2% | | | | | | 22,790,499 | | | | | | 17.9% | | | | | | — | | | | | | — | | | | | | 3.5% | | |
Laurent Faracci(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Gioel Molinari(3)(5)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 2,109,035 | | | | | | 1.3% | | | | | | — | | | | | | — | | | | | | * | | | | | | 2,109,035 | | | | | | 1.6% | | | | | | — | | | | | | — | | | | | | * | | |
David Perri(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Stephanie Fielding(3)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Darius Shahida(3)(6)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 354,723 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | | | | | 354,723 | | | | | | * | | | | | | — | | | | | | — | | | | | | * | | |
All Directors and Executive
Officers of New Butterfly as a Group (7 Individuals) (7) |
| | | | — | | | | | | — | | | | | | — | | | | | | 17,754,257 | | | | | | 10.9% | | | | | | 26,426,937 | | | | | | 100.0% | | | | | | 78.9% | | | | | | 25,254,257 | | | | | | 19.5% | | | | | | 26,426,937 | | | | | | 100.0% | | | | | | 84.4% | | |
Five Percent Holders: | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Jonathan M. Rothberg, Ph.D.(3)(4)
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 26,426,937 | | | | | | 100.0% | | | | | | 76.6% | | | | | | — | | | | | | — | | | | | | 26,426,937 | | | | | | 100.0% | | | | | | 80.6% | | |
Michael J. Rothberg Family Investments(3)(8)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 29,028,281 | | | | | | 18.0% | | | | | | — | | | | | | — | | | | | | 4.2% | | | | | | 29,028,281 | | | | | | 22.8% | | | | | | — | | | | | | — | | | | | | 4.4% | | |
Fosun Industrial Co., Limited(9)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 10,716,630 | | | | | | 6.6% | | | | | | — | | | | | | — | | | | | | 1.6% | | | | | | 10,716,630 | | | | | | 8.4% | | | | | | — | | | | | | — | | | | | | 1.6% | | |
Longview Investors
LLC(1)(2) |
| | | | 10,275,000 | | | | | | 19.8% | | | | | | 19.8% | | | | | | 15,290,499 | | | | | | 9.5% | | | | | | — | | | | | | — | | | | | | 2.2% | | | | | | 22,790,499 | | | | | | 17.9% | | | | | | — | | | | | | — | | | | | | 3.5% | | |
Entities affiliated with Fidelity Management & Research Company, LLC(10)
|
| | | | — | | | | | | — | | | | | | — | | | | | | 9,158,136 | | | | | | 5.7% | | | | | | — | | | | | | — | | | | | | 1.0% | | | | | | 9,158,136 | | | | | | 7.2% | | | | | | — | | | | | | — | | | | | | 1.0% | | |
|
Name
|
| |
Age
|
| |
Position
|
|
Executive Officers: | | | | | | | |
Laurent Faracci | | |
50
|
| | Chief Executive Officer and Director | |
Gioel Molinari | | |
45
|
| | President | |
David Perri | | |
49
|
| | Chief Operating Officer | |
Stephanie Fielding | | |
39
|
| | Chief Financial Officer | |
Darius Shahida | | |
29
|
| | Chief Strategy Officer and Chief Business Development Officer | |
Non-Employee Directors: | | | | | | | |
Jonathan M. Rothberg, Ph.D.
|
| |
57
|
| | Chairman of the Board | |
Larry Robbins | | |
51
|
| | Director | |
Name and Position
|
| |
Year
|
| |
Salary ($)
|
| |
Bonus ($)
|
| |
All Other
Compensation ($) |
| |
Total ($)
|
| |||||||||||||||
Gioel Molinari, President
|
| | | | 2019 | | | | | $ | 389,583 | | | | | $ | 400,000(1) | | | | | | — | | | | | $ | 789,583 | | |
Darius Shahida, Chief Strategy Officer and Chief Business Development Officer(4)
|
| | | | 2019 | | | | | $ | 203,125 | | | | | $ | 200,000(2) | | | | | $ | 10,500(3) | | | | | $ | 413,625 | | |
Name
|
| |
Grant Date
|
| |
Number of
Securities Underlying Unexercised Options Exercisable (#) |
| |
Number of
Securities Underlying Unexercised Options Unexercisable (#) |
| |
Option
Exercise Price |
| |
Option
Expiration Date |
| |||||||||
Gioel Molinari
|
| |
4/6/2017
|
| | | | 1,306,243(1) | | | | | | 593,757 | | | | | $ | 1.83 | | | |
4/6/2027
|
|
Darius Shahida
|
| |
1/16/2018
|
| | | | 150,000 | | | | | | — | | | | | $ | 2.57 | | | |
1/16/2028
|
|
| | |
9/18/2018
|
| | | | 49,984(2) | | | | | | 100,016 | | | | | $ | 4.31 | | | |
9/18/2028
|
|
Name
|
| |
Shares
|
| |
Aggregate
Purchase Price |
| |
Date of Issuance
|
| ||||||
Entities affiliated with Fidelity Management & Research Company, LLC(1)
|
| | | | 4,868,550 | | | | | $ | 50,000,009 | | | |
May 4, 2018
|
|
Fosun Industrial Co., Limited(2)
|
| | | | 10,321,324 | | | | | $ | 105,999,997 | | | |
August 15, 2018
|
|
Rothberg Family Fund I, LLC(3)
|
| | | | 1,949,283 | | | | | $ | 20,019,136 | | | |
May 4, 2018
|
|
Name
|
| |
Principal Note
Amount |
| |
Date of Issuance
|
| |||
Entities affiliated with Fidelity Management & Research Company, LLC(1)
|
| | | $ | 17,000,000 | | | |
May 21, 2020
|
|
| | |
Page
|
| |||
Audited Financial Statements of Longview Acquisition Corp. | | | | | | | |
| | | | F-2 | | | |
| | | | F-3 | | | |
| | | | F-4 | | | |
| | | | F-5 | | | |
| | | | F-6 | | | |
| | | | F-7 | | | |
Unaudited Condensed Interim Financial Statements of Longview Acquisition Corp. | | | | | | | |
| | | | F-18 | | | |
| | | | F-19 | | | |
| | | | F-20 | | | |
| | | | F-21 | | | |
| | | | F-22 | | |
| Audited Financial Statements as of and for the Years Ended December 31, 2019 and 2018 | | | | | | | |
|
Report of Independent Registered Public Accounting Firm
|
| | | | | | |
| | | | | F-36 | | | |
| | | | | F-37 | | | |
| | | | | F-38 | | | |
| | | | | F-39 | | | |
| | | | | F-40 | | | |
|
Unaudited Financial Statements as of and for the Nine-Month Periods Ended September 30, 2020 and
2019 |
| | | | | | |
|
Report of Independent Registered Public Accounting Firm
|
| | | | | | |
| | | | | F-62 | | | |
| | | | | F-63 | | | |
| | | | | F-64 | | | |
| | | | | F-65 | | | |
| | | | | F-66 | | |
| ASSETS | | | | | | | |
|
Current asset – cash
|
| | | $ | 20,000 | | |
|
Deferred offering costs
|
| | | | 75,303 | | |
|
TOTAL ASSETS
|
| | | $ | 95,303 | | |
| LIABILITIES AND STOCKHOLDER’S EQUITY | | | | | | | |
| Current liabilities: | | | | | | | |
|
Accrued expenses
|
| | | $ | 1,000 | | |
|
Accrued offering costs
|
| | | | 70,303 | | |
|
Promissory note – related party
|
| | | | — | | |
|
Total Current Liabilities
|
| | | | 71,303 | | |
| Commitments | | | | | | | |
| Stockholder’s Equity | | | | | | | |
|
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or outstanding
|
| | | | — | | |
|
Class A common stock, $0.0001 par value; 200,000,000 shares authorized; none issued or outstanding
|
| | | | — | | |
|
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 10,350,000 shares issued and outstanding(1)(2)
|
| | | | 1,035 | | |
|
Additional paid-in capital
|
| | | | 23,965 | | |
|
Accumulated deficit
|
| | | | (1,000) | | |
|
Total Stockholder’s Equity
|
| | | | 24,000 | | |
|
TOTAL LIABILITIES AND STOCKHOLDER’S EQUITY
|
| | | $ | 95,303 | | |
| | | | | | | | |
|
Formation and operating costs
|
| | | $ | 1,000 | | |
|
Net Loss
|
| | | $ | (1,000) | | |
|
Weighted average shares outstanding, basic and diluted(1)(2)
|
| | | | 9,000,000 | | |
|
Basic and diluted net loss per common share
|
| | | $ | (0.00) | | |
| | |
Class B
Common Stock |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Stockholder’s Equity |
| ||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||
Balance – February 4, 2020 (inception)
|
| | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Issuance of Class B common stock to Sponsor(1)(2)
|
| | | | 10,350,000 | | | | | | 1,035 | | | | | | 23,965 | | | | | | — | | | | | | 25,000 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | (1,000) | | | | | | (1,000) | | |
Balance – February 12, 2020
|
| | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | 23,965 | | | | | $ | (1,000) | | | | | $ | 24,000 | | |
| Cash Flows from Operating Activities: | | | | | | | |
|
Net loss
|
| | | $ | (1,000) | | |
|
Changes in operating assets and liabilities:
|
| | | | | | |
|
Accrued expenses
|
| | | | 1,000 | | |
|
Net cash used in operating activities
|
| | | | — | | |
| Cash Flows from Financing Activities: | | | | | | | |
|
Proceeds from issuance of Class B common stock to Sponsor
|
| | | | 25,000 | | |
|
Proceeds from promissory note – related party
|
| | | | — | | |
|
Payment of offering costs
|
| | | | (5,000) | | |
|
Net cash provided by financing activities
|
| | | | 20,000 | | |
|
Net Change in Cash
|
| | | | 20,000 | | |
|
Cash – Beginning
|
| | | | — | | |
| Cash – Ending | | | | $ | 20,000 | | |
| Non-cash investing and financing activities: | | | | | | | |
|
Deferred offering costs included in accrued offering costs
|
| | | $ | 70,303 | | |
| ASSETS | | | | | | | |
| Current assets: | | | | | | | |
|
Cash
|
| | | $ | 759,102 | | |
|
Prepaid expenses and other current assets
|
| | | | 240,602 | | |
|
Total Current Assets
|
| | | | 999,704 | | |
|
Investments held in Trust Account
|
| | | | 414,222,151 | | |
|
TOTAL ASSETS
|
| | | $ | 415,221,855 | | |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | | | | | | | |
|
Current liabilities
|
| | | | | | |
|
Accrued expenses
|
| | | $ | 280,690 | | |
|
Income taxes payable
|
| | | | 29,152 | | |
|
Total Current Liabilities
|
| | | | 309,842 | | |
|
Deferred underwriting fee payable
|
| | | | 14,490,000 | | |
|
TOTAL LIABILITIES
|
| | | | 14,799,842 | | |
| Commitments and Contingencies | | | | | | | |
|
Class A common stock, $0.0001 par value, subject to possible redemption, 39,542,201 shares at $10.00 per share
|
| | | | 395,422,010 | | |
| Stockholders’ Equity | | | | | | | |
|
Preferred stock, $0.0001 par value; 1,000,000 shares authorized; none issued or
outstanding |
| | | | — | | |
|
Class A common stock, $0.0001 par value; 200,000,000 shares authorized; 1,857,799 issued
or outstanding (excluding 39,542,201 shares subject to possible redemption) |
| | | | 186 | | |
|
Class B common stock, $0.0001 par value; 20,000,000 shares authorized; 10,350,000 shares
issued and outstanding |
| | | | 1,035 | | |
|
Additional paid-in capital
|
| | | | 5,389,917 | | |
|
Accumulated deficit
|
| | | | (391,135) | | |
|
Total Stockholders’ Equity
|
| | | | 5,000,003 | | |
|
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY
|
| | | $ | 415,221,855 | | |
| | |
Three Months
Ended September 30, 2020 |
| |
For the
Period from February 4, 2020 (Inception) Through September 30, 2020 |
| ||||||
Formation and operating costs
|
| | | $ | 462,905 | | | | | $ | 584,134 | | |
Loss from operations
|
| | | | (462,905) | | | | | | (584,134) | | |
Other income: | | | | | | | | | | | | | |
Interest earned on marketable securities held in Trust Account
|
| | | | 165,021 | | | | | | 222,151 | | |
Income (loss) before provision for income taxes
|
| | | | (297,884) | | | | | | (361,983) | | |
Provision for income taxes
|
| | | | (29,152) | | | | | | (29,152) | | |
Net loss
|
| | | $ | (327,036) | | | | | $ | (391,135) | | |
Weighted average shares outstanding of Class A redeemable common stock
|
| | | | 41,400,000 | | | | | | 40,617,323 | | |
Basic and diluted income per share, Class A
|
| | | $ | 0.00 | | | | | $ | 0.00 | | |
Weighted average shares outstanding of Class B non-redeemable common stock(1)
|
| | | | 10,350,000 | | | | | | 10,350,000 | | |
Basic and diluted net loss per share, Class B
|
| | | $ | (0.03) | | | | | $ | (0.04) | | |
| | |
Class A
Common Stock |
| |
Class B
Common Stock |
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
Stockholders’ Equity |
| |||||||||||||||||||||||||||
|
Shares
|
| |
Amount
|
| |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||||
Balance – February 4, 2020
|
| | | | — | | | | | $ | — | | | | | | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | | | | $ | — | | |
Issuance of Class B common stock to Sponsor(1)(2)
|
| | | | — | | | | | | — | | | | | | 10,350,000 | | | | | | 1,035 | | | | | | 23,965 | | | | | | — | | | | | | 25,000 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (1,000) | | | | | | (1,000) | | |
Balance – March 31, 2020
|
| | |
|
—
|
| | | |
|
—
|
| | | | | 10,350,000 | | | | | | 1,035 | | | | | | 23,965 | | | | | | (1,000) | | | | | | 24,000 | | |
Sale of 41,400,000 Units, net of underwriting discounts
|
| | | | 41,400,000 | | | | | | 4,140 | | | | | | — | | | | | | — | | | | | | 390,504,008 | | | | | | — | | | | | | 390,508,148 | | |
Sale of 6,853,333 Private Placement Warrants
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | 10,280,000 | | | | | | — | | | | | | 10,280,000 | | |
Common stock subject to possible redemption
|
| | | | (39,574,904) | | | | | | (3,957) | | | | | | — | | | | | | — | | | | | | (395,745,083) | | | | | | — | | | | | | (395,749,040) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (63,099) | | | | | | (63,099) | | |
Balance – June 30, 2020
|
| | | | 1,825,096 | | | | | $ | 183 | | | | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | 5,062,890 | | | | | $ | (64,099) | | | | | $ | 5,000,009 | | |
Change in value of common stock subject to possible redemption
|
| | | | 32,703 | | | | | | 3 | | | | | | — | | | | | | — | | | | | | 327,027 | | | | | | — | | | | | | 327,030 | | |
Net loss
|
| | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | (327,036) | | | | | | (327,036) | | |
Balance – September 30, 2020
|
| | | | 1,857,799 | | | | | $ | 186 | | | | | | 10,350,000 | | | | | $ | 1,035 | | | | | $ | 5,389,917 | | | | | $ | (391,135) | | | | | $ | 5,000,003 | | |
|
| Cash Flows from Operating Activities: | | | | | | | |
|
Net loss
|
| | | $ | (391,135) | | |
| Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | |
|
Interest earned on marketable securities held in Trust Account
|
| | | | (222,151) | | |
| Changes in operating assets and liabilities: | | | | | | | |
|
Prepaid expenses
|
| | | | (240,602) | | |
|
Accrued expenses
|
| | | | 280,690 | | |
|
Income taxes payable
|
| | | | 29,152 | | |
|
Net cash used in operating activities
|
| | | | (544,046) | | |
| Cash Flows from Investing Activities: | | | | | | | |
|
Investment of cash into Trust Account
|
| | | | (414,000,000) | | |
|
Net cash used in investing activities
|
| | | | (414,000,000) | | |
| Cash Flows from Financing Activities | | | | | | | |
|
Proceeds from issuance of Class B common stock to Sponsor
|
| | | | 25,000 | | |
|
Proceeds from sale of Units, net of underwriting discounts paid
|
| | | | 405,720,000 | | |
|
Proceeds from sale of Private Placement Warrants
|
| | | | 10,280,000 | | |
|
Proceeds from promissory note – related party
|
| | | | 191,000 | | |
|
Repayment from promissory note – related party
|
| | | | (191,000) | | |
|
Payment of offering costs
|
| | | | (721,852) | | |
|
Net cash provided by financing activities
|
| | | | 415,303,148 | | |
|
Net Change in Cash
|
| | | | 759,102 | | |
|
Cash – Beginning of period
|
| | |
|
—
|
| |
|
Cash – End of period
|
| | | $ | 759,102 | | |
| Supplemental Disclosure of Non-Cash Activities: | | | | | | | |
|
Initial classification of common stock subject to possible redemption
|
| | | $ | 395,812,140 | | |
|
Change in value of common stock subject to possible redemption
|
| | | $ | (390,130) | | |
|
Deferred underwriting fee payable
|
| | | $ | 14,490,000 | | |
| | |
Held-To-Maturity
|
| |
Amortized
Cost |
| |
Gross
Holding Gain |
| |
Level 1
Fair Value |
| |||||||||
September 30, 2020
|
| |
U.S. Treasury Securities
(Mature on 11/27/2020) |
| | | $ | 414,221,183 | | | | | $ | 41,669 | | | | | $ | 414,262,851 | | |
| | |
December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Assets | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 90,002 | | | | | $ | 214,578 | | |
Accounts receivable, net
|
| | | | 1,951 | | | | | | 756 | | |
Inventories
|
| | | | 9,441 | | | | | | 10,766 | | |
Current portion of vendor advances
|
| | | | 5,239 | | | | | | 9,620 | | |
Prepaid expenses and other current assets
|
| | | | 1,793 | | | | | | 1,762 | | |
Due from related parties
|
| | | | 829 | | | | | | 1,706 | | |
Total current assets
|
| | | $ | 109,255 | | | | | $ | 239,188 | | |
Property and equipment, net
|
| | | | 5,325 | | | | | | 1,611 | | |
Security deposits and non-current portion of vendor advances
|
| | | | 48,896 | | | | | | 5,528 | | |
Other assets – related party
|
| | | | 1,661 | | | | | | 1,743 | | |
Total assets
|
| | | $ | 165,137 | | | | | $ | 248,070 | | |
Liabilities, convertible preferred stock, and stockholders’ deficit | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 5,168 | | | | | $ | 2,619 | | |
Deferred revenue, current
|
| | | | 3,200 | | | | | | 248 | | |
Due to related parties
|
| | | | 6 | | | | | | 876 | | |
Accrued expenses and other current liabilities
|
| | | | 6,951 | | | | | | 2,222 | | |
Total current liabilities
|
| | | $ | 15,325 | | | | | $ | 5,965 | | |
Deferred revenue, non-current
|
| | | $ | 587 | | | | | $ | 42 | | |
Other non-current liabilities
|
| | | | 566 | | | | | | 69 | | |
Total liabilities
|
| | | $ | 16,478 | | | | | $ | 6,076 | | |
Commitments and contingencies (Note 15) | | | | | | | | | | | | | |
Convertible preferred stock: | | | | | | | | | | | | | |
Convertible preferred stock (Series A, B, C and D) $.0001 par value with an aggregate liquidation preference of $383,829; 103,242,914 shares authorized, issued and outstanding
|
| | | | 360,937 | | | | | | 360,937 | | |
Stockholders’ deficit: | | | | | | | | | | | | | |
Common stock $.0001 par value; 102,000,000 and 102,000,000 shares authorized at December 31, 2019 and 2018, respectively; 5,720,842 and 5,549,112 shares issued and outstanding at December 31, 2019 and 2018, respectively.
|
| | | | 1 | | | | | | 1 | | |
Special-voting common stock, $.0001 par value; 25,952,123 shares authorized; 0
shares issued and outstanding |
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 19,782 | | | | | | 13,420 | | |
Accumulated deficit
|
| | | | (232,061) | | | | | | (132,364) | | |
Total stockholders’ deficit
|
| | | $ | (212,278) | | | | | $ | (118,943) | | |
Total liabilities, convertible preferred stock and stockholders’ deficit
|
| | | $ | 165,137 | | | | | $ | 248,070 | | |
| | |
Year ended December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Revenue: | | | | | | | | | | | | | |
Product
|
| | | $ | 25,081 | | | | | $ | 1,516 | | |
Subscription
|
| | | | 2,502 | | | | | | 10 | | |
Total revenue
|
| | | $ | 27,583 | | | | | $ | 1,526 | | |
Cost of revenue: | | | | | | | | | | | | | |
Product (including losses on purchase commitments of $9.5 million and $0.0,
respectively) |
| | | $ | 47,857 | | | | | $ | 2,079 | | |
Subscription
|
| | | | 621 | | | | | | 176 | | |
Total cost of revenue
|
| | | $ | 48,478 | | | | | $ | 2,255 | | |
Gross margin
|
| | | | (20,895) | | | | | | (729) | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | $ | 48,934 | | | | | $ | 34,954 | | |
Sales and marketing
|
| | | | 14,282 | | | | | | 6,075 | | |
General and administrative
|
| | | | 18,185 | | | | | | 11,328 | | |
Total operating expenses
|
| | | | 81,401 | | | | | | 52,357 | | |
Loss from operations
|
| | | $ | (102,296) | | | | | $ | (53,086) | | |
Interest income
|
| | | $ | 2,695 | | | | | $ | 2,321 | | |
Other income (expense), net
|
| | | | (96) | | | | | | — | | |
Loss before provision for income taxes
|
| | | $ | (99,697) | | | | | $ | (50,765) | | |
Provision for income taxes
|
| | | | — | | | | | | — | | |
Net loss and comprehensive loss
|
| | | $ | (99,697) | | | | | $ | (50,765) | | |
Net loss per common share attributable to common stockholders, basic and diluted
|
| | | $ | (17.73) | | | | | $ | (9.63) | | |
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted
|
| | | | 5,622,752 | | | | | | 5,268,889 | | |
| | |
Convertible Preferred Stock
|
| | |
Common Stock
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
stockholders’ deficit |
| |||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
January 1, 2018
|
| | | | 78,900,168 | | | | | $ | 113,749 | | | | | | | 5,077,406 | | | | | $ | 1 | | | | | $ | 7,176 | | | | | $ | (81,599) | | | | | $ | (74,422) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (50,765) | | | | | | (50,765) | | |
Issuance of convertible preferred stock (net of issuance cost) − Series D
|
| | | | 24,342,746 | | | | | | 247,188 | | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | | | | | — | | |
Common stock issued upon exercise of stock options
|
| | | | — | | | | | | — | | | | | | | 471,706 | | | | | | — | | | | | | 655 | | | | | | — | | | | | | 655 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 5,589 | | | | | | — | | | | | | 5,589 | | |
December 31, 2018
|
| | | | 103,242,914 | | | | | $ | 360,937 | | | | | | | 5,549,112 | | | | | $ | 1 | | | | | $ | 13,420 | | | | | $ | (132,364) | | | | | $ | (118,943) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (99,697) | | | | | | (99,697) | | |
Common stock issued upon exercise of stock options
|
| | | | — | | | | | | — | | | | | | | 171,730 | | | | | | — | | | | | | 324 | | | | | | — | | | | | | 324 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 6,038 | | | | | | — | | | | | | 6,038 | | |
December 31, 2019
|
| | | | 103,242,914 | | | | | $ | 360,937 | | | | | | | 5,720,842 | | | | | $ | 1 | | | | | $ | 19,782 | | | | | $ | (232,061) | | | | | $ | (212,278) | | |
| | | | | | | | | | | | | | | | | | | | | | | |
| | |
Year ended December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Cash flows from operating activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (99,697) | | | | | $ | (50,765) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Depreciation and amortization
|
| | | | 758 | | | | | | 391 | | |
(Gain)/ loss on disposal of property and equipment
|
| | | | (4) | | | | | | 29 | | |
Write down of vendor advance
|
| | | | 9,500 | | | | | | — | | |
Write-down of inventories
|
| | | | 2,715 | | | | | | 143 | | |
Stock-based compensation expense
|
| | | | 6,038 | | | | | | 5,589 | | |
Changes in assets and liabilities:
|
| | | | | | | | | | | | |
Accounts receivable
|
| | | | (1,195) | | | | | | (756) | | |
Inventories
|
| | | | (1,390) | | | | | | (10,909) | | |
Prepaid expenses and other current assets
|
| | | | (31) | | | | | | (1,224) | | |
Security deposits and vendor advances
|
| | | | (48,488) | | | | | | (15,148) | | |
Due from related parties
|
| | | | 877 | | | | | | (1,336) | | |
Other assets – related party
|
| | | | 85 | | | | | | (21) | | |
Accounts payable
|
| | | | 2,549 | | | | | | 2,130 | | |
Deferred revenue
|
| | | | 3,497 | | | | | | 290 | | |
Due to related parties
|
| | | | (871) | | | | | | 70 | | |
Accrued expenses and other liabilities
|
| | | | 5,225 | | | | | | 1,936 | | |
Net cash used in operating activities
|
| | | $ | (120,432) | | | | | $ | (69,581) | | |
Cash flows from investing activities: | | | | | | | | | | | | | |
Purchases of property and equipment
|
| | | | (4,468) | | | | | | (1,098) | | |
Net cash used in investing activities
|
| | | $ | (4,468) | | | | | $ | (1,098) | | |
Cash flows from financing activities: | | | | | | | | | | | | | |
Proceeds from exercise of stock options
|
| | | | 324 | | | | | | 655 | | |
Proceeds from issuance of Series D convertible preferred stock
|
| | | | — | | | | | | 250,000 | | |
Stock issuance costs for Series D convertible preferred stock
|
| | | | — | | | | | | (2,812) | | |
Net cash provided by financing activities
|
| | | $ | 324 | | | | | $ | 247,843 | | |
Net (decrease) increase in cash and cash equivalents
|
| | | | (124,576) | | | | | | 177,164 | | |
Cash and cash equivalents, beginning of year
|
| | | | 214,578 | | | | | | 37,414 | | |
Cash and cash equivalents, end of year
|
| | | $ | 90,002 | | | | | $ | 214,578 | | |
Supplemental Disclosures | | | | ||||||||||
Cash paid for interest
|
| | | | — | | | | | | — | | |
Cash paid for income taxes
|
| | | | — | | | | | | — | | |
| | |
Pattern of
Recognition |
| |
2019
|
| |
2018
|
| ||||||
By Product Type: | | | | | | | | | | | | | | | | |
Devices and accessories
|
| | Point-in-time | | | | $ | 25,081 | | | | | $ | 1,516 | | |
Subscription services and other services
|
| | Over time | | | | | 2,502 | | | | | | 10 | | |
Total revenue
|
| | | | | | $ | 27,583 | | | | | $ | 1,526 | | |
By Geographical Market: | | | | | | | | | | | | | | | | |
United States
|
| | | | | | $ | 23,997 | | | | | $ | 1,524 | | |
International
|
| | | | | | | 3,586 | | | | | | 2 | | |
Total revenue
|
| | | | | | $ | 27,583 | | | | | $ | 1,526 | | |
|
| | |
December 31,
2019 |
| |
December 31,
2018 |
| ||||||
Accounts receivable, net
|
| | | $ | 1,951 | | | | | $ | 756 | | |
Deferred revenue, current
|
| | | | 3,200 | | | | | | 248 | | |
Deferred revenue, non-current
|
| | | | 587 | | | | | | 42 | | |
| | |
2019
|
| |
2018
|
| ||||||
Raw materials
|
| | | $ | 842 | | | | | $ | 2,695 | | |
Work-in-progress
|
| | | | 5,176 | | | | | | 7,731 | | |
Finished goods
|
| | | | 3,423 | | | | | | 340 | | |
Total inventories
|
| | | $ | 9,441 | | | | | $ | 10,766 | | |
| | |
2019
|
| |
2018
|
| ||||||
Security deposits
|
| | | $ | 1,956 | | | | | $ | 1,828 | | |
Vendor advances
|
| | | | 52,179 | | | | | | 13,320 | | |
| | | | | 54,135 | | | | | | 15,148 | | |
Less current portion of vendor advances
|
| | | | (5,239) | | | | | | (9,620) | | |
Total non-current security deposits and vendor advances
|
| | | $ | 48,896 | | | | | $ | 5,528 | | |
| | |
2019
|
| |
2018
|
| ||||||
Machinery and equipment
|
| | | $ | 4,485 | | | | | $ | 2,802 | | |
Leasehold improvements
|
| | | | 1,424 | | | | | | 15 | | |
Construction in progress
|
| | | | 1,311 | | | | | | — | | |
Other
|
| | | | 210 | | | | | | 158 | | |
| | | | | 7,430 | | | | | | 2,975 | | |
Less accumulated depreciation amortization
|
| | | | (2,105) | | | | | | (1,364) | | |
Property and equipment, net
|
| | | $ | 5,325 | | | | | $ | 1,611 | | |
| | |
2019
|
| |
2018
|
| ||||||
Employee compensation
|
| | | $ | 2,208 | | | | | $ | 1,334 | | |
Customer deposits
|
| | | | 1,171 | | | | | | 214 | | |
Accrued warranty liability
|
| | | | 876 | | | | | | 133 | | |
Non-income tax
|
| | | | 1,646 | | | | | | 294 | | |
Other
|
| | | | 1,050 | | | | | | 247 | | |
Total other current liabilities
|
| | | $ | 6,951 | | | | | $ | 2,222 | | |
| | |
2019
|
| |
2018
|
| ||||||
Balance, beginning of period
|
| | | $ | 133 | | | | | $ | — | | |
Warranty provision charged to operations
|
| | | | 2,203 | | | | | | 160 | | |
Warranty claims
|
| | | | (1,460) | | | | | | (27) | | |
|
| | |
2019
|
| |
2018
|
| ||||||
Balance, end of period
|
| | | $ | 876 | | | | | $ | 133 | | |
|
Class
|
| |
Year of
Issuance |
| |
Issuance
Price per share |
| |
Shares
Authorized, Issued and Outstanding |
| |
Total
Proceeds or Exchange Value |
| |
Issuance
Costs |
| |
Net
Carrying Value |
| |
Initial
Liquidation Price per share |
| ||||||||||||||||||
Series A
|
| |
2012
|
| | | $ | 0.04 | | | | | | 25,952,123 | | | | | $ | 1,038 | | | | | $ | 11 | | | | | $ | 1,027 | | | | | $ | 0.80 | | |
Series B
|
| |
2014
|
| | | | 0.80 | | | | | | 25,000,000 | | | | | | 20,000 | | | | | | 99 | | | | | | 19,901 | | | | | | 0.80 | | |
Series C
|
| |
2014 – 2015
|
| | | | 3.33 | | | | | | 27,948,045 | | | | | | 93,067 | | | | | | 246 | | | | | | 92,821 | | | | | | 3.33 | | |
Series D
|
| |
2018
|
| | | | 10.27 | | | | | | 24,342,746 | | | | | | 250,000 | | | | | | 2,812 | | | | | | 247,188 | | | | | | 10.27 | | |
| | | | | | | | | | | | | | 103,242,914 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Number of
Options |
| |
Weighted
Average Exercise Price |
| |
Weighted
Average Remaining Contractual Term |
| |
Aggregate
Intrinsic Value |
| ||||||||||||
Outstanding at January 1, 2018
|
| | | | 12,008,005 | | | | | $ | 1.63 | | | | | | 8.26 | | | | | | 11,287 | | |
Granted
|
| | | | 3,730,500 | | | | | | 3.89 | | | | | | | | | | | | | | |
Exercised
|
| | | | (471,706) | | | | | | 1.39 | | | | | | | | | | | | | | |
Forfeited
|
| | | | (1,593,248) | | | | | | 2.97 | | | | | | | | | | | | | | |
Outstanding at December 31, 2018
|
| | | | 13,673,551 | | | | | | 2.10 | | | | | | 7.74 | | | | | | 30,252 | | |
Granted
|
| | | | 1,785,056 | | | | | | 4.31 | | | | | | | | | | | | | | |
Exercised
|
| | | | (171,730) | | | | | | 1.89 | | | | | | | | | | | | | | |
Forfeited
|
| | | | (594,544) | | | | | | 2.68 | | | | | | | | | | | | | | |
Outstanding at December 31, 2019
|
| | | | 14,692,333 | | | | | $ | 2.35 | | | | | | 6.94 | | | | | | 47,820 | | |
Options exercisable at December 31, 2018
|
| | | | 7,157,149 | | | | | $ | 1.52 | | | | | | 6.88 | | | | | | 19,971 | | |
Options exercisable at December 31, 2019
|
| | | | 9,788,082 | | | | | $ | 1.90 | | | | | | 6.39 | | | | | | 36,207 | | |
Vested and expected to vest at December 31, 2018
|
| | | | 12,109,558 | | | | | $ | 2.02 | | | | | | 7.62 | | | | | | 27,785 | | |
Vested and expected to vest at December 31, 2019
|
| | | | 13,559,748 | | | | | $ | 2.27 | | | | | | 6.85 | | | | | | 45,138 | | |
| | |
2019
|
| |
2018
|
|
Risk free interest rate
|
| |
2.3% – 2.5%
|
| |
2.3% – 3.0%
|
|
Expected dividend yield
|
| |
0%
|
| |
0%
|
|
Expected term
|
| |
6 years – 6.1 years
|
| |
5.8 years – 6.6 years
|
|
Expected volatility
|
| |
50%
|
| |
55%
|
|
| | |
2019
|
| |
2018
|
|
Risk free interest rate
|
| |
1.5% – 2.7%
|
| |
2.6% – 3.1%
|
|
Expected dividend yield
|
| |
0%
|
| |
0%
|
|
Expected term
|
| |
8.1 years to 10 years
|
| |
9 years to 10 years
|
|
Expected volatility
|
| |
50%
|
| |
55%
|
|
| | |
2019
|
| |
2018
|
| ||||||
Employee awards
|
| | | $ | 2,853 | | | | | $ | 1,917 | | |
Nonemployee awards
|
| | | | 3,185 | | | | | | 3,672 | | |
Total stock-based compensation expense
|
| | | $ | 6,038 | | | | | $ | 5,589 | | |
| | |
2019
|
| |
2018
|
| ||||||
Stock options granted to employee
|
| | | | 1,344,000 | | | | | | 2,179,000 | | |
Stock options granted to nonemployee
|
| | | | 441,056 | | | | | | 1,551,500 | | |
Total stock options granted
|
| | | | 1,785,056 | | | | | | 3,730,500 | | |
| | |
2019
|
| |
2018
|
| ||||||
Cost of revenue – Subscription
|
| | | $ | 15 | | | | | $ | 15 | | |
Research and development
|
| | | | 3,693 | | | | | | 3,304 | | |
Sales and marketing
|
| | | | 1,041 | | | | | | 1,327 | | |
General and administrative
|
| | | | 1,289 | | | | | | 943 | | |
Total stock-based compensation expense
|
| | | $ | 6,038 | | | | | $ | 5,589 | | |
| | |
2019
|
| |
2018
|
| ||||||
Numerator: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (99,697) | | | | | $ | (50,765) | | |
Numerator for Basic and Dilutive EPS – Loss available to common stockholders
|
| | | $ | (99,697) | | | | | $ | (50,765) | | |
Denominator: | | | | | | | | | | | | | |
Common stock
|
| | | | 5,622,752 | | | | | | 5,268,889 | | |
Denominator for Basic and Dilutive EPS – Weighted-average common stock
|
| | | | 5,622,752 | | | | | | 5,268,889 | | |
|
| | |
2019
|
| |
2018
|
| ||||||
Basic and dilutive loss per share
|
| | | $ | (17.73) | | | | | $ | (9.63) | | |
| | |
2019
|
| |
2018
|
| ||||||
Outstanding options to purchase common stock
|
| | | | 14,692,333 | | | | | | 13,673,551 | | |
Outstanding Convertible Preferred Stock (Series A through D)
|
| | | | 103,242,914 | | | | | | 103,242,914 | | |
Total anti-dilutive common equivalent shares
|
| | | | 117,935,247 | | | | | | 116,916,465 | | |
| | |
Year Ended December 31,
|
| |||||||||
| | |
2019
|
| |
2018
|
| ||||||
Federal
|
| | | $ | (98,833) | | | | | $ | (50,765) | | |
Foreign
|
| | | | (864) | | | | | | — | | |
Loss before provision for income taxes
|
| | | $ | (99,697) | | | | | $ | (50,765) | | |
| | |
Year Ended December 31,
|
| |||||||||
(In Thousands)
|
| |
2019
|
| |
2018
|
| ||||||
Income at US Statutory Rate
|
| | | | 21.00% | | | | | | 21.00% | | |
State Taxes, net of Federal benefit
|
| | | | 3.30% | | | | | | 4.71% | | |
Permanent Differences
|
| | | | (0.44)% | | | | | | (0.49)% | | |
Tax Credits
|
| | | | 1.32% | | | | | | 1.98% | | |
Foreign Rate Differential
|
| | | | (0.01)% | | | | | | 0.00% | | |
Valuation Allowance
|
| | | | (25.04)% | | | | | | (26.71)% | | |
Other
|
| | | | (0.12)% | | | | | | (0.49)% | | |
| | | | | 0.00% | | | | | | 0.00% | | |
|
| | |
Year Ended December 31,
|
| |||||||||
(In Thousands)
|
| |
2019
|
| |
2018
|
| ||||||
Deferred tax assets | | | | | | | | | | | | | |
Net operating loss carryforwards
|
| | | $ | 52,717 | | | | | $ | 31,271 | | |
Tax Credits
|
| | | | 5,271 | | | | | | 3,855 | | |
Stock Compensation
|
| | | | 2,346 | | | | | | 1,596 | | |
Accruals & Reserves
|
| | | | 1,785 | | | | | | 433 | | |
Other
|
| | | | 154 | | | | | | 122 | | |
Total Deferred tax assets
|
| | | $ | 62,273 | | | | | $ | 37,277 | | |
Valuation Allowance
|
| | | | (62,157) | | | | | | (37,191) | | |
Total Deferred tax assets
|
| | | $ | 116 | | | | | $ | 86 | | |
Deferred tax liabilities | | | | | | | | | | | | | |
Depreciation
|
| | | | (116) | | | | | | (86) | | |
Net deferred tax assets
|
| | | $ | — | | | | | $ | — | | |
| Years ending December 31: | | | | | | | |
|
2020
|
| | | $ | 1,634 | | |
|
2021
|
| | | | 1,675 | | |
|
2022
|
| | | | 1,717 | | |
|
2023
|
| | | | 1,760 | | |
|
2024
|
| | | | 1,849 | | |
|
Thereafter
|
| | | | 8,273 | | |
|
Total future minimum rental payments
|
| | | $ | 16,908 | | |
| | |
September 30,
2020 |
| |
December 31,
2019 |
| ||||||
Assets | | | | | | | | | | | | | |
Current assets: | | | | | | | | | | | | | |
Cash and cash equivalents
|
| | | $ | 51,686 | | | | | $ | 90,002 | | |
Accounts receivable, net
|
| | | | 2,828 | | | | | | 1,951 | | |
Inventories
|
| | | | 14,942 | | | | | | 9,441 | | |
Current portion of vendor advances
|
| | | | 236 | | | | | | 5,239 | | |
Prepaid expenses and other current assets
|
| | | | 2,656 | | | | | | 1,793 | | |
Due from related parties
|
| | | | 446 | | | | | | 829 | | |
Total current assets
|
| | | $ | 72,794 | | | | | $ | 109,255 | | |
Property and equipment, net
|
| | | | 6,881 | | | | | | 5,325 | | |
Security deposits and non-current portion of vendor advances
|
| | | | 48,837 | | | | | | 48,896 | | |
Other assets – related party
|
| | | | 1,581 | | | | | | 1,661 | | |
Total assets
|
| | | $ | 130,093 | | | | | $ | 165,137 | | |
Liabilities, convertible preferred stock and stockholders’ deficit | | | | | | | | | | | | | |
Current liabilities: | | | | | | | | | | | | | |
Accounts payable
|
| | | $ | 8,330 | | | | | $ | 5,168 | | |
Deferred revenue, current
|
| | | | 5,350 | | | | | | 3,200 | | |
Due to related parties
|
| | | | 7 | | | | | | 6 | | |
Accrued purchase commitments, current
|
| | | | 63,376 | | | | | | — | | |
Accrued expenses and other current liabilities
|
| | | | 8,879 | | | | | | 6,951 | | |
Total current liabilities
|
| | | $ | 85,942 | | | | | $ | 15,325 | | |
Deferred revenue, non-current
|
| | | $ | 1,099 | | | | | $ | 587 | | |
Convertible debt
|
| | | | 21,019 | | | | | | — | | |
Loan payable
|
| | | | 4,366 | | | | | | — | | |
Other non-current liabilities
|
| | | | 624 | | | | | | 566 | | |
Total liabilities
|
| | | $ | 113,050 | | | | | $ | 16,478 | | |
Commitments and contingencies (Note 14) | | | | | | | | | | | | | |
Convertible preferred stock: | | | | | | | | | | | | | |
Convertible preferred stock (Series A, B, C and D) $.0001 par value with an aggregate liquidation preference of $383,829; 103,242,914 shares authorized, issued and outstanding
|
| | | | 360,937 | | | | | | 360,937 | | |
Stockholders’ deficit: | | | | | | | | | | | | | |
Common stock $.0001 par value; 102,000,000 and 102,000,000 shares authorized at September 30, 2020 and December 31, 2019, respectively; 5,865,800 and 5,720,842 shares issued and outstanding at September 30, 2020 and December 31, 2019, respectively.
|
| | | | 1 | | | | | | 1 | | |
Special-voting common stock, $.0001 par value; 25,952,123 shares authorized; 0 shares issued and outstanding
|
| | | | — | | | | | | — | | |
Additional paid-in capital
|
| | | | 27,969 | | | | | | 19,782 | | |
Accumulated deficit
|
| | | | (371,864) | | | | | | (232,061) | | |
Total stockholders’ deficit
|
| | | $ | (343,894) | | | | | $ | (212,278) | | |
Total liabilities, convertible preferred stock and stockholders’ deficit
|
| | | $ | 130,093 | | | | | $ | 165,137 | | |
| | |
Nine months ended September 30
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Revenue: | | | | | | | | | | | | | |
Product
|
| | | $ | 25,820 | | | | | $ | 15,405 | | |
Subscription
|
| | | | 4,777 | | | | | | 1,441 | | |
Total revenue
|
| | | $ | 30,597 | | | | | $ | 16,846 | | |
Cost of revenue: | | | | | | | | | | | | | |
Product (including losses on purchase commitments of $64.0 million and $0.0, respectively)
|
| | | $ | 99,259 | | | | | $ | 23,212 | | |
Subscription
|
| | | | 1,260 | | | | | | 427 | | |
Total cost of revenue
|
| | | $ | 100,519 | | | | | $ | 23,639 | | |
Gross margin
|
| | | $ | (69,922) | | | | | $ | (6,793) | | |
Operating expenses: | | | | | | | | | | | | | |
Research and development
|
| | | $ | 36,427 | | | | | $ | 34,593 | | |
Sales and marketing
|
| | | | 17,408 | | | | | | 8,216 | | |
General and administrative
|
| | | | 15,651 | | | | | | 12,164 | | |
Total operating expenses
|
| | | | 69,486 | | | | | | 54,973 | | |
Loss from operations
|
| | | $ | (139,408) | | | | | $ | (61,766) | | |
Interest income
|
| | | $ | 238 | | | | | $ | 2,332 | | |
Interest expense
|
| | | | (418) | | | | | | — | | |
Other income (expense), net
|
| | | | (183) | | | | | | (27) | | |
Loss before provision for income taxes
|
| | | $ | (139,771) | | | | | $ | (59,461) | | |
Provision for income taxes
|
| | | | 32 | | | | | | — | | |
Net loss and comprehensive loss
|
| | | $ | (139,803) | | | | | $ | (59,461) | | |
Net loss per common share attributable to common stockholders, basic and diluted
|
| | | $ | (24.09) | | | | | $ | (10.61) | | |
Weighted-average shares used to compute net loss per share attributable to common stockholders, basic and diluted
|
| | | | 5,804,354 | | | | | | 5,604,129 | | |
| | |
Convertible Preferred Stock
|
| | |
Common Stock
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
stockholders’ deficit |
| |||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
December 31, 2018
|
| | | | 103,242,914 | | | | | $ | 360,937 | | | | | | | 5,549,112 | | | | | $ | 1 | | | | | $ | 13,420 | | | | | $ | (132,364) | | | | | $ | (118,943) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (59,461) | | | | | | (59,461) | | |
Common stock issued upon exercise of stock options
|
| | | | — | | | | | | — | | | | | | | 97,749 | | | | | | — | | | | | | 201 | | | | | | — | | | | | | 201 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 4,112 | | | | | | — | | | | | | 4,112 | | |
September 30, 2019
|
| | | | 103,242,914 | | | | | $ | 360,937 | | | | | | | 5,646,861 | | | | | $ | 1 | | | | | $ | 17,733 | | | | | $ | (191,825) | | | | | $ | (174,091) | | |
| | |
Convertible Preferred Stock
|
| | |
Common Stock
|
| |
Additional
Paid-in Capital |
| |
Accumulated
Deficit |
| |
Total
stockholder’s deficit |
| |||||||||||||||||||||||||||
| | |
Shares
|
| |
Amount
|
| | |
Shares
|
| |
Amount
|
| ||||||||||||||||||||||||||||||
December 31, 2019
|
| | | | 103,242,914 | | | | | $ | 360,937 | | | | | | | 5,720,842 | | | | | $ | 1 | | | | | $ | 19,782 | | | | | $ | (232,061) | | | | | $ | (212,278) | | |
Net loss
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | — | | | | | | (139,803) | | | | | | (139,803) | | |
Common stock issued upon exercise of stock options
|
| | | | — | | | | | | — | | | | | | | 144,958 | | | | | | — | | | | | | 391 | | | | | | — | | | | | | 391 | | |
Stock-based compensation expense
|
| | | | — | | | | | | — | | | | | | | — | | | | | | — | | | | | | 7,796 | | | | | | — | | | | | | 7,796 | | |
September 30, 2020
|
| | | | 103,242,914 | | | | | $ | 360,937 | | | | | | | 5,865,800 | | | | | $ | 1 | | | | | $ | 27,969 | | | | | $ | (371,864) | | | | | $ | (343,894) | | |
| | |
Nine months ended September 30
|
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Cash flows from operating activities: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (139,803) | | | | | $ | (59,461) | | |
Adjustments to reconcile net loss to net cash used in operating activities: | | | | | | | | | | | | | |
Depreciation and amortization
|
| | | | 904 | | | | | | 497 | | |
Loss on disposal of property and equipment
|
| | | | 131 | | | | | | 3 | | |
Write-down of inventories
|
| | | | 6,923 | | | | | | 2,602 | | |
Stock-based compensation expense
|
| | | | 7,727 | | | | | | 4,112 | | |
Provision for bad debt
|
| | | | 598 | | | | | | — | | |
Accrued interest expense on convertible debt and loan payable
|
| | | | 418 | | | | | | — | | |
Changes in assets and liabilities:
|
| | | | | | | | | | | | |
Accounts receivable
|
| | | | (1,475) | | | | | | 168 | | |
Inventories
|
| | | | (12,426) | | | | | | (3,433) | | |
Prepaid expenses and other current assets
|
| | | | (863) | | | | | | 53 | | |
Security deposits and vendor advances
|
| | | | 5,064 | | | | | | (51,815) | | |
Due from related parties
|
| | | | 383 | | | | | | 657 | | |
Other assets – related party
|
| | | | 81 | | | | | | 111 | | |
Accounts payable
|
| | | | 3,236 | | | | | | 5,254 | | |
Deferred revenue
|
| | | | 2,662 | | | | | | 2,188 | | |
Due to related parties
|
| | | | 1 | | | | | | (624) | | |
Accrued purchase commitments
|
| | | | 63,376 | | | | | | — | | |
Accrued expenses and other liabilities
|
| | | | 1,986 | | | | | | 1,680 | | |
Net cash used in operating activities
|
| | | $ | (61,077) | | | | | $ | (98,008) | | |
Cash flows from investing activities: | | | | | | | | | | | | | |
Purchases of property and equipment
|
| | | | (2,597) | | | | | | (2,477) | | |
Net cash used in investing activities
|
| | | $ | (2,597) | | | | | $ | (2,477) | | |
Cash flows from financing activities:
|
| | | | | | | | | | | | |
Proceeds from exercise of stock options
|
| | | | 391 | | | | | | 201 | | |
Proceeds from loan payable
|
| | | | 4,317 | | | | | | — | | |
Proceeds from issuance of convertible debt, net
|
| | | | 20,650 | | | | | | — | | |
Net cash provided by financing activities
|
| | | $ | 25,358 | | | | | $ | 201 | | |
Net decrease in cash and cash equivalents
|
| | | $ | (38,316) | | | | | $ | (100,284) | | |
Cash and cash equivalents, beginning of period
|
| | | $ | 90,002 | | | | | $ | 214,578 | | |
Cash and cash equivalents, end of period
|
| | | $ | 51,686 | | | | | $ | 114,294 | | |
Supplemental Disclosures | | | | | | | | | | | | | |
Cash paid for interest
|
| | | | — | | | | | | — | | |
Cash paid for income taxes
|
| | | | — | | | | | | — | | |
| | | | | | | | |
Nine months ended
September 30 |
| |||||||||
| | |
Pattern of Recognition
|
| |
2020
|
| |
2019
|
| |||||||||
By Product Type | | | | | | | | | | | | | | | | | | | |
Device and accessories
|
| |
Point-in-Time
|
| | | $ | 25,820 | | | | | $ | 15,405 | | | |||
Subscription services and other services
|
| | | | OverTime | | | | | | 4,777 | | | | | | 1,441 | | |
Total | | | | | | | | | | $ | 30,597 | | | | | $ | 16,846 | | |
By geographical market: | | | | | | | | | | | | | | | | | | | |
United States
|
| | | | | | | | | $ | 22,021 | | | | | $ | 16,004 | | |
International
|
| | | | | | | | | | 8,576 | | | | | | 842 | | |
Total | | | | | | | | | | $ | 30,597 | | | | | $ | 16,846 | | |
|
| | |
September 30,
2020 |
| |
December 31,
2019 |
| ||||||
Accounts receivable, net
|
| | | $ | 2,828 | | | | | $ | 1,951 | | |
Deferred revenue, current
|
| | | | 5,350 | | | | | | 3,200 | | |
Deferred revenue, non-current
|
| | | | 1,099 | | | | | | 587 | | |
| | |
September 30,
2020 |
| |
December 31,
2019 |
| ||||||
Raw materials
|
| | | $ | 3,452 | | | | | $ | 842 | | |
Work-in progress
|
| | | | 5,562 | | | | | | 5,176 | | |
Finished goods
|
| | | | 5,928 | | | | | | 3,423 | | |
Total inventories
|
| | | $ | 14,942 | | | | | $ | 9,441 | | |
| | |
September 30,
2020 |
| |
December 31,
2019 |
| ||||||
Employee compensation
|
| | | $ | 3,223 | | | | | $ | 2,208 | | |
Customer deposits
|
| | | | 605 | | | | | | 1,171 | | |
Accrued warranty liability
|
| | | | 1,708 | | | | | | 876 | | |
Non-income tax
|
| | | | 2,743 | | | | | | 1,646 | | |
Other
|
| | | | 600 | | | | | | 1,050 | | |
Total other current liabilities
|
| | | $ | 8,879 | | | | | $ | 6,951 | | |
| | |
September 30,
2020 |
| |
September 30,
2019 |
| ||||||
Balance, beginning of period
|
| | | $ | 876 | | | | | $ | 133 | | |
Warranty provision charged to operations
|
| | | | 2,037 | | | | | | 1,627 | | |
Warranty claims
|
| | | | (1,205) | | | | | | (964) | | |
Balance, end of period
|
| | | $ | 1,708 | | | | | $ | 796 | | |
|
Class
|
| |
Year of
Issuance |
| |
Issuance
Price per share |
| |
Shares
Authorized, Issued and Outstanding |
| |
Total Proceeds or
Exchange Value |
| |
Issuance
Costs |
| |
Net Carrying
Value |
| |
Initial
Liquidation Price per share |
| ||||||||||||||||||
Series A
|
| |
2012
|
| | | $ | 0.04 | | | | | | 25,952,123 | | | | | $ | 1,038 | | | | | $ | 11 | | | | | $ | 1,027 | | | | | $ | 0.80 | | |
Series B
|
| |
2014
|
| | | | 0.80 | | | | | | 25,000,000 | | | | | | 20,000 | | | | | | 99 | | | | | | 19,901 | | | | | | 0.80 | | |
Series C
|
| |
2014 – 2015
|
| | | | 3.33 | | | | | | 27,948,045 | | | | | | 93,067 | | | | | | 246 | | | | | | 92,821 | | | | | | 3.33 | | |
Series D
|
| |
2018
|
| | | | 10.27 | | | | | | 24,342,746 | | | | | | 250,000 | | | | | | 2,812 | | | | | | 247,188 | | | | | | 10.27 | | |
| | | | | | | | | | | | | | 103,242,914 | | | | | | | | | | | | | | | | | | | | | | | | | | |
| | |
Number of
options |
| |
Weighted Average
Exercise Price |
| ||||||
Outstanding at December 31, 2019
|
| | | | 14,692,333 | | | | | $ | 2.35 | | |
Granted
|
| | | | 11,736,667 | | | | | | | | |
Exercised
|
| | | | 144,958 | | | | | | | | |
Forfeited
|
| | | | 985,589 | | | | | | | | |
Outstanding at September 30, 2020
|
| | | | 25,298,453 | | | | | | 3.52 | | |
Options exercisable at September 30, 2020
|
| | | | 12,045,389 | | | | | | 2.19 | | |
Vested and expected to vest at September 30, 2020
|
| | | | 22,155,266 | | | | | | 3.35 | | |
| | |
Nine Months Ended
September 30 |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Cost of revenue – Subscription
|
| | | $ | 12 | | | | | $ | 12 | | |
Research and development
|
| | | | 3,391 | | | | | | 2,524 | | |
Sales and marketing
|
| | | | 1,482 | | | | | | 705 | | |
General and administrative
|
| | | | 2,842 | | | | | | 871 | | |
|
| | |
Nine Months Ended
September 30 |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Total stock-based compensation expense
|
| | | $ | 7,727 | | | | | $ | 4,112 | | |
|
| | |
Nine Months Ended
September 30 |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Numerator: | | | | | | | | | | | | | |
Net loss
|
| | | $ | (139,803) | | | | | $ | (59,461) | | |
Numerator for Basic and Dilutive EPS – Loss available to Common stockholders
|
| | |
$
|
(139,803
)
|
| | | |
$
|
(59,461
)
|
| |
Denominator: | | | | | | | | | | | | | |
Common stock
|
| | | | 5,804,354 | | | | | | 5,604,129 | | |
Denominator for Basic and Dilutive EPS – Weighted-average Common stock
|
| | | | 5,804,354 | | | | | | 5,604,129 | | |
Basic and dilutive loss per share
|
| | | $ | (24.09 ) | | | | | $ | (10.61 ) | | |
| | |
Nine Months Ended
September 30 |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Outstanding options to purchase common stock
|
| | | | 24,347,961 | | | | | | 14,836,441 | | |
Outstanding convertible preferred stock (Series A through D)
|
| | | | 103,242,914 | | | | | | 103,242,914 | | |
Total anti-dilutive common equivalent shares
|
| | | | 127,590,875 | | | | | | 118,079,355 | | |
| | |
Nine months ended
September 30, |
| |||||||||
| | |
2020
|
| |
2019
|
| ||||||
Total incurred for operating expenses
|
| | | $ | 4,265 | | | | | $ | 5,329 | | |
| | |
September 31,
2020 |
| |
December 31,
2019 |
| ||||||
Due from related parties
|
| | | $ | 433 | | | | | $ | 812 | | |
Prepaid advances (included in Other assets – related party)
|
| | | | 1,424 | | | | | | 1,533 | | |
| Fiscal year ending December 31: | | | | | | | |
|
2020 (Remaining period)
|
| | | $ | 101 | | |
|
2021
|
| | | | 744 | | |
|
2022
|
| | | | 1,767 | | |
|
2023
|
| | | | 1,841 | | |
|
2024
|
| | | | 1,849 | | |
|
Thereafter
|
| | | | 8,273 | | |
|
Total future minimum rental payments
|
| | |
$
|
14,575
|
| |
| | |
Page
|
| |||
| | | | A-3 | | | |
| | | | A-3 | | | |
| | | | A-16 | | | |
| | | | A-16 | | | |
| | | | A-18 | | | |
| | | | A-18 | | | |
| | | | A-18 | | | |
| | | | A-19 | | | |
| | | | A-20 | | | |
| | | | A-20 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-21 | | | |
| | | | A-22 | | | |
| | | | A-23 | | | |
| | | | A-24 | | | |
| | | | A-24 | | | |
| | | | A-24 | | | |
| | | | A-26 | | | |
| | | | A-26 | | | |
| | | | A-26 | | | |
| | | | A-26 | | | |
| | | | A-27 | | | |
| | | | A-27 | | | |
| | | | A-30 | | | |
| | | | A-30 | | | |
| | | | A-31 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-32 | | | |
| | | | A-33 | | | |
| | | | A-33 | | | |
| | | | A-33 | | | |
| | | | A-33 | | | |
| | | | A-35 | | | |
| | | | A-35 | | | |
| | | | A-35 | | | |
| | | | A-36 | | | |
| | | | A-36 | | | |
| | | | A-36 | | |
| | |
Page
|
| |||
| | | | A-37 | | | |
| | | | A-37 | | | |
| | | | A-37 | | | |
| | | | A-37 | | | |
| | | | A-38 | | | |
| | | | A-39 | | | |
| | | | A-39 | | | |
| | | | A-40 | | | |
| | | | A-40 | | | |
| | | | A-40 | | | |
| | | | A-40 | | | |
| | | | A-41 | | | |
| | | | A-41 | | | |
| | | | A-42 | | | |
| | | | A-42 | | | |
| | | | A-43 | | | |
| | | | A-44 | | | |
| | | | A-44 | | | |
| | | | A-46 | | | |
| | | | A-47 | | | |
| | | | A-48 | | | |
| | | | A-49 | | | |
| | | | A-50 | | | |
| | | | A-50 | | | |
| | | | A-51 | | | |
| | | | A-52 | | | |
| | | | A-52 | | | |
| | | | A-53 | | | |
| | | | A-53 | | | |
| | | | A-54 | | | |
| | | | A-54 | | | |
| | | | A-55 | | | |
| | | | A-56 | | | |
| | | | A-56 | | | |
| | | | A-57 | | | |
| | | | A-57 | | | |
| | | | A-57 | | | |
| | | | A-57 | | | |
| | | | A-58 | | | |
| | | | A-59 | | | |
| | | | A-59 | | |
| | |
Page
|
| |||
| | | | A-60 | | | |
| | | | A-60 | | | |
| | | | A-60 | | | |
| | | | A-61 | | | |
| | | | A-61 | | | |
| | | | A-61 | | | |
| | | | A-61 | | | |
| | | | A-61 | | | |
| | | | A-62 | | | |
| | | | A-62 | | | |
| | | | A-62 | | | |
| | | | A-63 | | | |
| | | | A-63 | | | |
| | | | A-63 | | | |
| | | | A-63 | | | |
| | | | A-63 | | | |
| | | | A-64 | | | |
| | | | A-64 | | | |
| | | | A-64 | | | |
| | | | A-65 | | | |
| | | | A-65 | | | |
| | | | A-65 | | |
By: |
|
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 2 | | | |
| | | | | 3 | | | |
| | | | | 5 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 8 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 9 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 10 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 11 | | |
| | | | | 11 | | | |
| | | | | 11 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 12 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 13 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 14 | | | |
| | | | | 15 | | | |
| | | | | 15 | | | |
| | | | | 15 | | | |
| | | | | 15 | | | |
| | | | | 16 | | | |
| | | | | 16 | | | |
| | | | | 16 | | | |
| | | | | 16 | | | |
| | | | | 16 | | | |
| | | | | 16 | | |
|
If to the Company, to:
Longview Acquisition Corp. 767 Fifth Avenue, 44th Floor New York, NY 10153 Attn: Mark Horowitz Email: mark@glenviewcapital.com Telephone No.: (212) 812-4720 |
| |
with copies (which shall not constitute notice) to:
Ropes & Gray LLP 1211 Avenue of the Americas New York, NY 10036 Attn: Carl P. Marcellino Email: carl.marcellino@ropesgray.com Telephone No.: (212) 841-0623 |
|
Name(s) of Subscriber: |
|
Signature of Authorized Signatory of Subscriber: |
|
Name of Authorized Signatory: |
|
Title of Authorized Signatory: |
|
Attention: |
|
Email: |
|
Facsimile No.: |
|
Telephone No.: |
|
Number of Shares: |
|
EIN Number: |
|
Subscriber Name: |
|
By: |
|
Address: |
|
| | | | | C-1 | | | |
| | | | | C-1 | | | |
| | | | | C-1 | | | |
| | | | | C-1 | | | |
| | | | | C-1 | | | |
| | | | | C-1 | | | |
| | | | | C-2 | | | |
| | | | | C-2 | | | |
| | | | | C-2 | | | |
| | | | | C-2 | | | |
| | | | | C-3 | | | |
| | | | | C-5 | | | |
| | | | | C-8 | | | |
| | | | | C-8 | | | |
| | | | | C-8 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-9 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-10 | | | |
| | | | | C-11 | | | |
| | | | | C-11 | | | |
| | | | | C-11 | | | |
| | | | | C-11 | | |
| | | | | C-11 | | | |
| | | | | C-11 | | | |
| | | | | C-11 | | | |
| | | | | C-12 | | | |
| | | | | C-12 | | | |
| | | | | C-12 | | | |
| | | | | C-12 | | | |
| | | | | C-13 | | | |
| | | | | C-13 | | | |
| | | | | C-13 | | | |
| | | | | C-13 | | | |
| | | | | C-13 | | | |
| | | | | C-13 | | | |
| | | | | C-13 | | | |
| | | | | C-13 | | | |
| | | | | C-14 | | | |
| | | | | C-14 | | | |
| | | | | C-14 | | | |
| | | | | C-14 | | | |
| | | | | C-14 | | | |
| | | | | C-14 | | | |
| | | | | C-14 | | | |
| | | | | C-14 | | | |
| | | | | C-15 | | | |
| | | | | C-15 | | | |
| | | | | C-15 | | | |
| | | | | C-15 | | | |
| | | | | C-16 | | | |
| | | | | C-16 | | | |
| | | | | C-16 | | | |
| | | | | C-16 | | | |
| | | | | C-16 | | | |
| | | | | C-16 | | |
Exhibit
|
| |
Description
|
| ||||
| | 10 | .8+ | | | | Offer of Employment Letter, dated as of December 18, 2019, by and between Butterfly and Laurent Faracci. | |
| | 10 | .9+ | | | | Offer of Employment Letter, dated as of January 6, 2017, by and between Butterfly and Gioel Molinari. | |
| | 10 | .10+** | | | | Offer of Employment Letter, dated as of February 29, 2020, by and between Butterfly and Dave Perri, as supplemented by the Employment Agreement Letter, dated as of November 18, 2020, by and between Butterfly and Dave Perri. | |
| | 10 | .11+** | | | | Offer of Employment Letter, dated as of March 16, 2020, by and between Butterfly and Stephanie Fielding, as supplemented by the Employment Agreement Letter, dated as of November 18, 2020, by and between Butterfly and Stephanie Fielding. | |
| | 10 | .12+** | | | | Employment Agreement Letter, dated as of November 18, 2020, by and between Butterfly and Darius Shahida. | |
| | 10 | .13.1@ | | | |
Exclusive (Equity) Agreement by and between Butterfly and the Board of Trustees of the
Leland Stanford Junior University, dated as of June 28, 2013. |
|
| | 10 | .13.2@ | | | |
Amendment No. 1, made effective as of April 23, 2019, to Exclusive (Equity) Agreement,
dated as of June 28, 2013, by and between Butterfly and the Board of Trustees of the Leland Stanford Junior University. |
|
| | 10 | .14.1@ | | | | Manufacture and Supply Agreement, dated as of October 7, 2015, by and between Butterfly and Benchmark Electronics, Inc. | |
| | 10 | .14.2@ | | | | Amendment No. 1, made effective as of August 2, 2019, to Manufacture and Supply Agreement, dated as of October 7, 2015, by and between Butterfly and Benchmark Electronics, Inc. | |
| | 10 | .15@ | | | | Distribution Agreement, dated as of July 11, 2018, by and between Butterfly and Cardinal Health 105, Inc. | |
| | 10 | .16.1@** | | | | Foundry Service Agreement, dated as of March 31, 2019, by and between Butterfly and Taiwan Semiconductor Manufacturing Company Limited. | |
| | 10 | .16.2@** | | | |
Amendment No. 1, made effective as of October 1, 2020, to Foundry Service Agreement,
dated March 31, 2019, by and between Butterfly and Taiwan Semiconductor Manufacturing Company Limited. |
|
| | 23 | .1 | | | | Consent of WithumSmith+Brown, PC. | |
| | 23 | .2 | | | | Consent of Deloitte & Touche LLP. | |
| | 23 | .3 | | | | Consent of Ropes & Gray LLP (included in Exhibit 5.1 and 8.1 hereto). | |
| | 24 | .1 | | | | Power of Attorney (included on signature page to the proxy statement/prospectus which forms part of this registration statement). | |
| | 99 | .1** | | | | Form of Preliminary Proxy Card. | |
| | 101 | .INS | | | | XBRL Instance Document | |
| | 101 | .SCH | | | | XBRL Taxonomy Extension Schema Document | |
| | 101 | .CAL | | | | XBRL Taxonomy Extension Calculation Linkbase Document | |
| | 101 | .DEF | | | | XBRL Taxonomy Extension Definition Linkbase Document | |
| | 101 | .LAB | | | | XBRL Taxonomy Extension Label Linkbase Document | |
| | 101 | .PRE | | | | XBRL Taxonomy Extension Presentation Linkbase Document | |
| | | | LONGVIEW ACQUISITION CORP. | | |||
| | | | By: | | |
/s/ John Rodin
Name: John Rodin
Title: Chief Executive Officer |
|
|
Name
|
| |
Title
|
| |
Date
|
|
| | | | | | | | |
|
/s/ Larry Robbins
Larry Robbins
|
| |
Chairman
|
| |
November 27, 2020
|
|
|
/s/ John Rodin
John Rodin
|
| |
Chief Executive Officer and Director
(Principal Executive Officer) |
| |
November 27, 2020
|
|
|
/s/ Mark Horowitz
Mark Horowitz
|
| |
Chief Financial Officer
(Principal Financial and Accounting Officer) |
| |
November 27, 2020
|
|
|
/s/ Westley Moore
Westley Moore
|
| |
Director
|
| |
November 27, 2020
|
|
|
/s/ Derek Cribbs
Derek Cribbs
|
| |
Director
|
| |
November 27, 2020
|
|
|
/s/ Randy Simpson
Randy Simpson
|
| |
Director
|
| |
November 27, 2020
|
|
Exhibit 10.8
Laurent Faracci
Dear Laurent,
On behalf of Butterfly Network, I am pleased to offer you a position as Chief Executive Officer beginning as soon as practical. In addition, you will have a seat on the Board of Directors for Butterfly Network, for the period of time during which you remain the CEO of Butterfly Network. You will report to the Butterfly Network Board of Directors. Your annualized compensation in this position will consist of an annual base salary of $600,000 paid in twice monthly pay periods, less required deductions.
Beginning with the 2020 calendar year, you will be considered annually for a bonus targeted at 100% of your annual base salary. At the end of each calendar year, beginning with 2020, the Board of Directors after meaningful consultation with you, will establish performance goals and targets for the following year, review the bonus target for the current calendar year and discuss the opportunity to obtain a greater bonus for performance exceeding the calendar year’s targets. For the calendar year 2020, you will receive a guaranteed bonus which will be 25% of your annual base salary ($150,000). Such bonuses shall be paid each February of the following calendar year, and it will be a condition of your eligibility to receive any bonus that you remain employed with Butterfly Network through the scheduled date of payment of such bonuses.
In addition to the outlined cash compensation, as soon as reasonably practicable following your commencement of employment with Butterfly Network and subject to the approval of the Butterfly Network Board of Directors, you will receive stock options in Butterfly Network for approximately 4% of the outstanding shares of Butterfly Network common stock as of your start date, equal to 4,350,000 options (the “Time-Based Options”). The exercise price for the Time-Based Options will be equal to the fair market value of the common stock on the grant date. The Time-Based Options are expected to be issued at $5.02 per share (current IRS common stock valuation). The Time-Based Options will vest over a five year period with the following schedule: 20% on the last day of the calendar quarter following the anniversary of your start date, and 1.67% at the end of each of the next 48 months thereafter.
In the event that your employment with Butterfly Network is terminated by Butterfly Network without Cause (as defined below), or by you with Good Reason (as defined below), within three (3) months prior to, or twelve (12) months following a sale of the company, and subject to your executing a separation agreement that includes a general release of claims against Butterfly Network and all of its affiliates, the options will be vested in full, and there will be an extension to five (5) years from your date of termination to exercise any vested options, however, the extension period can in no case be later than ten (10) years from the original date of grant.
In addition, as soon as reasonably practicable following your commencement of employment with Butterfly Network and subject to the approval of the Butterfly Network Board of Directors, you will receive additional stock options in Butterfly Network for approximately 1.5% of the outstanding shares of Butterfly Network common stock as of your start date, equal to 1,635,000 options (the “2X Financing Options”). The 2X Financing Options are expected to be issued at $5.02 per share (current IRS common stock valuation). The vesting for the 2X Financing Options will be such that if a financing event where the amount raised exceeds $100 million occurs within two years of your start date at which time the Company’s stock price is valued in excess of two (2) times the last stock price ($10.27), and if existing stock holders (and vested options) are allowed to tender up to 5% of their position (the “2X Financing”), then the 2X Financing Options shall be vested in full upon the closing date of such 2X Financing. In the event that your employment with Butterfly Network is terminated by Butterfly Network without Cause (as defined below), or by you with Good Reason (as defined below), within three (3) months prior to the closing of such 2X Financing, and subject to your executing a separation agreement that includes a general release of claims against Butterfly Network and all of its affiliates, the 2X Financing Options will be vested in full upon the closing date of such 2X Financing, and there will be an extension to five (5) years from your date of termination to exercise any vested options, however, the extension period can in no case be later than ten (10) years from the original date of grant.
Additionally, as soon as reasonably practicable following your commencement of employment with Butterfly Network and subject to the approval of the Butterfly Network Board of Directors, you will receive additional stock options in Butterfly Network for approximately 1.5% of the outstanding shares of Butterfly Network common stock as of your start date, equal to 1,635,000 options(the “5X Financing Options”). The 5X Financing Options are expected to be issued at $5.02 per share (current IRS common stock valuation). The vesting for the 5X Financing Options will be such that if a financing event where the amount raised exceeds $100 million occurs within five years of your start date and the Company’s stock price is valued in excess of five (5) times the last stock price ($10.27), and if existing stock holders (and vested options) are allowed to tender up to 5% of their position (the “5X Financing”), then the 5X Financing Options shall be vested in full upon the closing date of such 5X Financing. In the event that your employment with Butterfly Network is terminated by Butterfly Network without Cause (as defined below), or by you with Good Reason (as defined below), within three (3) months prior to the closing of such 5X financing, and subject to your executing a separation agreement that includes a general release of claims against Butterfly Network and all of its affiliates, the 5X Financing Options will be vested in full upon the closing date of such 5X Financing, and there will be an extension to five (5) years from your date of termination to exercise any vested options, however, the extension period can in no case be later than ten (10) years from the original date of grant.
As soon as reasonably practicable following your commencement of employment with Butterfly Network and subject to the approval of the Hyperfine Research Board of Directors, you will receive stock options in Hyperfine Research for approximately 0.5% of the outstanding shares of Hyperfine Research common stock as of your start date, equal to 350,000 options (the “Hyperfine Options”). The exercise price for the options will be equal to the fair market value of the common stock on the grant date. Options are expected to be issued at $1.23 per share (current IRS common stock valuation). The options will vest over a five-year period with the following schedule: 20% on the last day of the calendar quarter following the anniversary of your start date, and 1.67% at the end of each of the next 48 months thereafter.
As soon as reasonably practicable following your commencement of employment with Butterfly Network and subject to the approval of the 4Bionics Board of Directors, you will receive incentive stock units in 4Bionics for approximately 0.5% of the outstanding units of 4Bionics units as of your start date, equal to 409,000 units (the “4Bionics Units”). 4Bionics LLC is set up to own equity of various operating subsidiaries, and currently holds all of the stock of Tesseract Health, EpilepsyCo and Homodeus. The threshold price for the units will be equal to the distribution value of the units on the grant date. Options are expected to be issued at a $0.96 per unit threshold price. The units will vest over a five-year period with the following schedule: 20% on the last day of the calendar quarter following the anniversary of your start date, and 1.67% at the end of each of the next 48 months thereafter.
In the event that your employment with Butterfly Network is terminated by Butterfly Network without Cause (as defined below), or by you with Good Reason (as defined below), and subject to your executing a separation agreement that includes a general release of claims against Butterfly Network and all of its affiliates that becomes effective and irrevocable within sixty (60) days following your termination of employment, you will receive: one year of unvested options acceleration with regard to the Time-Based Options; payment of one (1) year of your then annual base salary; payment of a bonus of 50% of your then annual base salary; and an extension to five (5) years from your date of termination to exercise any vested options, however, the extension period can in no case be later than ten (10) years from the original date of grant.
If the period for execution and non-revocation of the release spans two calendar years, payment of any severance amounts shall commence to be paid, as applicable, in the second calendar year. Any required release of claims shall be in Butterfly Network’s standard form of release applicable to senior executives and shall apply only to claims in respect of your employment and the termination therefrom.
“Cause” shall mean: (A) intentional misconduct or gross negligence in the performance of your duties or obligations; (B) alcohol or substance abuse that materially interferes with the performance of your duties or obligations; (C) conviction of, or plea of guilty or nolo contendere to, a felony; (D) engaging in fraud, misappropriation, dishonesty or embezzlement in connection with Butterfly Network; (E) violation of your Noncompetition, Confidentiality and Intellectual Property Agreement with Butterfly Network or any other uncured material breach of a material agreement between you and the company; or (F) repeated violation of any of the material written policies of Butterfly Network (including but not limited to discrimination or harassment), or a single serious violation of any of the material written policies or practices, which Butterfly Network, in its good faith discretion, determines is materially injurious to the company; provided, however, that none of the events described in the foregoing clauses shall constitute Cause unless Butterfly Network notifies you in writing the occurrence of such event(s) alleged to give rise to Cause with ninety (90) days thereof.
“Good Reason” shall mean, without your prior written consent, (A) a material reduction of your title, authorities, duties or responsibilities, (B) a material reduction of your Base Salary or guaranteed or target annual bonus opportunity, (C) a material breach by Butterfly Network of any other obligation owing to you under this Agreement or any other written agreement between you and Butterfly Network, or (D) Butterfly Network’s requiring you to be based in any office or location beyond a fifty (50) mile radius of your then principal place of employment; provided, however, that none of the events described in the foregoing clauses shall constitute Good Reason unless (x) you have notified Butterfly Network in writing the occurrence of such event(s) giving rise to Good Reason with ninety (90) days thereof, (y) Butterfly Network shall not have cured such event(s) within thirty (30) days after receipt of such written notice, and (z) your termination of employment occurs within ninety (90) days following the end of such 30-day cure period.
You will be based out of Butterfly Network’s facility in New York City, NY. You will receive a one-time payment of $100,000 (net), to cover the costs of your relocation. Butterfly Network will need supporting documentation that shows you have moved prior to the payment being paid. Such payment will be recoverable in full by Butterfly Network in the event that you voluntarily terminate your employment without Good Reason prior to 12 months from your start date.
Prior to your permanent relocation, you will receive a $5,000 per month (net) temporary housing stipend for a period of up to 12 months, to be paid upon securing an apartment in New York City. In addition, we will offer $1,000 per month (net) for furnishing costs should you need it.
Butterfly Network will reimburse you up to $10,000 (net) for your legal fees related to the current negotiation, subject to presentation of receipts for the costs incurred. These legal fee reimbursements will be recoverable in full by Butterfly Network in the event that you voluntarily terminate your employment without Good Reason prior to 12 months from your start date.
Butterfly Network recognizes the need for employees to take time away from the office to creatively recharge. We also believe in taking personal responsibility for managing our own time, workload and results. For these reasons our Flexible Paid Time Off (FPTO) policy affords eligible employees the flexibility to be given an indeterminate amount of paid time off from work for vacation, personal or family obligations and other personal requirements, subject to the requirements of the policy, including advance notice and prior approval in Butterfly Network’s discretion. In no event will any employee be compensated for unused vacation time. You will also be eligible to participate in medical and other benefit plans in accordance with the rules and eligibility of those plans currently in effect. Health insurance shall commence on your start date. Further, while we expect you to remain with Butterfly Network for a long time, this letter is not an employment contract and you will be an at-will employee. This letter is subject to successful completion of a background check. By signing this letter, you authorize Butterfly Network to conduct such background check.
Butterfly Network considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. As a condition of this offer of employment, you are required to sign Butterfly Network’s Noncompetition, Confidentiality and Intellectual Property Agreement.
Notwithstanding anything in this Agreement to the contrary: (a) to the extent any provision in this Agreement constitutes a “nonqualified deferred compensation plan” under Section 409A(d)(1) of the Internal Revenue Code of 1986, as amended (the “Code”), which provides benefits to you upon your “separation from service” under Section 409A(a)(2)(A)(i) of the Code, and at such time you are a “specified employee” under Section 409A(a)(2)(B)(i) of the Code, then any such payment to you shall not commence prior to the date that is six (6) months after the date of your separation from service and any amounts withheld during such six-month period shall be paid once benefits commence; (b) the right to a series of payments hereunder is treated as a right to a series of separate payments; (c) the provisions in this Agreement, and plans and arrangements referenced hereunder, are intended to comply with the applicable requirements of Section 409A of the Code and may be limited, construed and interpreted in accordance with such intent; (d) the amount of any reimbursements and benefits you receive in one year shall not affect amounts provided in any other year, and such reimbursements and benefits may not be liquidated or exchanged for any other reimbursement or benefit; and (e) no acceleration of any payment shall be permitted if such acceleration would result in you being taxed under Section 409A of the Code.
We appreciate your exceptional talent and are very excited about you joining our growing and dynamic team at Butterfly Network. We firmly believe that Butterfly Network offers a unique combination of emotional, intellectual, and interpersonal stimulation that will be truly enjoyable. As a member of our growing team you will be in the rare position of helping to shape the culture and direction of our organization. We have tremendous opportunities ahead of us, and I am confident you have the expertise required to help us achieve our objectives. If you have any questions regarding this offer, the position, or the benefits programs, please do not hesitate to reach out.
Sincerely,
Butterfly Network, Inc.
By: | /s/ Jonathan Rothberg |
Name: Jonathan Rothberg
Title: CEO & Founder
ACCEPTS AND AGREED
By: | /s/ Laurent Faracci |
Name: Laurent Faracci
Exhibit 10.9
January 6, 2017
Gioel Molinari
Dear Gioel:
On behalf of Butterfly Network, we are pleased to offer you the position of President beginning January 9, 2017, or as soon as practical. Your annualized compensation in this position will consist of an annual base salary of $350,000 paid in twice monthly pay periods, less required deductions. In addition, you will be eligible for a one-time bonus of up to 40% of your then current salary upon Butterfly’s product launch.
In addition to the outlined cash compensation, you will receive 1,900,000 stock options in Butterfly Network, which will vest over a four year period with the following schedule: 25% one year after the last day of the calendar quarter of your start date, and 2.08% at the end of each month thereafter. Immediately following a change of control in Butterfly Network 50% of any unvested shares will accelerate, and upon your termination without Cause (as defined below) following a change of control in Butterfly Network 100% of any unvested shares will accelerate.
“Cause” shall mean: (A) intentional misconduct or gross negligence in the performance of your duties or obligations; (B) alcohol or substance abuse that materially interferes with the performance of your duties or obligations; (C) repeated absence from work during normal business hours for reasons other than permitted absence; (D) commission of, or plea of guilty or nolo contendere to, a felony; (E) engaging in fraud, misappropriation, dishonesty or embezzlement in connection with Butterfly Network; (F) violation of your Non-Disclosure and Non-Competition Agreement with Butterfly Network or any other material agreement between you and the company; (G) repeated violation of any of the material policies or practices of Butterfly Network (including but not limited to discrimination or harassment), or a single serious violation of any of the material policies or practices which Butterfly Network, in its discretion, determines is materially injurious to the company.
You will be based out of Butterfly Network’s facility in Guilford, CT, subject to travel to Butterfly Network’s facility in New York, NY on an as needed basis.
As an employee of Butterfly Network, you will be eligible for 20 days of paid time off each calendar year, pro-rated for any partial year based on your start date. All vacation must be used by the end of each calendar year. In no event will any employee be compensated for unused vacation time. You will also be eligible to participate in medical and other benefit plans in accordance with the rules and eligibility of those plans currently in effect. Health insurance shall commence on the first of the month following your start date. Further, while we expect you to remain with Butterfly Network for a long time, this letter is not an employment contract and you will be an at-will employee.
Butterfly Network considers the protection of its confidential information, proprietary materials and goodwill to be extremely important. As a condition of this offer of employment, you are required to sign Butterfly Network’s Confidentiality, Intellectual Property, and Non-Compete Agreement.
We appreciate your exceptional talent and are very excited about you joining our growing and dynamic team at Butterfly Network. We firmly believe that Butterfly Network offers a unique combination of emotional, intellectual, and interpersonal stimulation that will be truly enjoyable. As one of the key members of our team you will be in the rare position of shaping the culture and direction of our organization. We have tremendous opportunities ahead of us, and I am confident you have the expertise required to help us achieve our objectives. If you have any questions regarding this offer, the position, or the company’s benefits programs, please do not hesitate to reach out.
Please note that this offer will expire on January 11, 2017 unless accepted by you in writing prior to such date.
Sincerely,
BUTTERFLY NETWORK, INC.
By: | /s/ Gregg Fergus |
Name: Gregg Fergus
Title: Board Member
ACCEPTED AND AGREED:
Signature: | /s/ Gioel Molinari |
Name: Gioel Molinari
Exhibit 10.13.1
EXCLUSIVE (EQUITY) AGREEMENT
This Agreement between THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Butterfly Network, Inc. (“Butterfly”), a corporation having a principal place of business at 530 Old Whitfield Street, Guilford, CT 06473, is effective on the 28 day of June, 2013 (“Effective Date”).
1 | BACKGROUND |
Stanford has an assignment of an invention entitled “[***] Wafer Bonding,” which was invented in the laboratory of [***], and is described in Stanford Docket [***]. The invention was made in the course of research supported by Stanford. Stanford wants to have the invention perfected and marketed as soon as possible so that resulting products may be available for public use and benefit. The invention has been licensed to multiple parties.
2 | DEFINITIONS |
2.1 | “Exclusive” means that, subject to Articles 3 and 5 and the Other Licensee, Stanford will not grant further licenses under the Licensed Patents, except under the Non-Exclusive Applications, in the Licensed Field of Use in the Licensed Territory. |
2.2 | “Fully Diluted Basis” means the total number of shares of Butterfly’s issued and outstanding common stock, assuming: |
(A) | the conversion of all issued and outstanding securities convertible into common stock; |
(B) | the exercise of all issued and outstanding warrants or options, regardless of whether then exercisable; and |
(C) | the issuance, grant, and exercise of all securities reserved for issuance pursuant to any Butterfly stock or stock option plan then in effect. |
2.3 | “Licensed Field of Use” means all ultrasound applications except for the Excluded Applications. |
2.4 | “Licensed Patent” means Stanford’s [***] (Stanford Docket [***]), any foreign patent application corresponding thereto, and any divisional, continuation, continuation-in-part (to the extent claiming priority to the parent) or reexamination application, extension, and each patent that issues or reissues from any of these patent applications. Any claim of an unexpired Licensed Patent is presumed to be valid unless it has been held to be invalid by a final judgment of a court of competent jurisdiction from which no appeal can be or is taken. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 1 of 20
2.5 | “Licensed Product” means a product or part of a product in the Licensed Field of Use the making, using, importing or selling of which by Butterfly or its sublicensee, absent this license, infringes, induces infringement, or contributes to infringement of a Licensed Patent. |
2.6 | “Licensed Territory” means the world. |
2.7 | “Net Sales” means all gross revenue derived by Butterfly or sublicensees from Licensed Product. Net Sales excludes the following items (but only as they pertain to the making, using, importing or selling of Licensed Products, are included in gross revenue, and are separately billed): |
(A) | [***]; |
(B) | [***]; |
(C) | [***]; and |
(D) | [***]. |
2.8 | “Nonroyalty Sublicensing Consideration” means any consideration received by Butterfly from a sublicensee hereunder but excluding any consideration for: |
(A) | [***]; |
(B) | [***]; |
(C) | [***]; |
(D) | [***] and |
(E) | [***]. |
2.9 | “Stanford Indemnitees” means Stanford and Stanford Hospitals and Clinics, and their respective trustees, officers, employees, students, and agents. |
2.10 | “Sublicense” means any agreement between Butterfly and a third party that contains a grant to Stanford’s Licensed Patents regardless of the name given to the agreement by the parties; however, an agreement to make, have made, use or sell Licensed Products on behalf of Butterfly is not considered a Sublicense. |
2.11 | “Non-exclusive Applications” means the applications listed in Appendix C. |
2.12 | “Excluded Applications” means: |
(A) | [***]; |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 2 of 20
(B) | [***]; and |
(C) | [***]. |
2.13 | “Other Licensee” means [***], including any assigns of the foregoing as a particular Stanford licensing agreement in effect or under license discussion as of the Effective Date hereof may allow. |
3 | GRANT |
3.1 | Grant. Subject to the terms and conditions of this Agreement, Stanford grants Butterfly a license under the Licensed Patent in the Licensed Field of Use to make, have made, use, import, offer to sell and sell Licensed Product in the Licensed Territory. |
3.2 | Exclusivity. |
(A) | The license is Exclusive, including the right to Sublicense under Article 4, in the Licensed Field of Use, but excluding the Non-exclusive Applications, beginning on the Effective Date and ending on the earlier of: |
(1) | December 31, 2023; or |
(2) | the 7th anniversary of the date of first sale of any Licensed Product by Butterfly or a sublicensee. Butterfly agrees to promptly inform Stanford in writing of this first sale. |
(B) | The license is non-exclusive with respect to the Non-exclusive Applications beginning on the Effective Date and ending when the last Licensed Patent expires. |
(C) | Stanford will consider an extension to the Exclusive term if Butterfly provides notice to Stanford, at least [***] ([***]) [***] prior to the Exclusive term, along with information regarding factors that might support extending the Exclusive term. |
3.3 | Nonexclusivity. After the Exclusive term, the license will be nonexclusive until the last Licensed Patent expires. |
3.4 | Retained Rights. Stanford retains the right, on behalf of itself and all other non-profit research institutions, to practice the Licensed Patent for any non-profit purpose, including sponsored research and collaborations. Butterfly agrees that, notwithstanding any other provision of this Agreement, it has no right to enforce the Licensed Patent against any such institution. Stanford and any such other institution have the right to publish any information included in the Licensed Patent. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 3 of 20
3.5 | Specific Exclusion. Stanford does not: |
(A) | grant to Butterfly any other licenses, implied or otherwise, to any patents or other rights of Stanford other than those rights granted under Licensed Patent, regardless of whether the patents or other rights are dominant or subordinate to any Licensed Patent, or are required to exploit any Licensed Patent; |
(B) | commit to Butterfly to bring suit against third parties for infringement; and |
(C) | agree to furnish to Butterfly any technology or technological information or to provide Butterfly with any assistance. |
4 | SUBLICENSING |
4.1 | Permitted Sublicensing. Butterfly may grant Sublicenses in the Licensed Field of Use during the Exclusive term, excluding the Non-Exclusive Applications, and only if Butterfly is developing or selling Licensed Products. Butterfly may grant Sublicenses in the Licensed Field after the Exclusive Term subject to Stanford’s prior approval on a case by case basis, such approval not to be unreasonably withheld. Sublicenses with any exclusivity must include diligence requirements commensurate with the diligence requirements of Appendix A. Stanford agrees that Butterfly may apportion without discrimination between Butterfly and Stanford patents a commercially reasonable percentage of sublicensing payments made to Stanford pursuant to Section 4.6, provided however that Butterfly provides Stanford with the proposed apportionment and justification prior Butterfly’s payment pursuant to Section 8.1. Stanford and Butterfly agree to meet to discuss such proposed apportionment if in Stanford’s opinion the apportionment does not reasonably reflect the value of the Licensed Patents. |
4.2 | Required Sublicensing. If Butterfly has not sold and is not aggressively developing (as evidenced by Butterfly’s internal records) Licensed Products in a potential market or market territory for which there is a company willing to be a sublicensee (hereafter “Willing Sublicensee”), Butterfly will, at Stanford’s request, negotiate in good faith a Sublicense with any such Willing Sublicensee. Stanford would like licensees to address unmet needs, such as those of neglected patient populations or geographic areas, giving particular attention to improved [***] for the developing world. Butterfly shall not be required to enter into a Sublicense with a Willing Licensee on any term(s) more favorable than those set forth in this Agreement. If Butterfly and Willing Sublicensee do not enter into a Sublicense within [***] of Willing Sublicensee’s first written request to Butterfly for a Sublicense, Stanford may provide to Butterfly written notice thereof. Butterfly shall have [***] ([***]) [***] from receipt of such notice to finalize a Sublicense with Willing Sublicensee. If Butterfly fails to finalize a Sublicense within such period, Stanford may grant a license directly to such Willing Sublicensee on terms no more favorable than those set forth in this Agreement. In the event of Stanford entering into a license with a Willing Sublicensee as permitted by this section, such Willing Sublicensee will upon execution thereof become an Other Licensee hereunder. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 4 of 20
4.3 | Sublicense Requirements. Any Sublicense: |
(A) | is subject to this Agreement; |
(B) | will reflect that any sublicensee will not further Sublicense; |
(C) | will prohibit sublicensee from paying royalties to an escrow or other similar account; |
(D) | will expressly include provisions consistent with Articles 8, 9, and 10 for the benefit of Stanford; |
(E) | will include the provisions of Section 4.4 and require the transfer of all the sublicensee’s obligations to Butterfly, including the payment of royalties specified in the Sublicense, to Stanford or its designee, if this Agreement is terminated. |
4.4 | Litigation by Sublicensee. Any Sublicense must include the following clauses: |
(A) | In the event sublicensee brings an action seeking to invalidate any Licensed Patent: |
(1) | sublicensee will [***] during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by the sublicensee is both valid and infringed by a Licensed Product, sublicensee will [***]; |
(2) | sublicensee will have no right to recoup any royalties paid before or during the period challenge; |
(3) | any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa Clara County, and the parties agree not to challenge personal jurisdiction in that forum; |
(4) | sublicensee shall not pay royalties into any escrow or other similar account. |
(B) | Sublicensee will provide written notice to Stanford at least [***] prior to bringing an action seeking to invalidate a Licensed Patent. Sublicensee will include with such written notice an identification of all prior art it believes invalidates any claim of the Licensed Patent. |
4.5 | Copy of Sublicenses and Sublicensee Royalty Reports. Butterfly will submit to Stanford a copy of each Sublicense, any subsequent amendments and all copies of sublicensees’ royalty reports. Beginning with the first Sublicense, the Chief Financial Officer or equivalent will certify annually regarding the name and number of sublicensees. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 5 of 20
4.6 | Sharing of Sublicensing Income. In addition to a pass-through earned royalty on Net Sales at the royalty rate specified in Section 7.9, Butterfly will pay to Stanford [***]% of all Nonroyalty Sublicensing Consideration for the sublicense of Licensed Patents. |
4.7 | Royalty-Free Sublicenses. If Butterfly pays all royalties due Stanford from a sublicensee’s Net Sales, Butterfly may grant that sublicensee a royalty-free or non-cash: |
(A) | Sublicense or |
(B) | cross-license. |
5 | SPONSOR RIGHTS |
The invention was disclosed to Stanford without any sponsor attribution, other than Stanford.
6 | DILIGENCE |
6.1 | Milestones. Butterfly will diligently develop, manufacture, and sell Licensed Product and will diligently develop markets for Licensed Product. In addition, Butterfly will meet the milestones shown in Appendix A, and notify Stanford in writing as each milestone is met. Butterfly shall have the right to propose alternative milestones, or modifications to the milestones, including for scientific, developmental, and/or commercial reasons. Stanford agrees to consider the reasons given and the efforts made by Butterfly to achieve the milestones. |
6.2 | Progress Report. By March 1 of each year, Butterfly will submit a written annual report to Stanford covering the preceding calendar year. The report will include information sufficient to enable Stanford to satisfy reporting requirements of the U.S. Government and for Stanford to ascertain progress by Butterfly toward meeting this Agreement’s diligence requirements. Each report will describe, where relevant: Butterfly’s progress toward commercialization of Licensed Product, including work completed, key scientific discoveries, summary of work-in-progress, current schedule of anticipated events or milestones, market plans for introduction of Licensed Product, and significant corporate transactions involving Licensed Product. Butterfly will specifically describe how Licensed Product and Licensed Patent are applicable to this Agreement. |
6.3 | Clinical Trial Notice. Butterfly will notify Stanford prior to commencing any clinical trials at Stanford. |
7 | ROYALTIES |
7.1 | Issue Royalty. Butterfly will pay to Stanford a noncreditable, nonrefundable license issue royalty of $[***] upon signing this Agreement. |
7.2 | [Intentionally Omitted] |
7.3 | [Intentionally Omitted] |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 6 of 20
7.4 | Section 7.4 is set forth in Appendix D of this Agreement. |
7.5 | Section 7.5 is set forth in Appendix D of this Agreement. |
7.6 | Section 7.6 is set forth in Appendix D of this Agreement. |
7.7 | Repurchase Obligation. If Stanford is to conduct any clinical trial on behalf of Butterfly or any agent of Butterfly, upon Stanford’s request, Butterfly will repurchase all Stanford’s equity interest in Butterfly (whether or not acquired pursuant to this Agreement) and Stanford’s right to acquire Butterfly securities under this Agreement will terminate upon the commencement of such trial. Butterfly cannot begin any such trial until Stanford either divests any equity interest in Butterfly or gives written approval for the clinical trial to proceed. The repurchase price for any such equity interest will be the fair market value for that equity at the time Butterfly and Stanford enter into a definitive agreement under which any such clinical research will be performed. Fair market value of publicly traded equity instruments will be determined by taking the average of the closing price for such equity over the five days preceding such date. Fair market value of non-public equity instruments will be at least as high as the greater of: |
(A) | the last value placed on any such equity in Butterfly through an arms-length transaction regarding the issuance or sale of any equity in Butterfly; or |
(B) | the last value placed on such equity by Butterfly’s Board of Directors in good faith in connection with any transaction purporting to value such equity at fair market value, other than this repurchase of shares from Stanford. |
7.8 | License Maintenance Fee. Beginning [***] and each [***] until the first sale of a Licensed Product, Butterfly will pay Stanford a yearly license maintenance fee of $[***]. Thereafter, on each [***] Butterfly will pay Stanford a yearly license maintenance fee of $[***]. Yearly maintenance payments are nonrefundable, but they are creditable each year as described in Section 7.11. |
7.9 | Earned Royalty. Butterfly will pay Stanford earned royalties of [***] percent ([***]%) (Y%) on Net Sales. |
7.10 | Earned Royalty if Butterfly Challenges the Patent. Notwithstanding the above, should Butterfly bring an action seeking to invalidate any Licensed Patent, Butterfly will pay royalties to Stanford at the rate of [***] x Y percent ([***]xY%) of the Net Sales of all Licensed Products sold during the pendency of such action. Moreover, should the outcome of such action determine that any claim of a patent challenged by Butterfly is both valid and infringed by a Licensed Product, Butterfly will pay royalties at the rate of [***] x Y percent ([***]xY%) of the Net Sales of all Licensed Products sold. |
7.11 | Creditable Payments. The license maintenance fee for a year may be offset against earned royalty payments due on Net Sales occurring in that year. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 7 of 20
For example:
(A) | if Butterfly pays Stanford a $[***] maintenance payment for year Y, and according to Section 7.9 $[***] in earned royalties are due Stanford for Net Sales in year Y, Butterfly will only need to pay Stanford an additional $[***] for that year’s earned royalties. |
(B) | if Butterfly pays Stanford a $[***] maintenance payment for year Y, and according to Section 7.9 $[***] in earned royalties are due Stanford for Net Sales in year Y, Butterfly will not need to pay Stanford any earned royalty payment for that year. Butterfly will not be able to offset the remaining $[***] against a future year’s earned royalties. |
7.12 | Obligation to Pay Royalties. If certain Licensed Products are made, used, imported, or offered for sale before the date this Agreement terminates, and those Licensed Products are sold after the termination date, Butterfly will pay Stanford an earned royalty for its exercise of rights based on the Net Sales of those Licensed Products. |
7.13 | No Escrow. Butterfly shall not pay royalties into any escrow or other similar account. |
7.14 | Currency. Butterfly will calculate the royalty on sales in currencies other than U.S. Dollars using the appropriate foreign exchange rate for the currency quoted by the Wall Street Journal on the close of business on the last banking day of each calendar quarter. Butterfly will make royalty payments to Stanford in U.S. Dollars. |
7.15 | Non-U.S. Taxes. Butterfly will pay all non-U.S. taxes related to royalty payments. These payments are not deductible from any payments due to Stanford. |
7.16 | Interest. Any payments not made when due will bear interest at the lower of (a) the Prime Rate published in the Wall Street Journal plus [***] basis points or (b) the maximum rate permitted by law. |
8 | ROYALTY REPORTS, PAYMENTS, AND ACCOUNTING |
8.1 | Quarterly Earned Royalty Payment and Report. Beginning with the first sale of a Licensed Product by Butterfly or a sublicensee, Butterfly will submit to Stanford a written report (even if there are no sales) and an earned royalty payment within [***] days after the end of each calendar quarter. This report will be in the form of Appendix B and will state the number, description, and aggregate Net Sales of Licensed Product during the completed calendar quarter. The report will include an overview of the process and documents relied upon to permit Stanford to understand how the earned royalties are calculated. With each report Butterfly will include any earned royalty payment due Stanford for the completed calendar quarter (as calculated under Section 7.9). |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 8 of 20
8.2 | No Refund. In the event that a validity or non-infringement challenge of a Licensed Patent brought by Butterfly is successful, Butterfly will have no right to recoup any royalties paid before or during the period challenge. |
8.3 | Termination Report. Butterfly will pay to Stanford all applicable royalties and submit to Stanford a written report within [***] days after the license terminates. Butterfly will continue to submit earned royalty payments and reports to Stanford after the license terminates, until all Licensed Products made or imported under the license have been sold. |
8.4 | Accounting. Butterfly will maintain records showing manufacture, importation, sale, and use of a Licensed Product for [***] years from the date of sale of that Licensed Product. Records will include general-ledger records showing cash receipts and expenses, and records that include: production records, customers, invoices, serial numbers, and related information in sufficient detail to enable Stanford to determine the royalties payable under this Agreement. |
8.5 | Audit. Butterfly will allow Stanford to designate a third-party independent auditing firm to examine Butterfly’s records (subject to confidentiality, pursuant to a non-disclosure agreement reasonably specified by Butterfly) to verify payments made by Butterfly under this Agreement. |
8.6 | Paying for Audit. Stanford will pay for any audit done under Section 8.5. But if the audit reveals an underreporting of earned royalties due Stanford of [***]% or more for the period being audited, Butterfly will pay the audit costs. |
9 | EXCLUSIONS AND NEGATION OF WARRANTIES |
9.1 | Negation of Warranties. Stanford provides Butterfly the rights granted in this Agreement AS IS and WITH ALL FAULTS. Stanford makes no representations and extends no warranties of any kind, either express or implied. Among other things, Stanford disclaims any express or implied warranty: |
(A) | of merchantability, of fitness for a particular purpose, |
(B) | of non-infringement or |
(C) | arising out of any course of dealing. |
9.2 | No Representation of Licensed Patent. Butterfly also acknowledges that Stanford does not represent or warrant: |
(A) | the validity or scope of any Licensed Patent, or |
(B) | that the exploitation of Licensed Patent or Technology will be successful. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 9 of 20
10 | INDEMNITY |
10.1 | Indemnification. Butterfly will indemnify, hold harmless, and defend all Stanford Indemnitees against any claim of any kind arising out of or related to the exercise of any rights granted Butterfly under this Agreement or the breach of this Agreement by Butterfly. |
10.2 | No Indirect Liability. Neither party shall be liable for any special, consequential, lost profit, expectation, punitive or other indirect damages in connection with any claim arising out of or related to this Agreement, whether grounded in tort (including negligence), strict liability, contract, or otherwise. |
10.3 | Workers’ Compensation. Butterfly will comply with all statutory workers’ compensation and employers’ liability requirements for activities performed under this Agreement. |
10.4 | Insurance. During the term of this Agreement, Butterfly will maintain Comprehensive General Liability Insurance, including Product Liability Insurance, with a reputable and financially secure insurance carrier to cover the activities of Butterfly and its sublicensees. The insurance will provide minimum limits of liability of $[***] and will include all Stanford Indemnitees as additional insureds. Insurance must cover claims incurred, discovered, manifested, or made during or after the expiration of this Agreement and must be placed with carriers with ratings of at least A- as rated by A.M. Best. Within [***] days of the Effective Date of this Agreement, Butterfly will furnish a Certificate of Insurance evidencing primary coverage and additional insured requirements. Butterfly will provide to Stanford [***] days prior written notice of cancellation or material change to this insurance coverage. Butterfly will advise Stanford in writing that it maintains excess liability coverage (following form) over primary insurance for at least the minimum limits set forth above. All insurance of Butterfly will be primary coverage; insurance of Stanford and Stanford Hospitals and Clinics will be excess and noncontributory. |
11 | EXPORT |
Butterfly and its affiliates and sublicensees shall comply with all United States laws and regulations controlling the export of licensed commodities and technical data. (For the purpose of this paragraph, “licensed commodities” means any article, material or supply but does not include information; and “technical data” means tangible or intangible technical information that is subject to US export regulations, including blueprints, plans, diagrams, models, formulae, tables, engineering designs and specifications, manuals and instructions.) These laws and regulations may include, but are not limited to, the Export Administration Regulations (15 CFR 730-774), the International Traffic in Arms Regulations (22 CFR 120-130) and the various economic sanctions regulations administered by the US Department of the Treasury (31 CFR 500-600).
Among other things, these laws and regulations prohibit or require a license for the export or retransfer of certain commodities and technical data to specified countries, entities and persons. Butterfly hereby gives written assurance that it will comply with, and will cause its affiliates and sublicensees to comply with all United States export control laws and regulations, that it bears sole responsibility for any violation of such laws and regulations by itself or its affiliates or sublicensees, and that it will indemnify, defend and hold Stanford harmless for the consequences of any such violation.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 10 of 20
12 | MARKING |
Before any Licensed Patent issues, Butterfly will mark Licensed Product with the words “Patent Pending.” Otherwise, Butterfly will mark Licensed Product with the number of any issued Licensed Patent.
13 | STANFORD NAMES AND MARKS |
Butterfly will not identify Stanford in any promotional statement, or otherwise use the name of any Stanford faculty member, employee, or student, or any trademark, service mark, trade name, or symbol of Stanford or Stanford Hospitals and Clinics, including the Stanford name, unless Butterfly has received Stanford’s prior written consent. Permission may be withheld at Stanford’s sole discretion. Stanford hereby consents to Butterfly identifying [***] (“[***]”) [***] as an advisor to Butterfly and a member of Butterfly’s scientific advisory board, provided however that Butterfly has permission for such identification by [***].
14 | PROSECUTION AND PROTECTION OF PATENTS |
14.1 | Patent Prosecution. Stanford will be responsible for preparing, filing, and prosecuting broad and extensive patent claims (including any interference or reexamination actions) and for maintaining all Licensed Patents. |
14.2 | Infringement Procedure. Butterfly will promptly notify Stanford if it believes a third party infringes a Licensed Patent or if a third party files a declaratory judgment action with respect to any Licensed Patent. Stanford will use reasonable efforts to enforce the Licensed Patents. If Stanford is unable to stop a suspected infringement, Stanford agrees to meet in good faith with Butterfly to discuss a mutually acceptable course of action to stop such infringement, including but not limited to, permitting Butterfly to enforce such Licensed Patent at its expense. |
15 | TERMINATION |
15.1 | Termination by Butterfly. Butterfly may terminate this Agreement by giving Stanford written notice at least 30 days in advance of the effective date of termination selected by Butterfly. |
15.2 | Termination by Stanford. |
(A) | Subject to the exception at the end of this Section 15.2, Stanford may also terminate this Agreement if Butterfly: |
(1) | is materially delinquent on any payment; |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 11 of 20
(2) | is not diligently developing and commercializing Licensed Product; |
(3) | materially misses a milestone described in Appendix A; |
(4) | is in material breach of any substantive provision; or |
(5) | knowingly provides any false report or is materially delinquent on any report. |
(B) | Termination under this Section 15.2 will take effect 60 days after written notice by Stanford unless Butterfly remedies the problem in that 60-day period. |
If Butterfly does not satisfy its obligations under 15.2(A)(2), 15.2(A)(3), or 15.2(A)(5), and does not remedy the problem as provided in 15.2(B), then this Agreement shall not terminate (but shall remain subject to termination in accordance with the teams hereof) and the license granted under this Agreement shall convert to non-exclusive.
15.3 | Surviving Provisions. Surviving any termination or expiration are: |
(A) | Butterfly’s obligation to pay royalties accrued or accruable; |
(B) | any claim of Butterfly or Stanford, accrued or to accrue, because of any breach or default by the other party; and |
(C) | the provisions of Articles 8, 9, and 10 and any other provision that by its nature is intended to survive. |
16 | ASSIGNMENT |
16.1 | Permitted Assignment by Butterfly. Subject to Section 16.3, Butterfly may assign this Agreement as part of a sale or change of control, regardless of whether such a sale or change of control occurs through an asset sale, stock sale, merger or other combination, or any other transfer of: |
(A) | Butterfly’s entire business; or |
(B) | that part of Butterfly’s business that exercises all rights granted under this Agreement. |
16.2 | Any Other Assignment by Butterfly. Any other attempt to assign this Agreement by Butterfly is null and void. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 12 of 20
16.3 | Conditions of Assignment. Prior to any assignment, the following conditions must be met: |
(A) | Butterfly must give Stanford [***] days prior written notice of the assignment, including the new assignee’s contact information; and |
(B) | the new assignee must agree in writing to Stanford to be bound by this Agreement; and |
(C) | Stanford must have received a $[***] assignment fee. |
16.4 | After the Assignment. Upon a permitted assignment of this Agreement pursuant to Article 16, Butterfly will be released of liability under this Agreement and the term “Butterfly” in this Agreement will mean the assignee. |
16.5 | Bankruptcy. In the event of a bankruptcy, assignment is permitted only to a party that can provide adequate assurance of future performance, including diligent development and sales, of Licensed Product. |
17 | DISPUTE RESOLUTION |
17.1 | Dispute Resolution by Arbitration. Any dispute between the parties regarding any payments made or due under this Agreement will be settled by arbitration in accordance with the JAMS Arbitration Rules and Procedures. The parties are not obligated to settle any other dispute that may arise under this Agreement by arbitration. |
17.2 | Request for Arbitration. Either party may request such arbitration. Stanford and Butterfly will mutually agree in writing on a third party arbitrator within [***] days of the arbitration request. The arbitrator’s decision will be final and nonappealable and may be entered in any court having jurisdiction. |
17.3 | Discovery. The parties will be entitled to discovery as if the arbitration were a civil suit in the California Superior Court. The arbitrator may limit the scope, time, and issues involved in discovery. |
17.4 | Place of Arbitration. The arbitration will be held in Stanford, California unless the parties mutually agree in writing to another place. |
17.5 | Patent Validity. Any dispute regarding the validity of any Licensed Patent shall be litigated in the courts located in Santa Clara County, California, and the parties agree not to challenge personal jurisdiction in that forum. |
18 | NOTICES |
18.1 | Legal Action. Butterfly will provide written notice to Stanford at least [***] prior to bringing an action seeking to invalidate any Licensed Patent or a declaration of non-infringement. Butterfly will include with such written notice an identification of all prior art it believes invalidates any claim of the Licensed Patent. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 13 of 20
18.2 | All Notices. All notices under this Agreement are deemed fully given when written, addressed, and sent as follows: |
All general notices to Butterfly are mailed or emailed to:
Name: | Butterfly Network, Inc. |
Address: | 530 Old Whitfield St. |
Guilford, CT 06437
Attn: President & Legal Dept.
Email: | [***] |
All financial invoices to Butterfly (i.e., accounting contact) are e-mailed to:
Name: | Darlene Allen |
Email: | [***] |
All progress report invoices to Butterfly (i.e., technical contact) are e-mailed to:
Name: | Greg Charvat, Tyler Ralston & Nevada Sanchez |
Email: | [***] |
All general notices to Stanford are e-mailed or mailed to:
Office of Technology Licensing
El Camino Real
Palo Alto, CA 94306-1106
[***]
All payments to Stanford are mailed to:
Stanford University
Office of Technology Licensing
Department #44439
P.O. Box 44000
San Francisco, CA 94144-4439
All progress reports to Stanford are e-mailed or mailed to:
Office of Technology Licensing
El Camino Real
Palo Alto, CA 94306-1106
[***]
Either party may change its address with written notice to the other party.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 14 of 20
19 | MISCELLANEOUS |
19.1 | Waiver. No term of this Agreement can be waived except by the written consent of the party waiving compliance. |
19.2 | Choice of Law. This Agreement and any dispute arising under it is governed by the laws of the State of California, United States of America, applicable to agreements negotiated, executed, and performed within California. |
19.3 | Entire Agreement. The parties have read this Agreement and agree to be bound by its terms, and further agree that it constitutes the complete and entire agreement of the parties and supersedes all previous communications, oral or written, and all other communications between them relating to the license and to the subject hereof. This Agreement may not be amended except by writing executed by authorized representatives of both parties. No representations or statements of any kind made by either party, which are not expressly stated herein, will be binding on such party. |
19.4 | Exclusive Forum. The state and federal courts having jurisdiction over Stanford, California, United States of America, provide the exclusive forum for any court action between the parties relating to this Agreement. Butterfly submits to the jurisdiction of such courts, and waives any claim that such a court lacks jurisdiction over Butterfly or constitutes an inconvenient or improper forum. |
19.5 | Headings. No headings in this Agreement affect its interpretation. |
19.6 | Electronic Copy. The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 15 of 20
The parties execute this Agreement in duplicate originals by their duly authorized officers or representatives.
THE BOARD OF TRUSTEES OF THE LELAND STANDFORD JUNIOR UNIVERSITY | ||
Signature: | /s/ Katharine Ka | |
Name: | Katharine Ka | |
Title: | Director Technology Licensing | |
Date: | June 28, 2013 | |
BUTTERFLY NETWORK, INC. | ||
Signature: | /s/ Alex Morgan | |
Name: | Alex Morgan | |
Title: | General Counsel | |
Date: | 6/28/13 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 16 of 20
Appendix A - Milestones
1. | By [***], Butterfly will provide Stanford a detailed document covering Butterfly’s plans as to projected product development, markets and sales forecasts, manufacturing and operations, and financial forecasts until at least $[***] (“Business Plan”). Stanford will treat this Business Plan as confidential information and to protect it as Stanford would its own confidential information. |
2. | By [***], Butterfly will have $[***] of available non-contingent, operating capital to proceed with the manufacturing scale-up of Licensed Product. Capital will be from [***] and unused capital will be on deposit in a financial institutional acceptable to both Stanford and Butterfly. |
3. | By [***], Butterfly will [***]. |
4. | By [***], Butterfly will [***]. |
5. | By [***], Butterfly will [***]. |
6. | Butterfly or a sublicensee must [***]. |
7. | By [***], Butterfly will [***]. |
8. | By [***], Butterfly will [***]. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 17 of 20
Appendix B — Sample Reporting Form
Stanford Docket No. S
This report is provided pursuant to the license agreement between Stanford University and (Company Name)
License Agreement Effective Date:
Name(s) of Licensed Products being reported:
Report Covering Period | |
Yearly Maintenance Fee | $ |
Number of Sublicenses Executed | |
Gross Revenue | $ |
Net Sales | $ |
Royalty Calculation | |
Royalty Subtotal | $ |
Credit | $ |
Royalty Due | $ |
Comments:
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 18 of 20
Appendix C — Non-exclusive Applications
1 - [***]
2 - [***]
3 - [***]
4 - [***]
5 - [***]
6 - [***]
7 - [***]
8 - [***]
9 - [***]
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 19 of 20
Appendix D — Equity Purchase Rights
7.4 | [***] Purchase Right. In any private offering of Butterfly’s equity securities (or securities convertible into or exercisable for Butterfly’s equity securities) for cash (or in satisfaction of debt issued for cash) having its final closing held on or after the date of this Agreement, Stanford may purchase for cash up to [***] securities issued in such offering. This right will expire following [***]. Notwithstanding the foregoing, this Section 7.4 will not apply to [***]; provided, however, that [***]. |
7.5 | Future Offerings; Limitation on Right to Purchase. In any private offering of Butterfly’s equity securities (or securities convertible into or exercisable for Butterfly’s equity securities) in exchange for cash (or in satisfaction of debt issued for cash), Stanford may purchase for cash that number of the securities issued in such offering as is necessary for Stanford to maintain its pro rata ownership interest in Butterfly on a Fully-Diluted Basis. For the avoidance of doubt, if both Section 7.4 and this Section 7.5 apply to an offering, the provision granting Stanford the superior rights will govern. |
7.6 Purchase Terms and Procedures; Financial Information; Notices.
(A) In any offering subject to Section 7.4 or 7.5:
(1) | Butterfly will give Stanford notice [***]; |
(2) | Stanford’s purchase right shall be [***], |
regardless of the [***]; provided, however, [***];
(3) | Stanford may elect to exercise its right of purchase, in whole or in part, by notice given to Butterfly within [***] Stanford business days (i.e., days other than Saturdays, Sundays, and holidays or other days on which Stanford is officially closed) after receipt of Butterfly’s notice; and |
(4) | If Stanford elects not to purchase, or fails to give an election notice within such period, Stanford’s purchase right will not apply to the offering if (and only if and to the extent) it is consummated within [***] days on the same or less favorable (to the investor) terms as stated in Butterfly’s notice to Stanford. |
(B) | If there is a conflict between the terms of this Agreement and those of any Butterfly investor rights or similar agreement to which Stanford is a party, this Agreement will prevail. |
(C) | Stanford’s rights under Sections 7.4 and 7.5 will not apply to [***]. |
(D) | In the event of the closing of a firm commitment underwritten public offering of Butterfly’s common stock, the rights granted in Sections 7.4 and 7.5 will terminate (in addition to any earlier termination pursuant to their terms) immediately before, and shall not apply to, such closing. |
(E) | Butterfly shall furnish to Stanford, as promptly as reasonably practicable, [***]. |
(F) | Notwithstanding any notice provision in this Agreement to the contrary, any notice given under this Agreement that refers or relates to any of Section 7.3 through and including Section 7.6 shall be copied concurrently to [***]; provided, however, that delivery of the copy will not by itself constitute notice for any purpose under this Agreement. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page: 20 of 20
Exhibit 10.13.2
S93-199 • EE | Amendment | 4/23/2019 |
AMENDMENT No. 001
TO THE
LICENSE AGREEMENT EFFECTIVE THE 28TH DAY OF JUNE 2013
BETWEEN
STANFORD UNIVERSITY
AND
BUTTERFLY NETWORK, INC.
Effective the 23rd day of April, 2019, THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY (“Stanford”), an institution of higher education having powers under the laws of the State of California, and Butterfly Network, Inc. (“Butterfly”), a corporation having a principal place of business at 530 Old Whitfield Street, Guilford, CT 06473, agree as follows:
1. | BACKGROUND |
1.1 | Stanford and Butterfly are parties to a License Agreement effective the 28th day of June, 2013 (“Original Agreement”) covering a portfolio of inventions directed to [***] invented in the laboratory of [***] and described in Stanford Docket [***] et al. |
Stanford and Butterfly wish to amend the Original Agreement to adjust the diligence milestones of the license.
2. | AMENDMENT |
2.1 | Paragraph 6.1 of Original Agreement is hereby deleted in its entirety and replaced with the following: |
Milestones. Butterfly will use commercially reasonable efforts to develop, manufacture, and sell Licensed Product and to develop markets for Licensed Product, consistent with the technical and process requirements of its chip manufacturer(s). Butterfly will promptly notify Stanford in writing when the first commercial sale of a Licensed Product has occurred.
3. | OTHER TERMS |
3.1 | All other terms of the Original Agreement remain in full force and effect. |
[***] = CERTAIN
CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT
MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page 1 OF 2
S93-199 • EE | Amendment | 4/23/2019 |
3.2 | The parties to this document agree that a copy of the original signature (including an electronic copy) may be used for any and all purposes for which the original signature may have been used. The parties further waive any right to challenge the admissibility or authenticity of this document in a court of law based solely on the absence of an original signature. |
The parties execute this Amendment No. 001 by their duly authorized officers or representatives.
THE BOARD OF TRUSTEES OF THE LELAND STANFORD JUNIOR UNIVERSITY | ||
Signature: | /s/ Scott Elrod |
Name: | Scott Elrod |
Title: | Associate Director |
Date: | April 23, 2019 |
BUTTERFLY NETWORK, INC. | ||
Signature: | /s/ Alex Magary |
Name: | Alex Magary |
Title: | VP, Legal & Asst. Corp. Secretary |
Date: | April 23, 2019 |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED
BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND
(II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Page 2 OF 2
Exhibit 10.14.1
MANUFACTURE AND SUPPLY AGREEMENT
by and between
BUTTERFLY NETWORK, INC.
and
BENCHMARK ELECTRONICS, INC.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
TABLE OF CONTENTS
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
i
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
ii
MANUFACTURE AND SUPPLY AGREEMENT
This Manufacture and Supply Agreement (this “Agreement”), effective as of October 1, 2015 (the “Effective Date”), is by and between BUTTERFLY NETWORK, INC., a Delaware corporation having a place of business at 530 Old Whitfield Street, Guilford, Connecticut 06437 (“Butterfly”), and BENCHMARK ELECTRONICS, INC., a corporation organized under the laws of the State of Texas USA having a place of business at 100 Innovative Way, Nashua, NH 03062 (“Manufacturer”). Butterfly and Manufacturer may be referred to individually as a “Party” and collectively as the “Parties.”
BACKGROUND
Butterfly is a medical device company that has developed certain proprietary diagnostic and therapeutic imaging technology and related products. Manufacturer is in the business of manufacturing and supplying medical devices. The Parties desire to enter into an agreement pursuant to which Manufacturer shall manufacture for, and supply to, Butterfly certain of Butterfly’s products under the terms set forth herein.
AGREEMENT
NOW, THEREFORE, in consideration of the mutual covenants and undertakings expressed in this Agreement, Manufacturer and Butterfly agree as follows:
1. DEFINITIONS.
As used in this Agreement:
(a) “Affiliate” means, with respect to a Party, any person or entity that controls, is controlled by, or is under common control with such Party, where “control” means ownership of fifty percent (50%) or more of the outstanding voting securities (but only as long as such person or entity meets these requirements).
(b) “Applicable Laws” mean all laws, statutes, rules, regulations, ordinances of any governmental authority (including any amendments thereto), applicable to the import, export, manufacture and distribution of Products, including, without limitation, (a) the applicable regulations and guidelines of the FDA Quality System Requirements (QSR), and (b) the applicable regulations and guidelines of the council of the European Communities Medical Device Directive (MDD) and CE mark standards.
(c) “Butterfly Marks” has the meaning given to such term in Section 3.6 below.
(d) “Butterfly Technology” means all Technology incorporated in or relating to any Product, including the Specifications and any Confidential Information of Butterfly, that is (a) owned or controlled by Butterfly as of the Effective Date or (b) acquired or developed by or for Butterfly or any of its Affiliates during the term of this Agreement.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 1 of 36 |
(e) “Certificate” has the meaning given to such term in Section 8.1 below.
(f) “cGMP” refers to current good manufacturing practice requirements to the extent applicable to a supplier of a Medical Component, as promulgated by the regulatory authority, including, without limitation, the Federal Food, Drug and Cosmetic Act and 21 C.F.R. Part 820; and in the future, as applicable, Canadian Medical Devices Conformity Assessment System to the extent necessary for Product to be distributed in Canada; Medical Device Directive MDD 93/42 EEC/AIMDD 90/385/EEC (Directive 2007/47/EC).
(g) “Claim” shall refer to the following that are asserted by third parties: demands, claims, actions, causes of action, proceedings, suits, assessments, losses, damages, liabilities, settlements, judgments, fines, penalties, interest, costs and expenses (including fees and disbursements of counsel) of every kind.
(h) “Completion” means the completion of all manufacturing, testing, and quality processes rendering a Product ready for shipment.
(i) “Confidential Information” has the meaning given to such term in Section 15.1 below.
(j) “Cost Reduction” shall refer to lower Product purchase prices based on [***].
(k) “Developed Product Technology” has the meaning given to such term in Section 5.2 below.
(l) “Delivered Cost” shall mean Manufacturer’s quoted cost of the Components together with any applicable VAT and/or in-process duties, plus a [***] percent ([***]%) markup on said costs for handling and reasonable restocking charges.
(m) “DFx” shall refer to any combination of DFC, DFM, DFT or DFQ, if any, provided by Manufacturer relative to any Product(s) in connection with volume production. “DFC” shall refer to any Design For Component services including component change proposals provided by Manufacturer relative to any Product(s). “DFM” shall refer to any Design For Manufacturability services including design changes proposals for manufacturability provided by Manufacturer relative to any Product(s). “DFT” shall refer to any Design For Testability services including proposed design changes for testability provided by Manufacturer relative to any Product(s). “DFQ” shall refer to any Design for Quality services including proposed design changes for testability provided by Manufacturer relative to any Product(s).
(n) “Disclosing Party” has the meaning given to such term in Section 15.1 below.
(o) “Excess Components” shall mean Authorized Purchases of individual Component inventory that exceeds a [***] ([***]) month demand for such Component based upon Butterfly’s Order(s) and/or then-current Forecast.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 2 of 36 |
(p) “Finished Device” shall have that same meaning set forth in 21CFR§820.3.
(q) “Governmental Authority” means any country, including any political subdivision thereof, court instrumentality, or agency thereof, and any other federal, state, or public authority, domestic or foreign, exercising governmental powers and having jurisdiction, and all statutes, laws, ordinances, regulations, orders, decrees, permits, writs, process and rules issued thereby which may be applicable to the Parties’ performance under this Agreement.
(r) “Improvements” has the meaning given to such term in Section 5.2
(s) “Intellectual Property Right” means any and all intellectual property rights and industrial property rights and all other proprietary rights, including patents, patent rights, copyrights, trademarks, and trade secrets and all registrations and applications for all of the foregoing in any jurisdiction.
(t) “Long Lead-Time Components” shall refer to those Components with procurement lead times greater than [***].
(u) “MOO” shall refer to that Minimum Order Quantity of Components that certain suppliers may require generally or at certain price points.
(v) “MRO” shall refer to Maintenance, Repair and Operations supplies and consumables that are necessary for normal equipment maintenance, repair and manufacturing operations but not typically included in the Specifications.
(w) “NCNR” shall refer to Component purchases that are non-cancellable and/or nonreturnable, whether designated as such at purchase or that become NCNR after purchase (including “broken” packages, open reels, or passage of time).
(x) “Manufacturer of Record” shall have that meaning set forth for “Manufacturer” in 21CFR§820.3.
(y) “Medical Component” shall have that meaning set forth for “Component” in 21CFR§820.3.
(z) “Nonconforming Product” shall refer to a Product that does not conform to the Product warranty provided in Section 12.3 below.
(aa) “Obsolete Components” shall mean the individual Authorized Purchase Component inventory for which there is no demand based upon Butterfly’s Orders and/or Forecast (whether as a result of an ECO or any other reason whatsoever), even though Butterfly considers the Products that incorporate such Components as “active” Products because such Products remain on Butterfly’s Product list or price list made available to Butterfly’s end users.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 3 of 36 |
(bb) “Passive Sourcing” shall include sending a letter to Component suppliers advising them of their PCR responsibilities, then archiving any data/certification communications received and forwarding such information to Butterfly.
(cc) “Product” means a Butterfly finished good or product listed in a Product Schedule, accepted quotation or purchase order.
(dd) “Product Content Regulation” or “PCR” shall refer to the following laws and/or regulations on content, packaging, or labeling of Products, Components or substances, and/or similar issues concerning the Products or Components: “RoHS” (EU Directive 2002/95/EC on Restriction on the use of certain Hazardous Substances in electrical and electronics equipment); “WEEE” (EU Directive 2002/96/EC on Waste Electrical and Electronic Equipment); “REACH” (EC Regulation No 1907/2006 on Registration, Evaluation and Authorization of Chemicals); and EU Member State’s implementations of the foregoing; “Conflict Minerals” as defined in the U.S. Dodd-Frank Wall Street Reform and Consumer Protection Act § 1502(b), implementing legislation and rules; the People’s Republic of China (PRC) Measures for Administration of the Pollution Control of Electronic Information Products of 2006; and/or any other mutually agreed PCR; together with implementing regulations and/or administrative rules.
(ee) “Product Schedule” means a schedule signed by both Parties under which Manufacturer will manufacture a specific Product. Each Product Schedule shall reference this Agreement. A sample form of Product Schedule is attached hereto as Exhibit A. The initial Product Schedule is attached hereto as Exhibit C.
(ff) “Quality Assurance Requirements” means the manufacture, assembly, quality assurance testing, labeling, packaging and storage in accordance with all Applicable Laws and with the requirements, procedures, and test results relating to a Product as set forth in Exhibit B, as may be modified or expanded by a Product Schedule.
(gg) “Receiving Party” has the meaning given to such term in Section 14.1 below.
(hh) “Regulatory Approval” means any approvals (including supplements, amendments, pre-and post-marketing approvals, and pricing and reimbursement approvals), licenses, registrations or authorizations of any national, supra-national (e.g., the European Commission), regional, state or local regulatory agency, department, bureau, commission, council or other governmental entity, necessary for the manufacture, distribution, use or sale of Products in a regulatory jurisdiction.
(ii) “Regulatory Requirements” has the meaning given to such term in Section 4.2 below.
(jj) “Special Tooling” has the meaning given to such term in Section 3.5 below
(kk) “Specifications” means the specifications, standards, drawings, procedures, criteria, branding and labeling requirements relating to a Product (including its manufacture, assembly, function, labeling, packaging and storage) provided by Butterfly, as may be set forth on or attached to the Product Schedule or accepted quotation.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 4 of 36 |
(ll) “Technology” means all know-how, methods, processes, techniques, proprietary information, specifications, protocols, schematics, diagrams, product designs, design layouts, databases, inventions (whether or not patentable), apparatus, hardware, devices, works of authorship, and other forms of technology.
(mm) “Test Fabrication” shall mean Manufacturer’s services for the third party design and/or build of production test equipment relative to the Products, as provided under a separate SOW for this purpose, and owned by Butterfly upon Butterfly’s inspection, approval and/or release of such production test equipment for use in manufacturing.
(nn) “Transfer Assistance” has the meaning given to such term in Section 15.3(c).
(oo) “Warranty Period” has the meaning given to such term in Section 11.3.
2. SCOPE OF AGREEMENT.
2.1 Order of Precedence. All Orders, order acknowledgments and invoices issued pursuant to this Agreement are issued for the convenience of the Parties only and shall be subject to the provisions of this Agreement and the Exhibits hereto. When interpreting this Agreement, precedence shall be given to the respective parts in the following descending order:
(a) this Agreement;
(b) Exhibits to this Agreement;
(c) SOWs subject to this Agreement;
(d) Product Quotations accepted by Customer;
(e) Product Schedules accepted by Manufacturer;
(f) if Orders are used to release product, those portions of the Order(s) which are accepted by Benchmark concerning part numbers, quantity and delivery dates, and excluding any other preprinted or referenced terms and conditions; and
(g) other documents incorporated by reference herein.
2.2 Manufacturer of Record. Manufacturer is a Manufacturer of Record and has certain responsibilities pertaining thereto as provided herein for all Products that are Finished Devices.
2.3 Quality. Manufacturer shall manufacture in conformity with ISO 13485 and cGMP.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 5 of 36 |
3. MANUFACTURING SERVICES
3.1 Product Schedule(s). Butterfly and Manufacturer may, from time to time, enter into Product Schedules under which Manufacturer will conduct the manufacturing, and related services, for the Product(s) identified thereon, in accordance with the terms of the Product Schedule and this Agreement. Butterfly may delete any Product from a Product Schedule upon written notice to Manufacturer in its sole discretion, and in such event Butterfly shall issue a Purchase Order covering the Delivered Cost of any Obsolete Inventory of materials and components to the extent such inventory was acquired by Manufacturer for fulfillment of any outstanding Butterfly purchase orders. Each Product Schedule incorporates the terms of this Agreement by reference, as fully as if they were set forth in the Product Schedule.
3.2 Manufacturing. Manufacturer shall manufacture and supply to Butterfly all Products ordered by Butterfly in accordance with this Agreement. All Products manufactured by Manufacturer must conform to the Specifications and all Applicable Laws of the United States, the EU and other jurisdictions specified by Butterfly, in each case as then in effect. Manufacturer must perform all manufacturing and packaging services at Manufacturer’s facility specified on the Product Schedule.
3.3 Quality Assurance. Manufacturer shall implement, undertake and maintain all Quality Assurance Requirements for each Product. All Products manufactured by Manufacturer must have undergone and successfully passed the Quality Assurance Requirements for such Product.
3.4 Exclusivity. Notwithstanding anything contained herein to the contrary, for [***] ([***]) years from the Effective Date Manufacturer shall not manufacture or package products at the Manufacturer’s [***] facility that are identical or substantially similar to the Products for any person or entity other than Butterfly. Notwithstanding anything contained herein, Butterfly will have the right to purchase the Products from third parties other than Manufacturer; provided, however, that if Butterfly decides to purchase any Products from a third party other than Manufacturer, Butterfly will provide Manufacturer with at least [***] ([***]) days’ notice prior to any such purchase and will agree to purchase any Product required to complete open Purchase Orders.
3.5 Materials and Tooling. Manufacturer is responsible for procuring all materials (including, without limitation, components) and equipment required to manufacture and package Products. Manufacturer shall be responsible for acquiring all special tooling or equipment (molds, test stands) designed exclusively for Products (“Special Tooling”). Butterfly will [***]. Title and ownership of such equipment shall be with Butterfly. Manufacturer agrees not to use Special Tooling to manufacture any products for any third party without Butterfly’s prior written consent. Manufacturer shall, at its own cost and expense, provide routine maintenance for the proper operation and storage of the Special Tooling while in its possession, ordinary wear and tear and 3rd party calibration excluded.
3.6 Branding. Manufacturer shall place all Butterfly marks and logos (“Butterfly Marks”) on Products as specified in writing by Butterfly. Manufacturer shall also place Butterfly Marks on all external shipping packages and/or labels. Butterfly is responsible for costs associated with this activity.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 6 of 36 |
3.7 Changes. Butterfly shall have the right, upon sufficient written notice to Manufacturer, to make any change it deems appropriate to the design of any Product or part. Such change shall be provided to Manufacturer by means of a Butterfly Engineering Change Order (ECO). The change shall be implemented on the date specified on the ECO. If any proposed ECO causes either an increase or decrease in Manufacturer’s cost or the time required to fulfill Orders following implementation of the ECO, the Parties shall mutually agree in writing upon the costs, impact on shipment dates for open Orders, inventory and any other item that may be impacted by the ECO prior to Manufacturer’s implementation of such ECO. Butterfly shall determine the disposition of on-hand inventory. Manufacturer will process [***] without non-recurring administrative cost; additional ECOs will cost a mutually agreed amount, but in no event less than [***] Dollars ($[***]) each plus [***]. If Manufacturer desires to make any change to the manufacturing processes, materials, or equipment used in the manufacture of Product or parts, and where such change affects the Product form, fit or function, or where such change triggers a 21 CFR 820 process validation, Manufacturer shall propose such change to Butterfly in writing. The proposed change shall describe the nature of the change, the reason(s) for change, anticipated schedule for implementation of change, and any validation data relevant to the change. Butterfly, in its sole discretion, shall approve or disapprove the change. Unless Butterfly has expressly approved the proposed change by approving the implementing documents, Manufacturer will continue to manufacture and deliver Product as prior to proposed change. Unless otherwise agreed upon by the Parties, Butterfly shall not be responsible for any additional charges resulting from a Manufacturer proposed change.
3.8 Inspections. Upon prior reasonable written notice, Manufacturer agrees to permit (and shall cause its third party supplier to permit with respect to any components they supply for the Products) Butterfly or designated representative to conduct inspections and test audits during Manufacturer’s regular business hours of Manufacturer’s facilities, operations and procedures, at appropriate and reasonable time intervals, to verify that the quality and performance of the Product manufacturing (and related services) are in compliance with the Specifications and the Quality Assurance Requirements, provided that such inspection does not unduly interfere with Manufacturer’s operations. Butterfly and its representatives shall: (i) comply with Manufacturer security requirements and execute any requested confidentiality or nondisclosure agreement(s) before entering Manufacturer’s premises; and (ii) observe all Manufacturer security and handling measures. Manufacturer shall cooperate with any inspection performed under this paragraph. Manufacturer and Butterfly shall mutually agree, in writing, upon corrective actions to be taken and dates scheduled for completion of such actions.
4. REGULATORY SUPPORT
4.1 Regulatory Filings. Except as otherwise expressly set forth herein, Butterfly shall have sole control over all filings necessary for Regulatory Approval of Products. Manufacturer agrees to use [***] efforts relevant to its role as manufacturer to assist Butterfly in obtaining such Regulatory Approvals throughout the world.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 7 of 36 |
4.2 Regulatory Conformance. Manufacturer agrees to conform to regulatory requirements of the FDA/QSR and ISO 13485, and any other regulatory requirements set forth in the Quality Assurance Requirements (collectively, “Regulatory Requirements”), and to cooperate with any inspections required by regulatory agencies with respect to Regulatory Requirements. Manufacturer shall obtain a Canadian Medical Device Regulations (CMDR) in concert with ISO 13485 re-certification, and shall conform to regulatory requirements of the Canadian Medical Device Regulations (CMDR). Manufacturer shall, on a timely basis, provide Butterfly with information in Manufacturer’s possession relevant to its role as the manufacturer of Products that is reasonably necessary for and relevant to Butterfly’s compliance with Regulatory Requirements. Manufacturer will provide to Butterfly such documentation, data and other information relating to Products as Butterfly may require for submission to Governmental Authorities. Manufacturer shall also provide, upon request by Butterfly, information concerning its production processes and quality control procedures (including procedures to comply with Quality Assurance Requirements) with respect to Products.
4.3 Regulatory Inspections. Manufacturer agrees to inform Butterfly within [***] ([***]) hours of notification of any regulatory inquiry, communication or inspection, which directly or indirectly relates to the manufacture of Products. In the event Manufacturer receives a notice of inspection or an inspection visit by any Governmental Authority, which involves a Product or could impact Manufacturer’s ability to produce a Product, Manufacturer shall notify Butterfly within [***] ([***]) hours of notification by such Governmental Authority. Butterfly, at its option, shall have the right to have its representatives present at any such inspection by a Government Authority. In the event there are written observations (or any other written communication) by a Governmental Authority that involve a Product or could impact Manufacturer’s ability to produce a Product, or any proposed written response by Manufacturer to any such inspection, Butterfly shall be informed within [***] ([***]) hours and be provided with copies of all documentation within [***] ([***]) hours, and shall have a reasonable opportunity to review and comment on the proposed response. If Butterfly elects to provide input to the response, such input shall be provided by Butterfly as promptly as possible and Manufacturer shall in good faith incorporate such input into the response.
4.4 Adverse Event Reporting. Butterfly shall have full control and authority for all reporting to Governmental Authorities of adverse events associated with the use of Products. If Manufacturer becomes aware of any adverse events associated with the use of such Products, it shall report all information in its possession regarding such event to Butterfly as soon as practicable after becoming aware of such information. Manufacturer shall cooperate with Butterfly in supplying information that may be used to investigate the cause of such event.
4.5 Incidents or Accidents. Manufacturer shall immediately notify Butterfly in writing of any incident or accident experienced by Manufacturer that Manufacturer in its reasonable judgment believes may affect the quality of Products that Manufacturer is obligated to deliver hereunder or its ability to meet delivery date obligations hereunder. Manufacturer shall immediately investigate such incident or accident, and Manufacturer shall provide a written report of the results of the investigation of such incidence or accident to Butterfly within [***] ([***]) business days of completion of the investigation. For avoidance of doubt, such notification shall not relieve Manufacturer of any of its obligations or liability hereunder, or waive any of Butterfly’s rights with respect thereto.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 8 of 36 |
4.6 Field Corrective Actions. In the event of a field corrective action, Butterfly shall have full control and authority over the coordination of the action, and Manufacturer shall use diligent efforts and cooperate in good faith. If the action arises out of a manufacturing nonconformance, Manufacturer’s responsibility is as stated in Section 11, Warranty. If the action arises out of a design or regulatory nonconformance directly attributable to Butterfly, Butterfly shall be responsible for all costs related to the action. If Manufacturer becomes aware of a nonconformance during the manufacturing process that might affect product already shipped, Manufacturer shall immediately inform Butterfly and shall cooperate in determining the extent of the nonconformance.
5. INTELLECTUAL PROPERTY AND LICENSES
5.1 IP Ownership. As between Butterfly and Manufacturer, Butterfly is the sole and exclusive owner of all right, title, and interest in and to Products and Butterfly Technology, and all Intellectual Property Rights therein.
5.2 Developed Product Technology. To the extent any employee or contractor of Manufacturer creates, invents, makes, reduces to practice, or develops any improvement or modification to Butterfly Technology or any other Technology that directly or indirectly relates to, or is embodied in or utilized in any Product (other than any manufacturing process Technology that is not specific to Products or products similar to the Products and was not specifically provided by Butterfly) (“Improvements”), whether solely or jointly with any employee or contractor of Butterfly, in connection with the performance of any obligations under this Agreement, Butterfly will own all rights, title, and interest in and to any such Improvements and/or Technology (including all Intellectual Property Rights therein) (collectively, “Developed Product Technology”). Manufacturer hereby irrevocably and unconditionally grants, conveys, assigns, and transfers to Butterfly any and all rights, title, and interest Manufacturer may have in the Developed Product Technology. Upon mutual agreement as to the scope of such activities, Manufacturer agrees to perform all acts deemed necessary or desirable by Butterfly to permit and assist Butterfly in perfecting and enforcing the full benefits, enjoyment, rights, and title throughout the world in the Developed Product Technology assigned under this Section 5.2. If Manufacturer has any rights in the Developed Product Technology that it cannot assign as a matter of law, Manufacturer hereby grants to Butterfly a worldwide, exclusive (without any reservation of rights), transferable, perpetual, irrevocable, fully-paid and royalty free license, with the right to sublicense, to (i) use, make, have made, sell, offer to sell, or import any product; (ii) use any process in manufacturing any product; (iii) use any method or process, or otherwise practice any invention, method, or technology embodied in such Developed Product Technology; (iv) reproduce, create derivative works of, distribute, publicly display, and publicly perform any copyrighted work included in such Developed Product Technology; and (v) otherwise exploit such Developed Product Technology in every conceivable manner.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 9 of 36 |
5.3 License Grant to Manufacturer. Subject to the terms and conditions of this Agreement, Butterfly hereby grants to Manufacturer a non-exclusive, non-transferable, revocable, fully-paid, and royalty-free license, without the right to sublicense, under all of Butterfly’s Intellectual Property Rights in Butterfly Technology and Developed Product Technology, to internally use Butterfly Technology and Developed Product Technology provided to Manufacturer for the sole purpose of manufacturing Products exclusively for Butterfly, and solely during the term of this Agreement. Manufacturer will not use any Butterfly Technology or Developed Product Technology for any other purpose, including manufacturing any product for any entity other than Butterfly.
5.4 No Implied Licenses. Except as expressly provided in Section 5, nothing contained in this Agreement is intended to confer by implication, estoppel, or otherwise, upon Manufacturer any license or rights in any Intellectual Property Rights of Butterfly.
6. FORECAST AND ORDERS
6.1 Forecast. During the term of this Agreement, except as otherwise set forth on the applicable Product Schedule, Butterfly shall provide to Manufacturer on or before the first business day of each month, a written, binding [***] ([***]) day firm Order(s), and an additional written, nonbinding [***] month rolling forecast setting forth its estimated requirement of shipment by month for Products (“Forecast”). Within [***] ([***]) business days after receiving a forecast, Manufacturer shall supply Butterfly with a written response acknowledging Manufacturer’s ability to meet the quantity and delivery date requirements of the forecast or to propose alternative quantity and delivery dates that Manufacturer is able to meet; provided that if Manufacturer does not respond within such [***]-day period, it shall be deemed to have acknowledged its ability to meet such requirements.
(a) Initial Firm Order / Forecast. The Order, and all subsequent Orders, shall be binding and may be rescheduled only in accordance with Section 7.1 below Manufacturer is authorized to make Component purchase commitments to suppliers (including Butterfly) (“Authorized Purchases”) based upon: (i) the Order(s); and (ii) the Forecast, limited to agreed Long Lead-Time Components, NCNR, and MOQ. Butterfly shall be liable to Manufacturer for all such Authorized Purchases.
(b) Subsequent Forecasts. Each month, Butterfly shall provide additional Order(s) and a Forecast update sufficient to maintain the firm Order and Forecast horizons. If Butterfly does not timely provide such additional Order(s) and a Forecast update, then the first Forecast month of the then-current Forecast shall become binding, and a new Forecast month shall be added, so that a rolling firm Order plus binding Forecast of [***] ([***]) days is always maintained.
(c) Long Lead-Time Components. Lead times for all Components are provided in Product Quotations accepted by Butterfly. Each revised Components lead time designation shall supersede the preceding one. In the event Manufacturer fails to present an updated designation of Components lead times, the Parties shall continue to rely on the preceding designations.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 10 of 36 |
(d) Minimum Order Quantity. The Parties shall periodically meet and agree on any MOQ Component purchases. Any MOQ that becomes Excess Components and/or Obsolete Components shall be dispositioned in accordance with Section 10 below.
(e) Shortages of, or Caused by, PCR Compliant Components. For any Products in which PCR Compliant Components are required, in the event that Manufacturer is unable to obtain such PCR Compliant Components within a reasonable amount of time after Manufacturer has accepted Butterfly’s Order due to market shortages of such PCR Compliant Components or any other cause or causes, Manufacturer may reschedule all or part of any scheduled shipment date related to those Products. If PCR Compliant Components can be obtained within a reasonable amount of time after Manufacturer has accepted Butterfly’s Order, Manufacturer shall be permitted to increase its Prices or pricing model for the affected Product in proportion to the increase in the cost of the Component(s). This Section shall also apply to the extent that Manufacturer is unable to obtain other Components within a reasonable amount of time after Manufacturer has accepted Butterfly’s Order due to market shortages of such other Components resulting from supplier transition to PCR Compliant Components.
6.2 Purchase Orders. Butterfly will submit purchase orders to Manufacturer for the purchase of Products. All purchase orders must be in writing and may be transmitted by mail, facsimile, or email. Each purchase order will describe the specific Products ordered, quantity, and the desired Completion date. Manufacturer must accept and fill all purchase orders to the extent consistent with this Agreement and the quantity and delivery date requirements of the acknowledged forecast. Manufacturer will use its best effort to accept any quantity that exceeds the quantity identified in the applicable forecast. Manufacturer will provide a written acknowledgement to each purchase order within [***] ([***]) business days after receiving the purchase order. Such acknowledgement will include Manufacturer’s delivery date for the order in accordance with the agreed to lead-time. Each Order shall be in the form of a written or electronic communication and shall contain the following information: (i) a description of the Product by model number; (ii) the quantity of the Product; (iii) the shipment date; (iv) the destination location to which the Product is to be delivered; and (v) transportation instructions. Each Order shall provide an order number for billing purposes.
7. RESCHEDULING AND CANCELLATION
7.1 Rescheduling. Butterfly may reschedule delivery [***] per part number per quarter, for a period not to exceed [***] ([***]) days from the original ship commit date, limited by the table below; provided, however, subject to Component availability and further that the aggregate sales dollars for all Orders issued within the time periods set forth below do not vary more than the aggregate sales dollar percentages specified therein. Additional reschedule(s) will be subject to a revised Product Quotation for reschedule impact. Any Excess Components and/or Obsolete Components resulting from such reductions in schedule shall be disposed of in accordance with Section 10.1 Manufacturer shall use commercially reasonable efforts to manufacture, deliver and ship in accordance with any rescheduling (pull-ins) request issued pursuant hereto. If Manufacturer is unable to fulfill Butterfly’s purchase order as to quantity or time of delivery, Manufacturer shall, as soon as Manufacturer becomes aware of the delay, inform Butterfly thereof in writing, stating the reason for the delay and proposing a new date for delivery; provided, for avoidance of doubt, that such notice shall not relieve Manufacturer of any obligations or liabilities therefor, or waive any of Butterfly’s rights with respect thereto.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 11 of 36 |
Calendar Days Before
P.O. Shipment Date |
Sales Dollars Percentage Change Allowance |
|
0 — 30 | [***] | |
31 —45 | [***] | |
46 — 90 | [***] | |
> 90 | [***] |
7.2 Cancellation. If Manufacturer cannot deliver Products within [***] ([***]) days of the agreed upon delivery date due solely to factors under Manufacturer’s sole control, Butterfly shall have the option to cancel the respective order without payment of any cancellation fee, but not affecting Butterfly’s material liability as otherwise provided herein. If more than [***] percent ([***]%) of Products ordered in any calendar quarter is not delivered on time due to factors under Manufacturer’s sole control, Butterfly may purchase Products from a third party and/or terminate this Agreement for material breach by Manufacturer. Butterfly may cancel an order in whole or in part, by prior written notice to Manufacturer. For purchase orders cancelled prior to the scheduled Completion date and not rescheduled for delivery, Butterfly shall be liable as provided under Section 16.5.
8. DELIVERY AND ACCEPTANCE
8.1 Delivery. Products will be considered delivered upon the completion of all manufacturing, testing and quality processes rendering the Product ready for shipment. Upon completion, Manufacturer shall transmit to Butterfly certificates of conformance (“Certificate”) certifying that Products have been manufactured, inspected and tested in accordance with all drawings and applicable Specifications, Applicable Laws, and Quality Assurance Requirements. The Certificate shall reference the product description and quantity, part no., rev level, work order number(s), serial numbers traceable to device history records, and date Completed.
8.2 Acceptance. Manufacturer shall inspect Products or Test Fabrication furnished hereunder at Manufacturer’s plant for conformance to drawings and Specifications and in compliance with the Quality Assurance Requirements. Butterfly reserves the right to inspect and test Products for purposes of verifying that such Products conform to the Specifications, the Quality Assurance Requirements and the warranties in this Agreement no later than [***] ([***]) days after Butterfly initial receipt of the Product or Test Fabrication (“Acceptance Period”), and shall be based solely on whether the Product passes a mutually agreed test procedure or inspection. If the results of the mutually agreed testing indicate Nonconforming Products, Butterfly may reject the Nonconforming Products (including all Product within the same lot) by giving written notice to Manufacturer. Manufacturer shall bring all Products into conformity or replace Nonconforming Products at Manufacturer’s own expense. Manufacturer must rework or destroy all Nonconforming Products. Manufacturer may not market, sell, or otherwise convey to any third party any Product (or component thereof) that has been rejected by Butterfly. After acceptance, all Product returns shall be handled in accordance with Section 12.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 12 of 36 |
9. SHIPPING AND PACKING
9.1 Shipping Instructions. Shipment of Product shall be in accordance with Butterfly instructions. All shipments of Products shall be EXW Manufacturer facility (Incoterms 2010), unless otherwise mutually agreed. Title to and risk of loss or damage to the Product shall pass to Butterfly upon delivery as defined in the specified Incoterm. Manufacturer shall mark, pack, package, and crate Products in accordance with the Specification. Butterfly shall be responsible for securing all export and/or import licenses, as required by applicable law, to export and/or import the Products. If requested by Butterfly, Manufacturer shall procure insurance for the shipment of the Products, with costs reimbursed by Butterfly in response to Manufacturer’s invoice therefor as set forth in Section 11 below.
9.2 Packaging. Assembled units and parts shall be packed according to Butterfly’s instructions, or otherwise packed properly to withstand transportation in accordance with Manufacturer’s standard procedures, and sound commercial practices. Prices for the assembled units shall include the cost of packing and/or protection required to prevent damage to Products during transportation.
9.3 Packing List. All shipments must be accompanied by a detailed packing list referencing customer name and ship to address, customer contact (recipient) name, the product part number and rev level for production units only, product description, quantity shipped, lot number(s) and serial number(s) and customer purchase order (obtained from Butterfly). A copy of the packing list containing the listed information shall be forwarded to Butterfly.
9.4 Ship Date. Manufacturer shall ship all Products on the scheduled ship date. Products shipped in advance of a scheduled ship date and without Butterfly’s approval may be returned to Manufacturer at Manufacturer’s expense or held at Manufacturer’s facility with deferred billing privileges. If Manufacturer becomes aware of any anticipated delay that would result in a change to the scheduled shipment date, Manufacturer will notify Butterfly as soon as possible; provided, for avoidance of doubt, that such notification shall not relieve Manufacture of any of its obligations or liabilities hereunder or waive any of Butterfly’s rights with respect thereto.
9.5 Partial Shipment. No shipment shall be deemed complete until all ordered Products have been shipped in accordance with Butterfly’s instructions. Partial shipments must be authorized by Butterfly.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 13 of 36 |
10. INVENTORY
10.1 Excess Components and Obsolete Components Inventory.
(a) Within [***] ([***]) business days after the end of each calendar quarter, Manufacturer shall provide Butterfly with a list of any Excess Components or Obsolete Components in its inventory and the Delivered Cost of such Components (the “E&O List”). Manufacturer will make good faith efforts to mitigate Butterfly’s liability by returning or selling Excess Components and Obsolete Components, and Butterfly shall be responsible for payment of all restocking fees and reimbursement of price variances from quoted standard cost.
(b) Within [***] ([***]) business days after receiving Manufacturer’s E&O List, Butterfly shall: (i) advise Manufacturer of any Component on the E&O List that it reasonably believes is not an Excess Component or Obsolete Component, and the reasons therefore; and (ii) shall issue to Manufacturer a purchase order for: (1) all undisputed Obsolete Components; and (2) all undisputed Excess Components wherein Manufacturer has elected to sell such Excess Components to Butterfly. Manufacturer shall invoice Butterfly no later than [***] ([***]) days from receipt of Butterfly’s purchase order for the Excess Components and Obsolete Components, and Butterfly shall pay Manufacturer its Delivered Cost for such undisputed Excess Components and Obsolete Components within the payment term specified in Section 11.2 below.
(c) The Parties may mutually agree to place Excess Components or Obsolete Components in consignment. Butterfly shall own all such consigned Components. Butterfly shall take actual delivery and possession of any consigned Excess Components or Obsolete Components that have been in Manufacturer’s inventory for more than [***] ([***]) months without activity.
(d) For those undisputed Excess Components that Butterfly requests and Manufacturer agrees to not sell to Butterfly, Manufacturer has the right to charge Butterfly an inventory carrying charge of [***] percent ([***]%) per month of the total Delivered Cost of Excess Components; provided, however, that Manufacturer shall only carry such Components for [***] ([***]) months from the date they became Excess Components, at which point Butterfly shall issue a purchase order to Manufacturer for any such Excess Components at the Delivered Cost.
(e) Notwithstanding anything to the contrary in this Agreement, Butterfly shall be liable to Manufacturer for any Excess Components and/or Obsolete Component inventory resulting from the transition of a Product to becoming PCR Compliant.
(f) If the Parties cannot mutually agree upon the proposed solution for an issue arising under this Section within [***] ([***]) business days after the end of each calendar quarter, then the Parties shall escalate the matter to the appropriate executive management level (General Manager or above) within the Parties’ organizations to resolve such dispute within [***] ([***]) days of escalation. If the dispute is not resolved to the satisfaction of both Parties within [***] ([***]) days from the date of the original escalation communication, either Party may immediately (notwithstanding the notice period required) terminate this Agreement in whole or in part for convenience.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 14 of 36 |
10.2 Prepaid Inventory Option. For Excess Components that the Parties agree to handle according to the “Prepaid Inventory Option” set forth in this Section, the following provisions shall apply:
(a) “Prepaid Inventory” shall consist of the undisputed Excess Components on the then current E&O List provided by Manufacturer to Butterfly that the Parties agree to handle according to the Prepaid Inventory Option and for which Manufacturer has issued Butterfly an invoice according to paragraph (c) below.
(b) Butterfly shall own the Prepaid Inventory upon invoice.
(c) The “Prepaid Inventory Balance” shall refer to Manufacturer’s total Delivered Cost for Prepaid Inventory. By the [***] ([***]) day of each month, or such other interval as may be mutually agreed between the Parties, Butterfly shall issue a Prepaid Inventory purchase order to Manufacturer in the amount of the Prepaid Inventory Balance for those items the Parties agree to be handled under the Prepaid Inventory Option pursuant to paragraph (a) above. Manufacturer shall invoice Butterfly for the amount of the Prepaid Inventory purchase order, and Butterfly shall pay such invoice within the payment term specified in Section 11.2 below.
(d) Within [***] ([***]) business days after the end of each month Manufacturer shall provide to Butterfly a complete Prepaid Inventory reconciliation detailing the total Prepaid Inventory previously purchased by Butterfly and in Manufacturer’s care custody or control.
(e) In the event of a decrease in the Prepaid Inventory for any reason, Manufacturer shall issue a credit to Butterfly for Manufacturer’s unburdened cost, in the amount of the decrease.
(f) Manufacturer will hold Prepaid Inventory items for a maximum of [***] ([***]) days from the date that such Excess Component is added to Prepaid Inventory, at which time Prepaid Inventory items will be shipped or dispositioned, at Butterfly’s discretion. Butterfly will be responsible for approved and reasonable costs incurred by Manufacturer for such shipment and/or disposal.
(g) Manufacturer shall retain such Excess Components in its inventory for the duration of the Prepaid Inventory process. In the event that Manufacturer, in its discretion, decides or agrees to terminate the Prepaid Inventory process or upon expiration or termination of this Agreement, the Parties shall complete a final Prepaid Inventory reconciliation as provided in paragraph (d) above to close the Prepaid Inventory process, at which time the Prepaid Inventory will be shipped and/or dispositioned at Butterfly’s discretion. Butterfly will be responsible for approved and reasonable costs incurred by Manufacturer for such shipment and/or disposal.
10.3 Inventory Turns. The agreed Inventory Turns is [***] ([***]). If any calendar quarter’s Inventory Turns falls below the agreed rate, then Manufacturer shall provide written notice of such to Butterfly. Thereafter, the Parties shall mutually agree in writing to prepayment against Total Inventory and/or to those contract amendments and/or modifications required to meet the agreed Inventory Turns in the most recent calendar quarter as well as the next calendar quarter. Such contract amendments and/or modifications may include adjustments to Product pricing, materials inventory handling, buffer, flexibility, availability, and other provision modification(s) or any combination thereof designed to meet Inventory Turns. Notwithstanding anything to the contrary in this Agreement, failure to achieve Inventory Turns in the most recent or next calendar quarter following such written notice shall constitute a material breach by Butterfly of this Agreement. “Inventory Turns” shall refer to the minimum inventory turns rate, calculated by dividing Manufacturer facility total annualized “Product Revenue” (product invoices issued by a Manufacturer facility to Butterfly under this Agreement within the measurement period) by the “Total Inventory” (all Authorized Purchases plus work in process and finished goods per Orders at the end of the measurement period). For example, if the measurement period is one calendar quarter, the current quarter-end Product Revenue is $[***] and Total Inventory is $[***], then ($[***] x [***]qtrs)/$[***] = [***] Inventory Turns.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 15 of 36 |
11. PRICES AND PAYMENT
11.1 Prices. Butterfly agrees to pay Manufacturer, in accordance with this Section 10, the price listed on the applicable Product Schedule, or another price that the Parties have agreed to in writing, that is applicable to each Product ordered by Butterfly, delivered to Butterfly and accepted by Butterfly. All changes in prices will become effective upon mutual agreement and will apply to all outstanding orders.
11.2 Invoices.
(a) Manufacturer will submit an invoice to Butterfly for payment upon shipment of the applicable Products. The invoice will include: the order number, a description of the products manufactured, unit prices and total prices. All invoices will be paid within [***] days after shipment of the Products without set-off of any kind. Invoices not paid by the due date thereof will be subject to a charge equal to the lesser of [***] percent ([***]%) per month or the highest rate allowed by law, as well as a credit hold on pending and further shipments. Manufacturer may also treat the failure to make any payment as a material and/or an anticipatory breach of this Agreement, and may immediately terminate the Agreement with the Butterfly, and/or seek all its rights and remedies under this Agreement or under any other laws applicable on behalf of Manufacturer.
(b) Manufacturer will submit an invoice to Butterfly for payment of shipping charges, including if applicable insurance charges, after shipment of Products. The invoice shall reference the packing list number(s). Shipping invoices will be paid within [***] ([***]) calendar days after shipment of Products.
11.3 Cost Savings. Manufacturer and Butterfly will periodically review Cost Reduction efforts undertaken by Manufacturer. Manufacturer cost savings realized as a result of implementing Cost Reductions proposed solely by Butterfly (without any input from Manufacturer) shall [***]. Manufacturer cost savings realized as a result of Cost Reductions proposed solely by Manufacturer shall be [***] ([***]) [***]. Manufacturer cost savings realized as a result of Cost Reductions proposed jointly by the Parties shall be [***]. The foregoing Cost Reductions will commence only after all open Orders have been closed and Manufacturer consumes all on-hand Components; or alternatively at Butterfly’s option, Butterfly may issue an Order for the cost of Manufacturer on-hand Component cost reduction buy down, in which case the Component Cost Reductions shall commence upon the issuance of the cost reduction buy down Order.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 16 of 36 |
12. WARRANTIES
12.1 General Warranties by Butterfly. Butterfly represents and warrants that (i) it has full right, power, and authority to enter into this Agreement and to perform its obligations and duties under this Agreement, and (ii) the performance of such obligations and duties does not and will not conflict with or result in a breach of any other agreements or any judgment, order, or decree by which Butterfly is bound.
12.2 General Warranties by Manufacturer. Manufacturer represents and warrants that (i) it has full right, power, and authority to enter into this Agreement and to perform its obligations and duties under this Agreement; (ii) the performance of such obligations and duties does not and will not conflict with or result in a breach of any other agreements or any judgment, order, or decree by which Manufacturer is bound; (iii) it has the skill, expertise, and experience in the industry necessary to perform the obligations set forth in this Agreement; (iv) it has sufficient capability and capacity to meet Butterfly’s current requirements of Products; and (v) it has, and will maintain during the term of this Agreement, all government permits, including without limitation health, safety, and environmental permits, necessary for the conduct of the actions and procedures that it undertakes pursuant to this Agreement.
12.3 Performance Warranties by Manufacturer.
(a) Manufacturing Services. Manufacturer warrants that Products shall: (i) conform to Specifications at each shipment; and (ii) be free from defects in Workmanship for a period of [***] from the date of manufacture. Manufacturer shall, at its option and at its expense, repair, replace or issue a credit for Nonconforming Products returned during the warranty period pursuant to the RMA Procedure below. In addition, Manufacturer will pass on, transfer and/or assign to Butterfly all Component manufacturer warranties to the extent that they are transferable, but will not independently warrant any Components.
(b) Test Fabrication. Manufacturer warrants that any Test Fabrication provided will be performed in a professional and workmanlike manner and in accordance with any applicable SOW, specification, or documentation for a period of [***] following acceptance. Should the Test Fabrication fail to conform to this warranty, [***].
(c) Prototypes. Manufacturer warrants that Prototypes shall: (i) conform to Specifications at shipment; and (ii) be free from defects in Workmanship for a period of [***] from the date of manufacture. Should the Prototypes fail to conform to this warranty, [***]. In addition, Manufacturer will pass on, transfer and/or assign to Butterfly all Component manufacturer warranties to the extent that they are transferable, but will not independently warrant any Components.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 17 of 36 |
(d) DFx. Any DFx provided under this Agreement are [***].
12.4 RMA Procedure. The Parties shall agree in advance on all Products to be returned for repair or replacement although such agreement shall not mean that such return cannot be found to be invalid or “no defect found” as further described below. An RMA number must be obtained by Butterfly, or as otherwise agreed by both Parties, from Manufacturer prior to return shipment, and displayed on the shipping container as well as on the packing slip or attached to the returned product. All returns shall state the specific reason for such return, and will be processed in accordance with Manufacturer’s RMA Procedure. [***]. The warranty for any replacement or repaired Product shall continue for the full remaining balance of the original warranty period, calculated as of the date that Buyer returns the defective Products to Manufacturer, or an additional [***] period from the date that the replacement Product is returned to Butterfly, whichever is greater.
12.5 Disclaimers. THE WARRANTY PROVIDED IN SECTION 12.3 above IS THE ONLY WARRANTY GIVEN BY BENCHMARK AND IN LIEU OF ANY OTHER WARRANTY, EITHER EXPRESS OR IMPLIED, STATUTORY OR OTHERWISE, INCLUDING IMPLIED WARRANTIES OF MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE OR USE, INFRINGEMENT AND WARRANTIES OF TITLE FOR ANY CUSTOMER SUPPLIED MATERIALS.
BENCHMARK DISCLAIMS ANY PRODUCT REQUIREMENTS, APPROVALS OR CERTIFICATIONS NOT EXPRESSLY AGREED IN WRITING.
12.6 Remedy. IN NO EVENT SHALL BENCHMARK’S LIABILITY FOR WARRANTY OR NON-WARRANTY CLAIMS EXCEED THE PURCHASE PRICE FOR THE PRODUCTS FOR WHICH A CLAIM IS MADE.
13. LIMITATIONS
13.1 Remedies. To the extent allowable under law, the remedies expressly conferred in a Party herein are not cumulative with and are exclusive of other inconsistent remedies available at law or in equity.
13.2 Consequential and Other Damages. Accordingly, to the fullest extent allowable by law and except as provided in Section 14 below (Indemnity), in no event shall Manufacturer be liable to Butterfly under any theory of liability arising in any way out of this Agreement (including any theory of contract, tort or strict liability) for any indirect, consequential, incidental, punitive or special damages (including damages for lost revenue or profits, attorney’s fees, loss of data, or costs of procurement of substitute goods or services or Butterfly’s customers claims for damages), even if Manufacturer has been advised of the possibility of such damages.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 18 of 36 |
13.3 Limitation of Liability. Manufacturer and Butterfly acknowledge and agree that this Agreement has been negotiated in consideration of the agreement to limit certain of Manufacturer’s liabilities. EXCEPT WITH RESPECT TO A BREACH OF THE CONFIDENTIALITY PROVISIONS IN SECTION 14 (CONFIDENTIALITY) OR A PARTY’S LIABILITY UNDER SECTION 13 (INDEMNITY), IN NO EVENT WILL EITHER PARTY BE LIABLE FOR ANY CONSEQUENTIAL, INDIRECT, EXEMPLARY, SPECIAL, OR INCIDENTAL DAMAGES, INCLUDING ANY LOST DATA, COSTS OF PROCUREMENT OF SUBSTITUTE GOODS OR SERVICES, BUTTERFLY’S CUSTOMERS CLAIMS FOR DAMAGES AND LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
13.4 Cumulative Damages. In no event will Manufacturer’s total cumulative liability to Butterfly arising out of or related to this Agreement exceed the greater of [***] dollars ($[***]) or [***] percent ([***]%) of the sums paid by Butterfly to Manufacturer for the product causing loss for the immediately preceding [***].
13.5 Limitations Essential. The Parties acknowledge that these limitations on potential remedies, damages and liabilities were an essential element in setting consideration under this Agreement and that, in the absence of such limitations, the economic terms of this Agreement would be substantially different.
14. INDEMNIFICATION
14.1 Manufacturer. Manufacturer agrees to defend (at Butterfly’s request), indemnify, and hold harmless Butterfly, its Affiliates, officers, directors, employees, and agents from and against any Claims, based on (a) any claim that any processing step, procedure, or method used by Manufacturer in manufacturing any Product and not specified by Butterfly directly infringes any patent or misappropriates any trade secret, (b) Manufacturer’s failure to manufacture any Product in accordance with the Specifications or the Quality Assurance Requirements, or (c) Manufacturer’s acts or omissions in performance of its obligations under this Agreement which have resulted in any bodily injury, death, or damage to property, including any manufacturing defect. For any claim or action which Butterfly desires Manufacturer to defend under this paragraph, Butterfly will notify Manufacturer of such claim or action, cooperate with Manufacturer, and at Manufacturer’s request and expense, assist in such defense, and Butterfly will have the right to participate, at its own expense, in the defense or settlement of the claim or action. Manufacturer will not accept any settlement or stipulated judgment of any claim or action without the prior written consent of Butterfly.
14.2 Butterfly. Butterfly agrees to defend (at Manufacturer’s request), indemnify, and hold harmless Manufacturer, its Affiliates and its and their officers, directors, employees, and agents from and against any Claims based on (a) any Product failures due to design or marketing defects based on Specifications provided by Butterfly, (b) field corrective actions due to design or marketing defects based on Specifications provided by Butterfly, (c) Butterfly’s acts or omissions in performance of its obligations under this Agreement which have resulted in any bodily injury, death, or damage to property, or (d) Butterfly’s breach of any provision of this Agreement. For any claim or action which Manufacturer desires Butterfly to defend under this paragraph, Manufacturer will notify Butterfly of such claim or action, cooperate with Butterfly, and at Butterfly’s request and expense, assist in such defense, and Manufacturer will have the right to participate, at its own expense, in the defense or settlement of the claim or action. Butterfly will not accept any settlement or stipulated judgment of any claim or action without the prior written consent of Manufacturer.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 19 of 36 |
14.3 Infringement Mitigation.
(a) Injunction Mitigation. In addition to Manufacturer’s indemnity obligation to Butterfly, if use of the Product is enjoined based on a claim of Intellectual Property Infringement solely due to Manufacturer’s manufacturing processes or Manufacturer Pre-Existing IP, Manufacturer will, at its sole expense and option and as Butterfly’s sole and exclusive remedy for such injunctions: (i) procure the right for Butterfly Indemnitees to continue using the Product; (ii) replace the Product with a non-infringing product of substantially similar function and performance; (iii) modify the Product to be non-infringing; or (iv) refund to Butterfly a pro rata amount for any payments made by Butterfly for the affected Product. In the event Manufacturer is unable, despite its best efforts, to avail itself of the options set forth in Section 14.3(a)(i), (ii) or (iii), Manufacturer shall have the right, in furtherance of its obligation to mitigate and/or prevent further damages and subject to receiving written advice from counsel of same (a copy of which shall be provided to Butterfly), to suspend manufacturing and its performance hereunder, solely as it relates to the item, Component and/or Product which is the subject of the Claim until such Claim is settled or otherwise resolved.
(b) Continued Infringement Mitigation. In the event of a claim of Intellectual Property Infringement under Section 14.1 above, Manufacturer shall have the right, in furtherance of its obligation to mitigate and/or prevent further damages and subject to receiving written advice from counsel of same (a copy of which shall be provided to Butterfly), to suspend manufacturing and its performance hereunder, solely as it relates to the item, Component and/or Product which is the subject of the Claim until such Claim is settled or otherwise resolved.
15. CONFIDENTIALITY
15.1 Confidential Information. During the term of this Agreement, each Party (the “Receiving Party”) may be provided with, have access to, or otherwise learn confidential. and/or proprietary information of the other Party (the “Disclosing Party”) (including certain technical information and materials) that is of substantial value to the Disclosing Party, which is identified as confidential at the time of disclosure or which should reasonably be considered, under the circumstances of its disclosure, to be confidential to the Disclosing Party (“Confidential Information”). “Confidential Information” shall mean information (in any form or media) provided by Disclosing Party to Receiving Party regarding Disclosing Party’s customers, prospective customers, methods of operation, engineering methods and processes, programs and databases, patents and designs, vendors and suppliers, prices, business methods and procedures, finances, management, or any other business information relating to Disclosing Party that is marked “Confidential”, or if disclosed orally or otherwise in non-documented form, is identified as confidential at the time of initial disclosure, and is designated as confidential in a writing provided to Receiving Party within [***] ([***]) days of disclosure. Manufacturer agrees that the Specifications, purchase orders and pricing are Confidential Information of Butterfly.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 20 of 36 |
15.2 Confidentiality Obligations. All Confidential Information remains the property of the Disclosing Party. The Receiving Party may disclose the Confidential Information of the Disclosing Party only to its employees and contractors who need to know the Confidential Information for purposes of performing under this Agreement and who are bound by the Receiving Party’s standard employee or contractor (as applicable) confidentiality agreements. The Receiving Party will not use the Confidential Information without the Disclosing Party’s prior written consent except in performance under this Agreement. The Receiving Party will take measures to maintain the confidentiality of the Confidential Information equivalent to those measures the Receiving Party uses to maintain the confidentiality of its own confidential information of like importance but in no event less than reasonable measures. The Receiving Party will give immediate notice to the Disclosing Party of any unauthorized use or disclosure of the Confidential Information that comes to the attention of the Receiving Party’s senior management and agrees to assist the Disclosing Party in remedying such unauthorized use or disclosure.
15.3 Exceptions. The confidentiality obligations do not extend to Confidential Information which: (i) becomes part of the public domain without the fault of the Receiving Party; (ii) is rightfully obtained by the Receiving Party from a third party with the right to transfer such information without obligation of confidentiality; (iii) is independently developed by the Receiving Party without reference to or use of the Disclosing Party’s Confidential Information, as evidenced by written records; or (iv) was lawfully in the possession of the Receiving Party at the time of disclosure, without restriction on disclosure, as evidenced by written records. In addition, the Receiving Party may disclose Confidential Information of the Disclosing Party as may be required by law, a court order, or a governmental agency with jurisdiction, provided that before making such a disclosure the Receiving Party first notifies the Disclosing Party promptly and in writing and cooperates with the Disclosing Party, at the Disclosing Party’s reasonable request and expense, in any lawful action to contest or limit the scope of such required disclosure.
15.4 Return of Confidential Information. Upon termination or expiration of this Agreement, the Receiving Party will return to the Disclosing Party all tangible copies of Confidential Information of the Disclosing Party in the Receiving Party’s possession or control and will erase from its computer systems all electronic copies thereof.
15.5 Confidentiality of the Agreement. Neither Party will disclose any terms of this Agreement to any third party without the prior written consent of the other Party, except: (i) as required by law; (ii) to its attorneys, accountants, and other professional advisors under a duty of confidentiality; or (iii) to a third party under a duty of confidentiality in connection with obtaining financing or a proposed merger or a proposed sale of all or part of such Party’s business.
15.6 Confidentiality of the Business Arrangement. Manufacturer will not disclose that they are performing activities on behalf of Butterfly for the term of this agreement. Manufacturer will restrict visitor, vendor, and/or contractor view of and access to Butterfly’s dedicated final assembly and test stations, except for visitor access required to satisfy regulatory requirements or Butterfly associated 4catalyzer companies.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 21 of 36 |
16. TERM AND TERMINATION
16.1 Term. This Agreement will commence as of the Effective Date and will continue in effect for a period of three (3) years, unless earlier terminated pursuant to this Agreement. Thereafter, this Agreement will automatically renew for additional two (2) year terms, unless either Party gives written notice of non-renewal at least one hundred-eighty (180) days before the end of the then-current term.
16.2 Termination for Cause. Either Party will have the right to terminate this Agreement, effective immediately, by giving the other Party written notice of termination, if:
(a) the other Party breaches any of its obligations under this Agreement and fails to cure such breach to the satisfaction of the terminating Party within thirty (30) days after written notice thereof from the terminating Party; or
(b) the other Party becomes insolvent or otherwise dissolves, liquidates, or ceases to conduct business.
(c) the occurrence of payment-related breaches;
(d) files a voluntary petition, or any involuntary petition is filed against Butterfly, under any bankruptcy law or similar statute that is not vacated within ten (10) days through court order.
16.3 Termination for Convenience. Either Party may terminate this Agreement and/or an Order hereunder for any reason at its convenience upon ninety (90) days’ prior written notice.
16.4 Effects of Termination. Upon termination or expiration of this Agreement:
(a) Unless specifically requested by Butterfly to cease all manufacturing of Products for any outstanding purchase orders, Manufacturer will complete and deliver all Products for any outstanding orders that have been accepted by Manufacturer prior to the effective date of termination;
(b) Manufacturer shall cooperate with Butterfly and provide reasonable assistance to effect the orderly and efficient transfer of the manufacturing of Product from Manufacturer to Butterfly or a third party designated by Butterfly and without disruption to Butterfly’s business (“Transfer Assistance”). Transfer Assistance shall include, without limitation, (i) the continued manufacture (including, for clarity, quality assurance services) of the Product by Manufacturer after the termination or expiration date for a transition period and on terms mutually agreeable to the Parties; (ii) the transfer of all Product and manufacturing inventory for which Butterfly has compensated Manufacturer; (iii) the transfer of any Special Tooling that has been purchased by Butterfly; and (iv) the transfer of any documents or electronic files relating to the manufacture of the Product;
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 22 of 36 |
(c) all licenses granted to Manufacturer under this Agreement will automatically terminate (except to the extent and for-the period necessary under clause (a));
(d) Manufacturer will return to Butterfly all Specifications and Confidential Information of Butterfly;
(e) Within thirty (30) days of request by Butterfly, Manufacturer shall provide to Butterfly a certification signed by an officer of Manufacturer with authority to bind Manufacturer on such matters that Manufacturer has complied with the terms of this Section 15.3; and
(f) Sections 4.1 (Regulatory Filings), 4.4 (Adverse Event Reporting), 4.6 (Field Corrective Actions), 5 (Intellectual Property and Licenses), 10 (Inventory), 11 (Prices and Payments), 12 (Warranties), 13 (Limitation of Liability), 13 (Indemnification), 14 (Confidentiality), 16.3 (Effects of Termination), 16.5 (Inventory Transfer at Termination), 17 (Insurance), 19.1 (Governing Law), 19.6 (Captions), 19.7 (Severability), 19.8 (Notice), 19.9 (Remedy), 19.10 (Entire Agreement) and 19.11 (Counterparts) will survive any expiration or termination of this Agreement.
16.5 Inventory Transfer at Termination. Upon the expiration or termination of this Agreement (in whole or in part) and/or an Order, for any reason, Manufacturer shall invoice Butterfly no later than [***] ([***]) days from the effective date of expiration or termination, and Butterfly shall pay Manufacturer within the payment term specified herein, for the following inventory transfers: (i) the contract price for all finished goods existing at the time of expiration or termination; (ii) Manufacturer’s cost for all work in process (including labor, materials, any applicable VAT and a reasonable mark-up for recovery of handling costs incurred of [***] percent ([***]%) of the value of the work in process); (iii) Manufacturer’s Delivered Cost for all Components, including Long Lead-Time Components, MOQ and NCNR ordered to meet Butterfly’s Orders and/or Forecasts; and/or (iv) any vendor cancellation and restocking charges, including Manufacturer’s cost for NCNR Components on open orders with suppliers where the Components have not yet been shipped to Manufacturer. Upon payment in full of the charges set forth in this Section 16.5, neither Party shall incur any additional liability by reason of the expiration or termination of this Agreement, and each Party shall have been deemed to release the other Party from any claims of any nature (including damages sustained on account of loss of prospective profits, or on investments, contracts, leases or other commitments) resulting from or arising out of such expiration or termination.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 23 of 36 |
17. INSURANCE.
17.1 Manufacturer Insurance Requirements. Throughout the term of this Agreement and for a period of [***] ([***]) years thereafter, Manufacturer will maintain (i) commercial general liability insurance covering bodily injury, property damage, contractual liability, products liability and completed operations; (ii) Worker’s Compensation and employer’s liability insurance; and (iii) auto insurance, all in such amounts as are necessary to insure against the risks to Manufacturer’s operations, but in no event less than the following minimum amounts:
Insurance
Worker’s Compensation
Commercial General Liability (Including Products Liability)
Umbrella/Excess Liability
|
Minimum Limits of Liability
Statutory
$[***] per occurrence
$[***] per occurrence
|
All policies must be primary and non-contributing and must include Butterfly as an additional insured with a waiver of all rights of subrogation. Manufacturer will notify Butterfly at least [***] ([***]) calendar days prior to the cancellation or implementation of any material change in the foregoing policy coverage that would affect Butterfly’s interests. Upon request, Manufacturer will furnish to Butterfly as evidence of insurance a certificate of insurance stating that the coverage will not be canceled or materially altered without [***] ([***]) calendar days prior notice to Butterfly.
17.2 Butterfly Insurance Requirements. Without limiting any other obligations of Butterfly, Butterfly shall, at its sole cost and expense, procure and maintain during the term of this Agreement:
i) Workers’ Compensation and Employers Liability Insurance as prescribed by state or country law with minimum limits of $[***] per accident / $[***] per disease / $[***] limit;
ii) Commercial Automobile Liability — Bodily Injury/Property Damage Insurance covering all motor vehicles used in connection with this Agreement, with minimum limits of $[***] combined single limit per occurrence;
iii) Commercial General Liability Insurance, including blanket contractual liability and broad form property damage, with minimum limits of $[***] combined single limit per occurrence and an aggregate limit of at least USD $[***] but in no event less than the amount otherwise carried by the contract holder. Coverage must be written on ISO occurrence form CG 00 01 12 04 (or an equivalent substitute form) or ISO claims-made form CG 00 02 12 04 (or an equivalent substitute form). The policy must include coverage for, but not limited to, Bodily Injury and Property Damage, Personal Injury and Advertising Injury, Fire legal liability, Products Liability (including with respect to the design of the Products and all components) and completed operations; and
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 24 of 36 |
iv) Medical Products Liability Insurance including broad form contractual liability with a combined single limit of a minimum of USD$ [***] each occurrence and an aggregate limit of at least USD$ [***] but in no event less than the amount otherwise carried by the contract holder.
(b) Policy Requirements.
i) All policy(s) and coverages must be written in a form acceptable to Manufacturer.
ii) All policy(s) specified herein shall each contain an additional insured endorsement in favor of and acceptable to Manufacturer, which shall not be limited by Butterfly’s liability under any Butterfly indemnity obligation under this Agreement.
iii) Prior to and a condition precedent to Manufacturer’s commencing Product manufacture, Butterfly shall furnish to Manufacturer an acceptable certificate(s) of insurance from an authorized representative evidencing the required coverage(s), endorsements, and amendments. Butterfly shall deliver a copy of each additional insured endorsement within [***] ([***]) business days of request. Failure to provide evidence as required shall entitle, but not require, Manufacturer to terminate this Agreement immediately. Acceptance of a certificate that does not comply with this Section (b) shall not operate as a waiver of Butterfly’s obligations hereunder.
iv) All policies shall require notice to Manufacturer in writing at least [***] ([***]) days prior to any cancellation, non-renewal, substitution or material alteration of such policy(s).
v) All policies shall be written by a reputable insurance company acceptable to Manufacturer or with a current Best’s Guide Rating of A- and Class VII or better, and authorized to do business in the state(s) in which the service is to be provided.
vi) If coverage(s) under Sections 17.2.i), 17.2.ii), or 17.2.iii) above is written on a claims-made form, the policies shall provide, and Butterfly warrants, that any retroactive date applicable to coverage under the policy precedes the effective date of this Agreement; and that continuous coverage will be maintained for a period of [***] ([***]) years beginning from the time this Agreement is no longer in effect or the policies extended discovery period, if any, will exercised for the maximum time of the policy.
(c) Waiver of Right of Recovery. Butterfly waives its right of recovery, and its insurers also waive their right of subrogation, against Manufacturer for loss of its owned or leased property or property under Butterfly’s care, custody or control. Allocated Loss Expense shall be in addition to all policy limits for coverages referenced above.
(d) No Release. The fact that insurance (including, without limitation, self-insurance) is obtained by Butterfly shall not be deemed to release or diminish the liability of Butterfly including, without limitation, liability under the indemnity provisions of this Agreement. Damages recoverable by Manufacturer shall not be limited by the amount of the required insurance coverage.
i) Policy Copies. In the event of a claim or lawsuit involving Manufacturer arising out of this Agreement, Butterfly will make available any required policy covering such claim or lawsuit.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 25 of 36 |
18. COMPLIANCE WITH LAWS
18.1 General.
With regard to each Party’s respective responsibilities under and performance of this Agreement, each Party shall at all times comply with all applicable governmental laws, statutes, ordinances, rules, regulations, orders, and other requirements, including such governmental requirements applicable to environmental protection (except as may otherwise be provided herein), health, safety, wages, hours, immigration, equal employment opportunity, nondiscrimination, working conditions, import or export control, customs, and transportation (individually and collectively referred to as “Laws”). Each Party shall promptly notify the other Party in the event the other Party’s assistance is necessary to achieve compliance with any applicable Laws. Upon request, each Party shall provide the other Party with reasonable documentation demonstrating such compliance.
(a) Anti-Corruption /Anti-Bribery. In addition, the Parties shall:
i) comply with all applicable country laws relating to anticorruption or anti-bribery, including but not limited to legislation implementing the Organization for Economic Cooperation and Development “Convention on Combating Bribery of Foreign Public Officials in International Business Transactions”, or other anti-corruption/anti-bribery convention, the Foreign Corrupt Practices Act as amended (FCPA) (15 U.S.C. §§78dd-1, et. seq.), whether either Party is within the jurisdiction of the United States; and
ii) neither directly nor indirectly, pay, offer, give, or promise to or give, anything of value received from a Party to a non-U.S. public official or any person in violation of the FCPA and/or any applicable country laws relating to anti-corruption or anti-bribery.
(b) Nondiscrimination. Executive Orders 11246 and 13201 and 29 C.F.R. Part 470 and 41 C.F.R. Parts 60-1.4, 60-1.8, 60-250.5, 60-300.5 and 60-741.5, as amended, are incorporated, as applicable.
18.2 Import/Export.
(a) With regard to each Party’s respective obligations under and performance of this Agreement, each Party shall at all times comply with all export/import laws (including re-export), sanctions, regulations, orders, and authorizations (including the Export Administration Regulations (EAR), International Traffic in Arms Regulations (ITAR), and the U.S. Department of the Treasury’s Office of Foreign Assets Control (OFAC)) that are applicable to the export or import of goods, software, technology, or technical data (“Items”) or services (collectively, “Export/Import Laws”).
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 26 of 36 |
(b) The Party conducting the export or import shall obtain all export or import authorizations which are required under the Export/Import Laws for such Party to execute its obligations under this Agreement. Each Party shall reasonably cooperate and exercise reasonable efforts at its own expense to support the other Party in obtaining any necessary licenses or authorizations required to perform its obligations under this Agreement. Reasonable cooperation shall include providing reasonably necessary documentation, including import, end user and re-transfer certificates.
(c) The Party providing Items or services under this Agreement shall, upon request by the other Party, notify the other Party of the export classification (e.g. the Export Control Classification Numbers or U.S. Munitions List (USML) category and subcategory) of such Items or services as well as the export classification of any components or parts thereof if the classification is different from the export classification of the Item or service at issue. The Parties acknowledge that this representation means that an official capable of binding the Party providing such Items or services knows or has otherwise determined the proper export classification. Each Party agrees to reasonably cooperate with the other in providing, upon request by the other Party, documentation or other information that supports or confirms this representation.
18.3 Product Content Regulation.
(a) Manufacturer Responsibilities. Upon written request by Butterfly, Manufacturer shall:
i) certify in writing that its Product manufacturing processes comply with applicable PCR;
ii) provide Butterfly with compliance information regarding applicable PCR for the consumable (MRO) materials which Manufacturer adds to the Product and which are not typically listed on the BOM (for example, solder paste), and for open source Components, if any, for which Butterfly has delegated independent selection authority to Manufacturer;
iii) provide Butterfly with SVHC compliance information on Products received through Passive Sourcing, as may be required of Manufacturer under REACH Article 33;
iv) provide Butterfly with Product environmental documentation received from Component suppliers through Passive Sourcing; and
v) provide disclosures legally required regarding Conflict Minerals.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 27 of 36 |
Except as expressly provided above, Manufacturer has no responsibility or obligation to evaluate, document or demonstrate that any design, Specification(s), BOM, Components, Products, packaging or labeling satisfy any PCR which may be applicable to the Components and/or Product(s).
(b) Butterfly Responsibilities. Butterfly shall have the sole responsibility to evaluate and ensure that all Product design elements (including any DFx, Specifications, BOM, Components, AVL and/or AML) meet the requirements of any applicable PCR, including whether all Components and materials incorporated into, and the packaging and labeling of, such Product(s) conform to any applicable PCR. Butterfly shall have the sole responsibility and expense for any Product’s required PCR compliance, including: (i) any REACH-required application and registration, and/or otherwise obtaining compliance for all Products, customer-directed processes and/or Components; and (ii) any WEEE-required funding or utilizing recycling mechanisms applicable to any Product and/or Component.
19. GENERAL
19.1 Governing Law/Venue. This Agreement is governed by the laws of the state of New York, without regard to any conflicts of laws principles that would result in application of laws of any other jurisdiction and without regard to the United Nations Convention on Contracts for the International Sale of Goods. The sole jurisdiction and venue for actions related to the subject matter of this Agreement shall be the state and U.S. federal courts located in Utah. Both Parties hereby consent to the jurisdiction of such courts. Notwithstanding the foregoing, either Party at its sole option shall be entitled to seek to apply to a court of competent jurisdiction for a temporary restraining order, a preliminary injunction, or similar equitable relief from any competent court having jurisdiction over the other Party.
19.2 Force Majeure. Neither Party shall be held liable or responsible to the other Party nor be deemed to have defaulted under or breached this Agreement for failure or delay in fulfilling or performing any term of the Agreement (other than payment obligation) when such failure or delay is caused by or results from causes beyond the reasonable control of the affected Party, including, without limitation, fire, floods, earthquakes, natural disasters, embargoes, war, acts of war (whether war be declared or not), acts of terrorism, insurrections, riots, civil commotions, shortage of materials, strikes, lockouts or other labor disturbances, acts of God or acts, omissions or delays in acting by any governmental authority or the other Party, provided that such Party promptly notifies the other Party and resumes performance as soon as possible. Notwithstanding the foregoing, if Manufacturer is unable to perform due to a force majeure event for more than [***] ([***]) days, Butterfly may purchase Products from another supplier or elect either to terminate this Agreement in its entirety or cancel any outstanding purchase order(s) with liabilities as outlined in Section 16.4 above.
19.3 Assignment. Butterfly may assign this Agreement, in its entirety, to another entity. Manufacturer may not assign or transfer its rights or obligations under this Agreement to a third party without Butterfly’s prior written consent. For the purposes of this Section, a change in the persons or entities that control fifty percent (50%) or more of the equity securities or voting interest of Manufacturer will be considered an assignment of Manufacturer’s rights. Any attempted assignment or transfer in violation of the foregoing will be null and void.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 28 of 36 |
19.4 Waiver. Except as specifically provided for herein, the waiver from time to time by either Party of any right or failure to exercise any remedy shall not operate or be construed as a continuing waiver of the same right or remedy or of any other of such Party’s rights or remedies provided under this Agreement. All waivers must be in writing.
19.5 Independent Contractors. It is expressly agreed that the Parties shall be independent contractors and that the relationship between the Parties shall not constitute a partnership, joint venture or agency of any kind. Neither Party shall have the authority to make any statements, representations or commitments of any kind, or to take any action, which shall be binding on the other Party, without the prior written consent of the other Party.
19.6 Captions. The captions contained in this Agreement are not a part of this Agreement, but are merely guides or labels to assist in locating and reading the several Sections hereof.
19.7 Severability. If any provision of this Agreement is declared by a court of competent jurisdiction to be invalid, void or unenforceable, then such provision will be changed and interpreted to accomplish the objectives of such provision to the greatest extent possible under applicable law and the remaining provisions of this Agreement will continue in full force and effect.
19.8 Notice. Any notices required or permitted hereunder shall be given in writing to the appropriate Party at the address specified below or at such other address as such Party shall specify in writing. Such notice shall be deemed given upon personal delivery, one (1) day after the date such notice is provided by overnight delivery service, three (3) days after the date of mailing when sent by certified or registered mail, postage prepaid, or (4) upon acknowledgement of receipt if notice is transmitted by facsimile.
If to Butterfly:
Butterfly Network, Inc. 530 Old Whitfield Street Guilford, CT 06437 Attention: Legal Dept. |
If to Manufacturer:
Benchmark Electronics Inc. 100 Innovative Way Nashua, NH 03062 Attn: General Manager
|
With a copy to:
Benchmark Electronics Inc. 3000 Technology Drive Angleton, TX 77515 Attn: Corporate Legal
|
19.9 Remedy. If any legal action is brought to enforce this Agreement, the prevailing Party will be entitled to receive its attorneys’ fees, court costs, and other collection expenses, in addition to any other relief it may receive. Each Party acknowledges and agrees that any actual or threatened breach of Section 3.4 (Exclusivity) or Section 14 (Confidentiality) by the other Party will constitute immediate and irreparable harm to such Party for which monetary damages would be an inadequate remedy and that injunctive relief is an appropriate remedy for such breach.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 29 of 36 |
19.10 Entire Agreement. This Agreement (including the exhibits hereto) sets forth all of the agreements and understandings between the Parties with respect to the subject matter hereof, and supersedes and terminates all prior agreements and understandings between the Parties with respect to the subject matter hereof; provided, for clarity, that any confidentiality agreement between the Parties shall remain in effect and shall apply with respect to any information exchanged under such agreement. Except as expressly set forth in this Agreement, no subsequent amendment, modification or addition to this Agreement shall be binding upon the Parties hereto unless reduced to writing and signed by the respective authorized officers of the Parties.
19.11 Counterparts. This Agreement may be executed in two or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument.
[Remainder of This Page Intentionally Left Blank]
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 30 of 36 |
IN WITNESS WHEREOF, the Parties have executed this Agreement as of the date first above written.
BUTTERFLY NETWORK, INC. | MANUFACTURER | ||||
BENCHMARK ELECTRONICS, INC. | |||||
By: | /s/ Alexander C. Magary | By: | /s/ Gayla J. Delly | ||
Signature | Signature | ||||
Alexander C. Magary | Gayla J. Delly | ||||
Printed Name | Printed Name | ||||
Assistant Secretary | 10/7/2015 | Pres/CEO | 10/2/2015 | ||
Title | Date | Title | Date |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 31 of 36 |
EXHIBIT A
FORM OF PRODUCT SCHEDULE
PRODUCT SCHEDULE NO. [__]
This Product Schedule No. [____] (“Product Schedule”) is dated [ ] (“Schedule Date”) and is made by and between Butterfly Network, Inc. (“Butterfly”) and [_________] (“Manufacturer”) pursuant to that certain Manufacture and Supply Agreement entered into by and between the Parties effective [________], 2015 (“Agreement”). Capitalized terms used but not defined in this Product Schedule have the meanings ascribed to them in the Agreement.
1) | Product: [____________] |
2) | Price: The price for Product is [___________] and such price is fixed for the term of this Product Schedule. |
3) | Lead Time: The Delivery Date must be no less than [_________] weeks from Manufacturer’s receipt of the Purchase Order. |
4) | Safety Stock: Manufacturer agrees to keep at least [months] worth of the following critical components in its inventory throughout the production run for the Products: [_______]. |
5) | Manufacturing Facility: [_________] |
6) | Third Party Vendors: The following vendors will supply components to Manufacturer: Bills of Material (BOM) including AVL shall reside in Butterfly’s Product line Management System (Omnify). The Manufacturer shall be provided an account to log-in to Omnify and extract pertinent design documents, BOMs, and other information required to produce products for Butterfly. |
7) | Term: The term of this Product Schedule will commence on the Schedule Date and, unless earlier terminated in accordance with the Agreement, will continue until [_________]. |
8) | Specifications: See [ATTACH OR REFERENCE SPECIFICATIONS DOCUMENT HERE.] |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 32 of 36 |
MANUFACTURER | ||||
BUTTERFLY NETWORK, INC. | BENCHMARK ELECTRONICS, INC. | |||
By: | By: | |||
Signature | Signature | |||
Printed Name | ||||
Printed Name | ||||
Title | Date | |||
Title | Date |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 33 of 36 |
EXHIBIT B
QUALITY ASSURANCE REQUIREMENTS
1. REGULATORY AND ACCREDITATION
a. | CFR. Manufacturer must maintain compliance with 21 CFR 820, and all related guidance issued by the FDA and be FDA registered. |
b. | ISO. Manufacturer must maintain registration under ISO 13485, with the scope of registration covering all activities pertaining to Products. |
c. | Process Qualification. Manufacturer must implement and perform a process and equipment qualification process as required by FDA (IQ/OQ/PQ). |
2. INTERNAL PROCESSES
a. | Inspection System Requirement. Manufacturer shall develop and implement an inspection system capable of inspecting all finished Product dimensions and features to associated tolerances and requirements prior to shipment. Manufacturer to provide documentation to Butterfly that all inspections carried out are in compliance with IPC 610 class 2 requirements, latest revision. |
b. | Record Retention. Manufacturer must retain all quality and manufacturing records associated with Products for a minimum of [***] years, unless otherwise specified by Butterfly, and provide copies of all applicable production and quality control related records related to Products upon Butterfly’s request. This requirement applies to all records required by the regulations including 21 CFR Part 820. Prior to the destruction of any such records Manufacturer shall first notify Butterfly with sufficient notice to allow Butterfly to assume control of said Records. In the event that Manufacturer requests that Butterfly assume control of some or all of the records, Manufacturer shall assist with the transfer of these Records from Manufacturer to Butterfly. |
c. | Device History Record. Manufacturer shall create and maintain the device history record and make it available to Butterfly upon request. |
d. | In-process/Incoming Inspection Sampling Plan. Manufacturer’s sampling procedures must follow Zero Acceptance Number Sampling Plans, 5th Edition with an AQL of 0.65. |
e. | Final Inspection. 100% inspection is required in accordance with key characteristics as defined on the final level assembly drawing. |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 34 of 36 |
3. PART/LOT TRACEABILITY
a. Serial Numbers. All individual parts will be marked with a lot or serial number when indicated on the associated drawing. Manufacturer’s processing records shall be maintained at all times by the lot or serial number. Traceability must be maintained to all raw materials used, testing performed, employee performing activities and dates of performance of activities. Manufacturer must maintain a system to ensure that lot or serial numbers are unique. Inspection Data. Verifiable inspection data must be furnished and maintained for each lot of parts furnished. Actual Final Inspection data for key characteristics of each item delivered must be retained by Manufacturer as part of the Device History Record. The In-process inspection data must also indicate the total number of parts accepted and/or rejected for each characteristic. The Final inspection data must be signed for by a member of the Quality Assurance Group at the Manufacturer facility.
4. QUALITY ASSURANCE
a. | First Article inspection. Manufacturer to inspect every dimension on the first single part produced — additional parts upon mutual cost allocation agreement. |
b. | Certification of Compliance (CoC). A certification of compliance, signed by Manufacturer’s quality representative, must accompany each shipment of parts to Butterfly. This CoC is a statement of compliance to all specifications of the order and any associated drawings, specifications, or purchase order requirements. Manufacturer must similarly obtain a CoC for all raw materials used in manufacture of Butterfly parts. |
5. NONCONFORMING PRODUCT
Manufacturer will notify Butterfly as soon as possible, and in any event within [***] ([***]) hours, if Manufacturer has determined that non-conforming material may have been shipped. Butterfly requires direct involvement in the disposition of any non-conforming material affecting a purchase order.
6. BUSINESS CONTINUITY PLAN
Manufacturer shall maintain a complete formal business continuity/disaster recovery plan to ensure there is no interruption in the supply of our products. While contingency plans cannot be developed for all potential scenarios, Manufacturer shall maintain robust plans to facilitate rapid response and recovery in the event of disruptions. Upon request, the Manufacturer shall provide risk management and business continuity plans to Butterfly.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 35 of 36 |
EXHIBIT C
INITIAL PRODUCT SCHEDULE
(To be determined by the Parties)
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics inc. | Page 36 of 36 |
Exhibit 10.14.2
AMENDMENT NO. 1
TO
MANUFACTURE AND SUPPLY AGREEMENT
This Amendment No. 1 to Manufacture and Supply Agreement (this “Amendment”) is entered into effective as of August 2, 2019 (the “Amendment Effective Date”) by and between BUTTERFLY NETWORK, INC., a Delaware corporation (“Butterfly”) and BENCHMARK ELECTRONICS, INC., a Texas corporation and BENCHMARK ELECTRONICS (THAILAND) PCL, a Thailand public limited company (“Manufacturer”), to amend the Manufacture and Supply Agreement between Butterfly and Manufacturer effective as of October 1, 2015 (the “Agreement”). Butterfly and Manufacturer are each a “Party” and collectively the “Parties”. The capitalized terms herein shall have the meaning ascribed to them in the Agreement unless stated otherwise.
The Parties hereby agree to amend the Agreement as follows:
1. | The Agreement is modified to include the following Party as an additional Manufacturer under the Agreement: BENCHMARK ELECTRONICS (THAILAND) PCL, a Thailand public limited company, with offices located at located at 94 Moo 1 Hi-Tech Industrial Estate, Banlane, Bang Pa-in, Ayudhaya 13160 Thailand (“Manufacturer”). |
2. | The first sentence of Section 6.1 (Forecast) is deleted in its entirety and the following is inserted in lieu thereof: |
“Forecast. During the term of this Agreement, except as otherwise set forth on the applicable Product Schedule, Butterfly shall provide to Manufacturer on or before the first business day of each month, a written, binding [***] day ([***]) day firm Order(s), and an additional written, non-binding [***] ([***]) day rolling forecast setting forth its estimated requirement of shipment by month for Products (“Forecast”).”
3. | Section 6.1(b) (Subsequent Forecasts) is deleted in its entirety and the following is inserted in lieu thereof: |
“(b) Subsequent Forecasts. Each month, Butterfly shall provide additional Order(s) and a Forecast update sufficient to maintain the firm Order and Forecast horizons. If Butterfly does not timely provide such additional Order(s) and a Forecast update, then the first Forecast month of the then-current Forecast shall become binding, and a new Forecast month shall be added, so that a rolling firm Order plus non-binding Forecast of [***] ([***]) days is always maintained.”
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
amendment no. 1 | |
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics, inc. | Page 1 of 4 |
2. | Section 12.7 (Epidemic Failures) is added to the Agreement as follows: |
“12.7. (a) Epidemic Failure. An “Epidemic Failure” shall be deemed to have occurred in the event that, at any time within the Product warranty period, [***] percent ([***]%) or more of any at least [***] ([***]) given Products sold and delivered to Butterfly within any [***] ([***]) month period fails to operate properly as the result of a particular defect in Workmanship or substantially similar pattern of defective Workmanship performed by Manufacturer. Upon written notice by Butterfly to Manufacturer of any Epidemic Failure, Manufacturer shall promptly develop a corrective action plan to eliminate the problem causing the Epidemic Failure in all continuing production, and to correct the problem in all affected units of Product previously sold, or to provide a commercially reasonable alternative solution. Manufacturer shall submit such corrective action plan to Butterfly for Butterfly’s approval. Upon receiving Butterfly’s approval of the corrective action plan, Manufacturer shall use reasonable efforts to initiate the corrective action plan at its expense within [***] ([***]) days. Transportation costs for the return and replacement of defective Products due to Epidemic Failure shall be at Manufacturer’s sole expense.
(b) In the event of a systemic Product failure that does not qualify as an Epidemic Failure, due to reasons including but not limited to Product defects related to (i) a Butterfly Product Design Specification, (ii) a Butterfly-supplied test design, (iii) a Butterfly Proprietary Component, or (iv) materials supplied by a third party; the Parties will use reasonable efforts to determine, address and resolve such failure and its consequences. If such cause is related to defects in materials supplied to Manufacturer by any third party, Manufacturer agrees to share, assign or pass through to Butterfly any related concession it may receive from or claims against the relevant supplier; however, Manufacturer does not independently warrant any such defective materials.
(c) In the event an Epidemic Failure or a failure described under Paragraph 12.7(b) affects current production, Manufacturer shall use reasonable commercial efforts to identify the root cause of such failure and develop a plan to eliminate such cause within [***] ([***]) hours of Butterfly’s notice.”
4. | Section 19.8 (Notice) of the Agreement is hereby deleted and replaced with the following for Manufacturer: |
If to Manufacturer:
Benchmark Electronics Inc.
100 Innovative Way
Nashua, NH 03062
Attn: General Manager
Benchmark Electronics (Thailand) PCL
94 Moo 1 Hi-Tech Industrial Estate,
Banlane, Bang Pa-in, Ayudhaya 13160
Thailand
Attn: General Manager
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
amendment no. 1 | |
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics, inc. | Page 2 of 4 |
With a copy to:
Benchmark Electronics Inc.
56 South Rockford Drive
Tempe, Arizona 85281
Attn: Corporate Legal
5. | All other terms and conditions of the Agreement shall remain in full force and effect, unless expressly modified by this Amendment. This Amendment may be executed in multiple counterparts, each of which so executed shall be considered an original. Once signed, any reproduction of this Amendment made by reliable means (eg. electronics image, photocopy or facsimile) shall be considered an original. |
IN WITNESS WHEREOF, the parties have caused this Amendment to be executed by their authorized representatives.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
amendment no. 1 | |
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics, inc. | Page 3 of 4 |
BUTTERFLY NETWORK, INC. | MANUFACTURER: | |||
BENCHMARK ELECTRONICS, INC. | ||||
By: | /s/ Alexander C. Magary | By: | /s/ Michael Busemin | |
Signature | Signature | |||
Alexander C. Magary | Michael Busemin | |||
Printed Name | Printed Name |
VP, Legal & Asst. Corp. Secretary | 8/8/2019 | EVP – Global Ops | 8-2-19 | |
Title | Date | Title | Date |
BENCHMARK ELECTRONICS | |||
(THAILAND) PCL | |||
By: | /s/ Ronald Rocha | ||
Signature | |||
Ronald Rocha | |||
Printed Name |
Group VP Asia | 08-02-19 | |
Title | Date |
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
amendment no. 1 | |
manufacture and supply agreement | |
butterfly networks, inc. and benchmark electronics, inc. | Page 4 of 4 |
Exhibit 10.15
DISTRIBUTION AGREEMENT
This Exclusive Distribution Agreement (the “Agreement”) is made as of this 11th day of July, 2018 (the “Effective Date”), between Butterfly Network, Inc., a Delaware corporation, with an address of 530 Old Whitfield Street, Guilford, CT 06437 (“Client”), and Cardinal Health 105, Inc., an Ohio corporation, with a place of business at 501 Mason Road, Suite 200, La Vergne, Tennessee, 37086 (“Cardinal Health”) each individually a (“Party”) and collectively (the “Parties”).
RECITALS
A. Client is, among other things, in the business of developing and marketing medical devices in the United States, its territories, possessions and commonwealths (“Territory”).
B. Cardinal Health is, among other things, in the business of distributing medical devices to wholesalers, specialty distributors, physicians, clinics, hospitals, pharmacies, and other health care providers in the Territory, and of providing information systems and other services that support its clients’ use of its distribution capabilities.
C. Client desires to engage Cardinal Health as a third-party logistics distribution agent for commercial sales of all pharmaceutical Products manufactured and/or marketed by Client in all formulations (collectively, “Product”), and to perform certain other services described in this Agreement, all upon the terms and conditions set forth in this Agreement.
THEREFORE, in consideration of the mutual covenants, terms and conditions set forth below, the Parties agree as follows:
ARTICLE
1
APPOINTMENT/AUTHORIZATION
1.1 Appointment. Subject to the terms and conditions set forth in this Agreement, during the term of this Agreement, Client appoints Cardinal Health as a third-party logistics distribution agent and as an authorized distributor of record of Product in the Territory to Client’s Customers, including, but not limited to, wholesalers, specialty distributors, physicians, clinics, hospitals, pharmacies and other health care providers in the Territory (collectively, “Customers”).
1.2 Acceptance of Appointment. Subject to the terms and conditions set forth in this Agreement, Cardinal Health accepts the appointment to represent Client as a third-party logistics distribution agent and as an authorized distributor of record of Product to Customers in the Territory.
ARTICLE
2
SERVICES
2.1 Services. Cardinal Health shall provide the services set forth in the Operating Guidelines (“OPG”), which include, without limitation, storage, distribution, returns, customer support, financial support, EDT and system access support (“Services”). The OPG is attached hereto as Exhibit A and incorporated herein in its entirety by this reference.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
1
2.2 Operating Guidelines. The OPG may be amended from time to time upon the mutual written agreement of the Parties; provided, however, that any change, modification or amendment to the OPG may result in an increase or decrease in the Fees (as defined in Article 5) as set forth in the amended OPG.
2.3 Compliance to Operating Guidelines. Cardinal Health’s services shall comply with the OPG for up to [***]% of Client’s Forecast (defined below). If (i) Client’s shipments of Product to Cardinal Health or (ii) Client’s Customers’ Product orders exceed Client’s Forecast by more than [***] percent ([***]%), Cardinal Health shall use commercially reasonable efforts to meet the requirements of the OPG, provided however, that Client acknowledges that Cardinal Health may not be able to meet all guidelines relating to response and shipping times.
2.4 Product Returns. Customer may request Cardinal Health to process and handle Product Returns. Product returns shall be processed and handled by Cardinal Health in accordance with the OPG; and any customization or additional return services requested by Client shall be performed at an additional fee as agreed by the Parties.
2.5 Product Recalls. Client is solely responsible for all Product recalls, provided however that Cardinal Health shall be responsible for Product recalls to the extent arising from Cardinal Health’s negligence or willful misconduct, subject to the terms of this Agreement. In the event Product is subject to recall, or Client, on its own initiative, recalls any Product, Cardinal Health shall provide assistance to Client as set forth in the OPG and as mutually agreed upon, provided that Client shall pay to Cardinal Health an amount equal to Cardinal Health’s actual out-of-pocket costs incurred with any such recall services as agreed in writing. Such cost shall be in addition to the Fees described in Article 5 below.
ARTICLE
3
PRODUCT SUPPLY/CLIENT RESPONSIBILITIES
3.1 Facility. Client shall deliver Product to Cardinal Health at Cardinal Health’s facility located at [***], or to such other distribution facility(ies) as may be agreed by Cardinal Health and Client in writing (“3PL Facility”).
3.2 Delivery and Title. Client shall be responsible for delivery of Product to and from the 3PL Facility, including all costs, expenses and risk of loss associated with such delivery, unless otherwise agreed to by both parties. Title to Product shall remain with Client at all times, even when Product is stored or warehoused at the 3PL Facility. Client shall at all times insure the Product for damage, loss, destruction, theft or any such other property damage (“Loss”) as further set forth in Article 13 below. Except for Loss resulting solely from the negligence or willful misconduct of Cardinal Health, Client shall bear all risk of loss or damage with respect to the Product.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
2
3.3 Forecast and Price List.
A. Forecast. Client shall provide Cardinal Health with a forecast of the volume of Product to be handled by Cardinal Health under this Agreement, not less often than semi-annually (“Forecast”). All forecasts, including the Forecast, are used for the express purpose of operational planning. In the event of a significant variance from the Forecast or a change in core business that could reasonably be expected to have a material effect upon the obligations of either Party hereunder, the Party so affected may notify the other Party that it wishes to negotiate an appropriate adjustment to the Fees. The Parties must meet within thirty (30) days of such notification to discuss the merits and implementation of any such adjustment and during such meeting, the Parties shall negotiate in good faith. If the Parties are unable to come to a resolution regarding any such adjustment, then either Party may terminate this Agreement upon one hundred eighty days (180) prior written notice to the other Party.
B. Price List. Intentionally omitted.
3.4 Shipment Inspection. Cardinal Health shall visually inspect each shipment of Product for external damage or loss in transit and notify Client of any such evident damage or loss as provided in the OPG.
ARTICLE
4
INFORMATION SYSTEM ACCESS
4.1 Access. During the Term of this Agreement and subject to the terms herein, Client may use password(s) and identification number(s) provided by Cardinal Health to remotely access Client’s data maintained on Cardinal Health’s SmartData web portal (collectively, the “System”) provided that such access is used solely by Client’s employees and for Client’s own internal business purposes. Client shall use that access solely to access Client’s data and shall not access or attempt to access any other data, systems or software. Client shall be responsible for all use of the passwords and identification elements by its employees and agents and shall ensure that such employees and agents use the passwords and identification elements solely to effect the limited access authorized herein. The limited license to access the System granted herein does not include the right to copy, download or otherwise use any software or non-Client data maintained on the System.
4.2 Fees. The System shall be made available to Client at the fees set forth in the Fee Schedule. If Cardinal Health agrees to perform any custom enhancements to the System requested by Client, such customization services shall be billed separately based on an hourly rate set forth in the Fee Schedule (as defined in Article 5) and prior to such performance, Cardinal Health shall notify Client of any related increase in the periodic Fees hereunder relative to the ongoing support of the customizations.
4.3 Security. During the term of this Agreement, Cardinal Health shall employ reasonable security measures and policies designed to safeguard the integrity, accessibility, and confidentiality of Client’s data resident on the System and establish and maintain reasonable disaster and emergency recovery plans designed to minimize disruption from System operation interruptions. Such measures shall be no less secure than those utilized by Cardinal Health to protect its own confidential information.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
3
4.4 Client Obligations. Client shall not reverse engineer, reverse assemble, decompile, create derivative works, modify, or otherwise attempt to derive the source code of any software on the System or copy, download, modify, or create derivative works of such software. Also, Client shall not permit access to the System or related documentation to any third party. The System and all parts thereof, in all of their tangible and intangible manifestations, all existing or new enhancements, developments, derivative works, and other modifications to the System (or any part thereof), and all related proprietary rights, are and shall remain the exclusive property of Cardinal Health.
4.5 Disclaimer. EXCEPT AS EXPRESSLY SET FORTH IN THIS AGREEMENT, (i) THE SYSTEM, THE SOFTWARE THEREON AND ANY RESULTS OBTAINED THEREFROM ARE PROVIDED ON AN “AS IS” BASIS, WITHOUT WARRANTY OF ANY KIND, WHETHER EXPRESS, IMPLIED, STATUTORY OR OTHERWISE, AND (ii) CARDINAL HEALTH MAKES NO REPRESENTATIONS OR WARRANTIES, AND HEREBY EXPRESSLY DISCLAIMS ALL REPRESENTATIONS AND WARRANTIES, EXPRESS OR IMPLIED, RELATING DIRECTLY OR INDIRECTLY TO THE SYSTEM OR ANY PART THEREOF INCLUDING WITHOUT LIMITATION WARRANTIES OF MERCHANTABILITY, NONINFRINGEMENT AND FITNESS FOR A PARTICULAR PURPOSE.
4.6 System Availability. Cardinal Health shall use reasonable efforts to make the System available for access twenty-four (24) hours a day, seven (7) days a week absent scheduled and emergency maintenance periods. Scheduled maintenance shall be performed as set forth in the OPG.
4.7 Suspension of Access. In the event of a threatened breach of the System, Cardinal Health may temporarily revoke or suspend any or all passwords and identification numbers provided to Client hereunder in order to take emergency steps to address such breach or threatened breach, provided that Cardinal Health shall provide new passwords and identification numbers as soon as practicable, provided that, Cardinal Health shall otherwise provide access to Client’s data to Client during such period of revocation or suspension by promptly responding to Client’s request for such data by e-mail or facsimile.
ARTICLE
5
PRICING AND PAYMENT TERMS
5.1 Fees. As compensation for the Services, Client shall pay to Cardinal Health the fees (“Fees”) set forth on Exhibit B (“Fee Schedule”) attached hereto and incorporated by reference.
5.2 Invoices. Cardinal Health shall issue an electronic invoice to Client for the Services rendered under this Agreement or for any other amounts due on a monthly basis. Payment is due within [***] ([***]) days of the invoice date. If an invoice is not paid within such [***] ([***]) day period, Cardinal Health may, at its option elect to (i) impose a service charge on the unpaid amount calculated at the rate of [***]% per month (or the maximum rate permitted by law) until such amount is paid in full and /or (ii) suspend any further Services until such invoice is paid in full; provided that, this provision shall not apply in the event any unpaid portion of the invoice is the subject of an unresolved good faith dispute. In the event of any good faith dispute with regard to an invoice, Client shall notify Cardinal Health of such dispute within [***] ([***]) days of the invoice date, and any undisputed portion of the invoice shall be paid as provided herein. The Parties will work together in good faith to resolve any dispute with respect to an invoice. Any amounts owed to Cardinal Health shall be paid within [***] ([***]) days of resolution of such dispute.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
4
5.3 Fee Adjustment.
A. The Fees shall be held firm for the first contract year. Thereafter, Cardinal Health will evaluate the fee schedule and may adjust the Fees not more often than [***] by up to [***] percent ([***]%).
B. Notwithstanding the terms set forth above in Section 5.3(A), if Cardinal Health can reasonably demonstrate that the costs for providing the Services have materially increased due to the adoption of any applicable law or regulation (or any material change in the interpretation or administration thereof), or due to unforeseen circumstances beyond Cardinal Health’s reasonable control, then upon notice from Cardinal Health, the Parties agree to meet in good faith and negotiate a mutually acceptable adjustment to the Fees. If the Parties are unable to agree on such fee adjustment within [***] ([***]) days, then such fee adjustment shall not take effect, and for a period of [***] ([***]) days after expiration of such period, either party shall have the right to terminate this Agreement upon [***] ([***]) days’ advance written notice to the other party.
5.4 Taxes. Client shall pay when due all sales, use, gross receipts, excise and personal property taxes associated with the Product (excluding any personal property tax associated with Cardinal Health’s equipment used in connection with the Services), and other taxes now or hereafter imposed as a result of the transactions contemplated by this Agreement, none of which have been included in the fees payable to Cardinal Health under this Agreement; provided that the amounts payable by Client under this section shall not include taxes based on the net income of Cardinal Health.
ARTICLE
6
TERM AND TERMINATION
6.1 Term. The Initial Term of this Agreement shall begin on the Effective Date and shall continue until August 31, 2020 (“Initial Term”), unless terminated earlier pursuant to this Agreement. Thereafter, this Agreement shall automatically renew for additional terms of two (2) years each (each, a “Renewal Term,” and together with the Initial Term, the “Term”), unless (i) Client provides at least ninety (90) days prior written notice of termination to Cardinal Health, or (ii) Cardinal Health provides written notice of non-renewal to Client at least one hundred eighty (180) days prior to the end of the Initial Term or any Renewal Term, provided that, if Client terminates this Agreement during the Initial Term, such termination shall be effective only upon payment to Cardinal Health of all undisputed outstanding amounts and (a) [***] percent ([***]%) of all remaining Fixed Fees set forth on the Fee Schedule for the remainder of the Initial Term if the Client so terminates within the first year after the Effective Date or (b) [***] ([***]%) of all remaining Fixed Fees set forth on the Fee Schedule for the remainder of the Initial Term if the Client so terminates after the first year after the Effective Date but prior to end of the second year after the Effective Date (“Termination Fee”). “Fixed Fees” shall mean the fees specified on the Fee Schedule to be paid monthly by Client to Cardinal Health that are not dependent on the quantity of Product handled by Cardinal Health.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
5
6.2 Immediate Termination. Either Party shall have the right to immediately terminate this Agreement if:
A. the other Party files a petition in bankruptcy, or enters into an agreement with its creditors, or applies for or consents to the appointment of a receiver or trustee, or makes an assignment for the benefit of creditors, or suffers or permits the entry of any order adjudicating it to be bankrupt or insolvent and such order is not discharged within thirty (30) days; or
B. the other Party materially breaches any of the provisions of this Agreement, and such breach is not cured within thirty (30) days after the giving of written notice; and in the case of a failure of Client to make payments in accordance with the terms of this Agreement, Cardinal Health may terminate this Agreement upon ninety (90) days prior written notice if such payment breach is not cured within fifteen (15) business days following Cardinal Health’s delivery of a written notice of non-payment to Client.
6.3 Effect of Termination. Expiration or termination of this Agreement shall be without prejudice to any rights or obligations that accrued to the benefit of either Party prior to such expiration or termination. Client shall pay Cardinal Health for all Services performed up to the date of termination, plus any applicable Termination Fee under Article 6.1, and shall reimburse Cardinal Health for all costs and expenses incurred, and all non-cancelable commitments made, in the performance of Services. Upon termination or expiration of this Agreement, all Product shall be returned to Client or a designee of Client, at Client’s sole cost and expense except to the extent that termination was due to breach by Cardinal Health in which case Cardinal Health will cover all costs to return stored product.
ARTICLE
7
REGULATORY
7.1 Audits. [***] per calendar year, Client or its designee has the right during normal business hours [i.e., 8:00 a.m. to 5:00 p.m. local 3PL Facility time and not to exceed a total of eight business hours], to conduct a complete quality audit upon [***] ([***]) days’ prior, written notice to Cardinal Health. Client or its designee additionally has the right, [***] per calendar year, during normal business hours, to conduct an inventory audit upon [***] ([***]) days’ prior written notice to Cardinal Health. If the timing of any of the foregoing audits falls during “quarter-end” or “year-end” then Cardinal Health will use best efforts to accommodate Client’s request. Client shall have the right to conduct for cause audits immediately if necessary to ensure Product safety or if otherwise necessary to implement or support a Product recall.
7.2 Compliance with Laws. Each Party shall conduct its activities in connection with this Agreement in compliance with all applicable United States laws, rules, regulations and guidelines.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
6
ARTICLE
8
REPRESENTATIONS AND WARRANTIES
8.1 Cardinal Health. Cardinal Health represents and warrants to Client that, unless otherwise agreed to by the Parties, Cardinal Health shall perform Services in a professional and workmanlike manner, in accordance with this Agreement, the OPG, and all applicable laws, rules, regulations, guidelines, and generally accepted industry standards.
8.2 Client. Client represents, warrants and covenants to Cardinal Health that:
A. Product. The Product shall not be adulterated or misbranded as provided in the Food, Drug and Cosmetic Act, as amended from time to time;
B. Promotion. Client’s activities relating to the promotion, sale and distribution of the Product shall comply with all applicable laws, rules, regulations and guidelines;
C. No Infringement. It has all necessary authority and right, title and interest in and to any intellectual property related to each Product or that is otherwise provided by Client under this Agreement;
D. Safe Handling Instructions. It has provided all safe handling instruction, health and environmental information and material safety data sheets applicable to the Product or to any materials supplied by Client in writing in sufficient time for review and training by Cardinal Health prior to delivery; and
8.3 Mutual. Each Party represents and warrants to the other Party that:
A. Existence and Power. Such Party (i) is duly organized, validly existing and in good standing under the laws of the state in which it is organized, (ii) has the power and authority and the legal right to own and operate its property and assets, and to carry on its business as it is now being conducted, and (iii) is in compliance with all requirements of applicable laws, except to the extent that any noncompliance would not materially adversely affect such Party’s ability to perform its obligations under the Agreement;
B. Authorization and Enforcement of Obligations. Such Party (i) has the power and authority and the legal right to enter into this Agreement and to perform its obligations hereunder and (ii) has taken all necessary action on its part to authorize the execution and delivery of this Agreement and the performance of its obligations hereunder;
C. Execution and Delivery. This Agreement has been duly executed and delivered on behalf of such Party, and constitutes a legal, valid, binding obligation, enforceable against such Party in accordance with its terms;
D. No Consents. All necessary consents, approvals and authorizations of all regulatory authorities and other persons required to be obtained by such Party in connection with the Agreement have been obtained; and
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
7
E. No Conflict. The execution and delivery of this Agreement and the performance of such Party’s obligations hereunder (i) do not conflict with or violate any requirement of applicable laws; and (ii) do not materially conflict with or constitute a material default or require any consent under, any contractual obligation of such Party.
8.4 Limitations. THE REPRESENTATIONS AND WARRANTIES SET FORTH IN THIS ARTICLE 8 ARE THE SOLE AND EXCLUSIVE REPRESENTATIONS AND WARRANTIES MADE BY EACH PARTY TO THE OTHER AND NEITHER PARTY MAKES ANY OTHER REPRESENTATIONS, WARRANTIES OR GUARANTEES OF ANY KIND WHATSOEVER, INCLUDING WITHOUT LIMITATION ANY IMPLIED WARRANTIES OF MERCHANTABILITY, NON-INFRINGEMENT OR FITNESS FOR A PARTICULAR PURPOSE.
ARTICLE
9
TRADEMARKS
Neither Party shall have the right to use the name of the other Party or any Affiliate of the other Party, or the other Party’s or such Affiliates’ trademarks, service marks, logos, or other similar marks in any manner except with the prior written approval of that Party; provided that the foregoing shall not prohibit Cardinal Health’s use of Client’s names or marks in connection with the performance of the Services in a manner consistent with this Agreement. “Affiliate,” as used in this Agreement, means any legal entity which, during the Term hereof, controls, is controlled by, or is under common control with, such Party. For purposes of this definition, an entity shall be deemed to control another entity if it owns or controls, directly or indirectly, at least fifty percent (50%) of the voting interest of all equity interests of the other entity (or other such comparable ownership interest for an entity other than a corporation).
ARTICLE
10
CONFIDENTIALITY AND NON-USE
10.1 Mutual Obligation. Cardinal Health and Client agree that they shall not use the other Party’s Confidential Information (defined below) except as necessary for the receiving Party to perform its obligations under this Agreement or disclose the other Party’s Confidential Information to any third Party without the prior written consent of the other Party except as required by law, regulation or court or administrative order; provided, however, that prior to making any such legally required disclosure, the Party making such disclosure shall give the other Party as much prior notice of the requirement for and contents of such disclosure as is practicable under the circumstances. Notwithstanding the foregoing, each Party may disclose the other Party’s Confidential Information to any of its Affiliates that (A) need to know such Confidential Information for the purpose of performing under this Agreement, (B) are advised of the contents of this article, and (C) agree to be bound by the terms of this article.
10.2 Definition. As used in this Agreement, the term “Confidential Information” includes all such information furnished by Cardinal Health or Client, or any of their respective representatives or Affiliates, to the other or its representatives or Affiliates in connection with the services or performance of this Agreement, whether furnished before, on or after the date of this Agreement and furnished in any form, including but not limited to written, verbal, visual, electronic or in any other media or manner. Confidential Information includes, but is not limited to, all proprietary technologies, know-how, trade secrets, discoveries, inventions and any other intellectual property (whether or not patented), analyses, compilations, prospective and/or actual customer information, business or technical information and other materials prepared by either Party, or any of their respective representatives, containing or based in whole or in part on any such information furnished by the other Party or its representatives. Confidential Information also includes the terms of this Agreement.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
8
10.3 Exclusions. Notwithstanding Section 10.2, Confidential Information does not include information that (A) is or becomes generally available to the public other than as a result of a breach of this Agreement, or (B) is already known by the receiving Party at the time of disclosure as evidenced by the receiving Party’s written records, or (C) becomes available to the receiving Party on a non-confidential basis from a source that is entitled to disclose it on a non-confidential basis, or (D) was or is independently developed by or for the receiving Party without reference to the Confidential Information, as evidenced by the receiving Party’s written records.
10.4 No Implied License. The receiving Party shall obtain no right of any kind or license under any patent application or patent by reason of this Agreement. All Confidential Information shall remain the sole property of the Party disclosing such information or data.
10.5 Return of Confidential Information. Upon termination of this Agreement, the receiving Party shall, upon request, promptly return within [***] ([***]) days all such information, including any copies thereof, and cease its use or, at the request of the disclosing Party, shall promptly destroy the same and certify such destruction to the disclosing Party; except for a single copy thereof, which may be retained, subject to continuing obligations of confidentiality and non-use, for the sole purpose of determining the scope of the obligations incurred under this Agreement.
10.6 Survival. The obligations of this Article 10 shall terminate [***] ([***]) years from the expiration of this Agreement.
ARTICLE
11
INDEMNIFICATION
11.1 Indemnification by Cardinal Health. Cardinal Health shall indemnify and hold harmless Client, its Affiliates, and their respective directors, officers, employees and agents (“Client Indemnitees”) from and against any and all suits, claims, losses, demands, liabilities, damages, costs and expenses (including reasonable attorney’ fees) in connection with any suit, demand or action by any third party (“Liabilities”) arising out of or resulting from (A) any breach of its representations, warranties or obligations set forth in this Agreement or (B) any negligence or willful misconduct by Cardinal Health, except to the extent that any of the foregoing arises out of or results from any Client Indemnitee’s negligence, willful misconduct or breach of this Agreement.
11.2 Indemnification by Client. Client shall indemnify and hold harmless Cardinal Health, its Affiliates, and their respective directors, officers, employees and agents (“Cardinal Health Indemnitees”) from and against all Liabilities arising out of or resulting from (A) any breach of its representations, warranties or obligations set forth in this Agreement; (B) any manufacture, sale, promotion, distribution, shipping, use of or exposure to the Product or any materials supplied by Client, including, without limitation, product liability or strict liability; (C) Client’s exercise of control over the Services to the extent that Client’s instructions or directions violate applicable law; (D) any actual or alleged infringement or violation of any patent, trade secret, copyright, trademark or other proprietary rights concerning the Product or provided by Client; or (E) any negligence or willful misconduct by Client, except to the extent that any of the foregoing arises out of or results from any Cardinal Health Indemnitee’s negligence, willful misconduct or breach of this Agreement.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
9
11.3 Indemnification Procedures. All indemnification obligations in this Agreement are conditioned upon the Party seeking indemnification: (A) promptly notifying the indemnifying Party of any claim or liability of which the Party seeking indemnification becomes aware (including a copy of any related complaint, summons, notice or other instrument); provided, however, that failure to provide such notice within a reasonable period of time shall not relieve the indemnifying Party of any of its obligations hereunder except to the extent the indemnifying Party is prejudiced by such failure; (B) reasonably cooperating with the indemnifying Party in the defense of any such claim or liability (at the indemnifying Party’s expense); and (C) not compromising or settling any claim or liability without prior written consent of the indemnifying Party. The indemnifying party shall not, without the prior written consent of the indemnified party, enter into any settlement or other resolution that includes any admission of wrongdoing or that imposes any liability or other detriment on the indemnified party.
ARTICLE
12
LIMITATIONS OF LIABILITY
12.1 CARDINAL HEALTH’S TOTAL LIABILITY UNDER THIS AGREEMENT, FOR ANY AND ALL ACTS, OMISSIONS, BREACH OR NEGLIGENCE (EACH, AN “ACT”) OF CARDINAL HEALTH DURING [***], WHETHER IN CONTRACT OR TORT, INCLUDING, WITHOUT LIMITATION, ANY OF CARDINAL HEALTH’S INDEMNITY OR OTHER FINANCIAL OBLIGATIONS UNDER ARTICLE 11, SHALL NOT EXCEED: [***]. FOR PURPOSES OF THIS SECTION, [***].
12.2 NEITHER PARTY SHALL BE LIABLE TO THE OTHER PARTY FOR INDIRECT, INCIDENTAL, SPECIAL OR CONSEQUENTIAL DAMAGES ARISING OUT OF PERFORMANCE UNDER THIS AGREEMENT, INCLUDING WITHOUT LIMITATION, LOSS OF REVENUES, PROFITS OR DATA, WHETHER IN CONTRACT OR TORT, EVEN IF SUCH PARTY HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH DAMAGES.
12.3 NOTWITHSTANDING ANYTHING TO THE CONTRARY HEREIN, THE LIMITATIONS IN THIS ARTICLE 12 SHALL NOT LIMIT CLIENT’S LIABILITY OR RESPONSIBILITY RELATING TO A BREACH OF ITS OBLIGATIONS UNDER ARTICLE 4 HEREIN.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
10
ARTICLE
13
INSURANCE
13.1 Insurance Policies. During the term of this Agreement, Client shall obtain and maintain the following insurance with limits not less than those specified below:
A. Products and Completed Operations Liability Insurance covering the Products included in this Agreement with a limit of not less than $[***] per occurrence;
B. All-Risk Property Insurance, including transit coverage, in an amount equal to full replacement value covering Client’s property while it is at the 3PL Facility or in transit to or from the 3PL Facility. Client’s all-risk property insurance shall apply to all losses and be primary (with respect both to any insurance issued to Cardinal Health and to any deductible amount or self-insured amount retained by Cardinal Health) except for losses resulting solely from the gross negligence or willful misconduct of Cardinal Health.
In the event that any of the required policies of insurance are written on a claims-made basis, then such policies shall be maintained during the entire term of this Agreement and for a period of not less than [***] ([***]) years following the termination or expiration of this Agreement.
13.2 Waiver. Client shall obtain a waiver from any insurance carrier with whom Client carries Property Insurance releasing its subrogation rights against Cardinal Health except for losses resulting solely from the gross negligence or willful misconduct of Cardinal Health. Client shall not seek reimbursement for any property claim, or portion thereof that is not fully recovered from Client’s property insurance except for losses resulting solely from the gross negligence or willful misconduct of Cardinal Health.
13.3 Additional Insured Status. Cardinal Health, Inc., and its Affiliates shall be named as additional insureds under the Products and Completed Operations Liability insurance policies as respects the Products and completed operations outlined in this Agreement. Such insurance shall be primary (with respect both to any insurance issued to Cardinal Health and to any self-insured amount retained by Cardinal Health) with regard to Cardinal Health’s liability for damage arising out of those products for which they have been added as additional insureds. Such additional insurance status shall continue during the term and, if the policies are written on a claims-made basis, shall continue for not less than [***] ([***]) years following termination or expiration of this Agreement.
13.4 Certificates. Client shall furnish certificates of insurance to Cardinal Health evidencing the required insurance and additional insured status as soon as practicable after the Effective Date and within [***] ([***]) days after renewal of such policies. Such certificates shall state that Client’s insurers will endeavor to provide [***] ([***]) days written notice of any cancellation prior to the policy(ies) expiration date(s). Each insurance policy that is required under this article shall be obtained from an insurance carrier with an A.M. Best rating of at least A-VII.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
11
ARTICLE
14
NOTICES
All notices and other communications hereunder shall be in writing and shall be deemed given: (A) when delivered personally; (B) when delivered by facsimile transmission (receipt verified); (C) when received or refused, if mailed by registered or certified mail (return receipt requested), postage prepaid; or (D) when delivered if sent by express courier service, to the Parties at the following addresses (or at such other address for a Party as shall be specified by like notice; provided, that notices of a change of address shall be effective only upon receipt thereof):
To Client: | Butterfly Network, Inc. |
530 Old Whitfield Street | |
Guilford, CT 06437 | |
Attn: President | |
With a required copy to: | Attn: Legal Dept. (at above address) |
To Cardinal Health: | Cardinal Health 105, Inc. |
Specialty Pharmaceutical Services | |
15 Ingram Boulevard | |
La Vergne, TN 37086 | |
Attn: VP, Third-Party Logistics Services | |
With a copy to: | Cardinal Health, Inc. |
7000 Cardinal Place | |
Dublin, Ohio 43017 | |
Attn: Associate General Counsel | |
Facsimile: [***] |
ARTICLE
15
MISCELLANEOUS
15.1 Entire Agreement; Amendments. This Agreement, the attachments and any amendments thereto constitute the entire understanding between the Parties and supersede any contracts, agreements or understanding (oral or written) of the Parties with respect to the subject matter hereof. No term of this Agreement may be amended except upon written agreement of both Parties, unless otherwise provided in this Agreement.
15.2 Captions. The captions in this Agreement are for convenience only and are not to be interpreted or construed as a substantive part of this Agreement
15.3 Further Assurances. The Parties agree to execute, acknowledge and deliver such further instruments and to take all such other incidental acts as may be reasonably necessary or appropriate to carry out the purpose and intent of this Agreement.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
12
15.4 No Waiver. Failure by either Party to insist upon strict compliance with any term of this Agreement in any one or more instances shall not be deemed to be a waiver of its rights to insist upon such strict compliance with respect to any subsequent failure.
15.5 Severability. If any term of this Agreement is declared invalid or unenforceable by a court or other body of competent jurisdiction, the remaining terms of this Agreement shall continue in full force and effect.
15.6 Independent Contractors. The relationship of the Parties is that of independent contractors, and neither Party shall incur any debts or make any commitments for the other Party except to the extent expressly provided in this Agreement. Nothing in this Agreement is intended to create or shall be construed as creating between the Parties the relationship of joint venturers, co-partners, employer/employee or principal and agent.
15.7 Successors and Assigns. This Agreement shall be binding upon and inure to the benefit of the Parties, their successors and permitted assigns. Neither Party may assign this Agreement, in whole or in part, without the prior written consent of the other Party, except that either Party may, without the other Party’s consent, assign this Agreement to an Affiliate or to a successor to substantially all of the business or assets of the assigning company to which this Agreement relates.
15.8 Governing Law. This Agreement shall be governed by and construed under the laws of the State of Delaware, excluding its conflicts of law provisions. The United Nations Convention on Contracts for the International Sale of Goods shall not apply to this Agreement.
15.9 Dispute Resolution. If any dispute, controversy or disagreement arises between the Parties (“Dispute”), such Dispute shall be presented to the respective presidents or senior executives of Cardinal Health and Client for their consideration and resolution. If such Parties cannot reach a resolution of the Dispute within [***] ([***]) days, either Party may submit the Dispute to a court of appropriate jurisdiction.
15.10 Prevailing Party. Intentionally omitted.
15.11 Counterparts. This Agreement may be executed in one or more counterparts, each of which shall be deemed an original but all of which together shall constitute one and the same instrument. Any photocopy, facsimile or electronic reproduction of the executed Agreement shall constitute an original.
15.12 Publicity. Neither Party shall make any press release or other public disclosure regarding this Agreement or the transactions contemplated hereby without the other Party’s express prior written consent, except as required under applicable law or by any governmental agency, in which case the Party required to make the press release or public disclosure shall use commercially reasonable efforts to obtain the approval of the other Party as to the form, nature and extent of the press release or public disclosure prior to issuing the press release or making the public disclosure.
15.13 Setoff. Intentionally omitted.
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
13
15.14 Survival. The rights and obligations of the Parties shall continue under Articles 10 (Confidentiality and Non-Use), to the extent expressly stated therein, 11 (Indemnification), 12 (Limitations of Liability), 13 (Insurance), to the extent expressly stated therein, 14 (Notice) and 15 (Miscellaneous) and Section 6.4 (Effect of Termination), notwithstanding expiration or termination of this Agreement.
15.15 Force Majeure. Except as to payments required under this Agreement, neither Party shall be liable in damages for, nor shall this Agreement be terminable or cancelable by reason of, any delay or default in such Party’s performance hereunder if such default or delay is caused by events beyond such Party’s reasonable control including, but not limited to, acts of God, regulation or law or other action or failure to act of any government or agency thereof, war or insurrection, civil commotion, destruction of production facilities or materials by earthquake, fire, flood or storm, labor disturbances, epidemic, or failure of suppliers, public utilities or common carriers; provided however, that the Party seeking relief hereunder shall immediately notify the other Party of such cause(s) beyond such Party’s reasonable control. The Party that may invoke this section shall use all reasonable endeavors to reinstate its ongoing obligations to the other. If the cause(s) shall continue unabated for [***] ([***])) days, then the affected Party may terminate this Agreement with immediate effect.
< Signature Page to Distribution Agreement Follows >
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
14
IN WITNESS WHEREOF, the undersigned have caused their duly authorized representative to execute this Agreement effective as of the date first written above.
CARDINAL HEALTH 105, INC. | BUTTERFLY NETWORK, INC. | |||
By: | /s/ Joel Wayment | By: | /s/ Alex Magary | |
Joel Wayment | Print Name: | Alex Magary | ||
VP, Operations | Title: | VP, Legal & Asst. Corp. Secretary | ||
Date: | Jul 13, 2018 | Date: | Jul 13, 2018 |
< Signature Page to Distribution Agreement >
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED. |
15
Exhibit A
Traditional 3PL Operating Guidelines
(“OPG”)
Between
Butterfly Network, Inc
(“Client”)
And
Cardinal Health 105, Inc. – Third Party Logistics Services
(“Cardinal Health”)
[***]
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
[***]
[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, HAS BEEN OMITTED BECAUSE THE INFORMATION (I) IS NOT MATERIAL AND (II) WOULD BE COMPETITIVELY HARMFUL IF PUBLICLY DISCLOSED.
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We hereby consent to the use in this Registration Statement on Form S-4, of our report dated May 20, 2020, relating to the balance sheet of Longview Acquisition Corp. as of February 12, 2020, and the related statements of operations, changes in stockholder’s equity and cash flows for the period from February 4, 2020 (inception) through February 12, 2020, and to the reference to our Firm under the caption “Experts” in the Prospectus.
/s/ WithumSmith+Brown, PC
New York, New York
November 25, 2020
Exhibit 23.2
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the use in this Registration Statement on Form S-4 of our report dated November 27, 2020, relating to the financial statements of Butterfly Network, Inc. We also consent to the reference to us under the heading "Experts" in such Registration Statement.
/s/ Deloitte & Touche LLP
New York, New York
November 27, 2020